On the natural and laboratory evolution of an antibiotic resistance gene by Salverda, M.L.M.
  
 
On the natural and laboratory evolution  
of an antibiotic resistance gene 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Promotor:    
Prof. dr. R.F. Hoekstra 
 Hoogleraar in de Genetica  
 Wageningen Universiteit 
 
Co-promotoren:  
Dr. J.A.G.M. de Visser 
 Universitair Hoofddocent, Laboratorium voor Erfelijkheidsleer 
 Wageningen Universiteit 
 
 Prof. Dr. J. van der Oost 
 Persoonlijk Hoogleraar, Leerstoelgroep Microbiologie 
 Wageningen Universiteit 
 
Promotiecommissie:   
Prof. Dr. A. van Belkum, Erasmus Medisch Centrum, Rotterdam 
Prof. Dr. J.A.M. Leunissen, Wageningen Universiteit 
Prof. Dr. S. Tans, FOM Instituut voor Atoom- en Molecuulfysica, Amsterdam  
Prof. Dr. P.H. van Tienderen, Universiteit van Amsterdam 
 
Dit onderzoek is uitgevoerd binnen de onderzoeksschool Production Ecology and Resource Conservation 
 Merijn Salverda 
 
On the natural and laboratory evolution  
of an antibiotic resistance gene 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Proefschrift 
 
ter verkrijging van de graad van doctor 
op gezag van de rector magnificus 
van Wageningen Universiteit, 
Prof. Dr. M.J. Kropff, 
in het openbaar te verdedigen 
op woensdag 8 oktober 2008 
des namiddags te vier uur in de Aula. 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Salverda, Merijn Louis Marten (2008) 
‘On the natural and laboratory evolution of an antibiotic resistance gene’ 
Thesis Wageningen University – with references and summary in Dutch 
 
ISBN: 978-90-8504-999-9 
 
7 
Thesis abstract 
 
TEM-1 ß-lactamase is one of the most notorious antibiotic resistance enzymes around. It 
exists at high frequencies in antibiotic-resistant bacteria around the world and confers 
resistance to ß-lactam antibiotics, including penicillins (e.g. ampicillin) and cephalosporins. 
The enzyme displays a remarkable phenotypic plasticity in response to the introduction of 
new drugs; within a few years after the clinical debut of most new ß-lactam antibiotics 
resistance conferring variants of TEM-1 are isolated. Such a shift in resistance phenotype is 
typically caused by just a few amino acid substitutions. Until today, more than 150 variants of 
TEM-1 with a unique amino acid sequence have been identified. 
 Because of the clear link between genotype and phenotype (i.e. level of resistance or 
fitness) and because of the ease of selecting for increased antibiotic resistance, TEM-1 has 
been used as a model in studies that seek new methods to optimize proteins. These studies 
combine the power of in vitro mutagenesis and in vivo selection and have resulted in a wealth 
of information about which mutations can increase resistance when the enzyme is exposed to 
an antibiotic that it initially hydrolyzes inefficiently. At a later stage, these techniques were 
adopted and used to repeat and predict the natural evolution of TEM-1 under various selective 
conditions. Recently, TEM-1 is increasingly being used as an experimental model for the 
study of fundamental evolutionary questions, particularly those that benefit from the direct 
relationship between genotype and phenotype.  
In this thesis, both the natural and laboratory evolution of TEM-1 are studied. The aim of 
the laboratory work is to increase our understanding of the way in which adaptive mutations 
interact. For this purpose, TEM-1 is mutagenized using error-prone PCR, which creates 
variation in the resulting copies of the TEM-1 gene. Mutated gene-copies are placed in 
bacteria which are subsequently selected for increased resistance to cefotaxime (an antibiotic 
that TEM-1 hydrolyzes poorly). By repeating this process multiple times in independent 
experiments, the mutations and mutational trajectories involved in the increase of cefotaxime 
resistance are studied. At a fundamental level, this has lead to a better understanding of the 
nature of mutation interaction and its consequences for evolutionary contingency and 
constraint. Evidence indicating that certain ‘silent’ mutations (i.e. mutations that alter the 
codon sequence but not the amino acid that the respective codon encodes) can also play a role 
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in increased resistance was found in these data as well.  
A phylogenetic study of the sequences of the ~150 different TEM-alleles that have been 
isolated in hospitals and clinics so far indicates that recombination has played a significant 
role in the evolution of TEM-alleles, contrary to what is often assumed. Furthermore, amino 
acid substitutions present in these clinical isolates are compared to those found in laboratory 
evolution studies of TEM-1, in order to investigate to what extent laboratory evolution can be 
used as a predictive tool for the natural evolution of antibiotic resistance genes. This overview 
indicates that laboratory evolution very accurately repeats the natural evolution of TEM-1. 
Based on these findings, predictions are made about substitutions that may appear in future 
clinical TEM-isolates, and directions are given how laboratory evolution can be exploited as a 
predictive tool most efficiently. 
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-Chapter 1- 
 
General introduction 
Merijn Salverda 
 
A brief history of antibiotics and the problem of antibiotic resistance 
The use of antibiotics dates back to long before Alexander Fleming’s famous discovery. 
Ancient cultures have been reported to use antibiotic containing materials like moulds, honey 
and plants for the treatment of skin infections (MOELLERING 1995) and the secretions of 
maggots, ancient helpers in wound-care (SHERMAN et al. 2000), have been shown to contain 
antimicrobial compounds (KERRIDGE et al. 2005). In 1928, Fleming discovered a halo of 
inhibition of bacterial growth around a Penicillium notatum mould that had infected one of his 
plate cultures of Staphylococcus aureus. Although several researchers had reported 
antimicrobial characteristics of moulds before him, Fleming was the first to demonstrate that a 
substance that was secreted by the mould, which he named ‘penicillin’, was the cause of this 
antimicrobial effect. Because of problems with the purification and mass production of 
penicillin it took until the end of the Second World War before the drug proved its success in 
clinical use. Ironically and perhaps illustrative of the problems that would soon suppress the 
initial optimism about this ‘wonder drug’ (Figure 1.1), the first enzyme able to destroy 
penicillin was identified before penicillin made its clinical debut in 1941 (ABRAHAM and 
CHAIN 1940). Experiments testing the ability of bacteria to evolve resistance to penicillin at 
the same time forecasted similar problems (ABRAHAM et al. 1941): 
 
‘In order to find an answer to the questions whether bacteria will acclimatise themselves to 
inhibitory concentrations of penicillin (…) a strain of Staph. aureus was cultivated for some 
months in broth in the presence of increasing quantities of (…) crude penicillin. Even after a 
few daily subcultures there was evidence of increased resistance, the coccus showing growth 
in at least twice the previously inhibitory concentration. In about nine weeks, with sub 
cultivation every few days, an approximately 30-fold adaptation was reached, and after a 
further 7 weeks the microbe was able to multiply in a concentration of penicillin a thousand 
times greater than that which inhibited the parent strain in a parallel test (…)’  
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Indeed, within a year after the clinical debut of penicillin, the first resistant bacterial isolates 
were reported. The rise in penicillin resistance was the most striking in Staphylococcus aureus 
(Medeiros 1997): 
 
1941 clinical introduction of penicillin 
1942 resistant isolates of S. aureus found in patients treated with penicillin 
1944 resistant isolates of S. aureus found in patients not treated with penicillin 
1946 14%  
1947 38% percentage of S. aureus isolates resistant to penicillin in an English hospital 
1948 59% 
1953 80%  resistant S. aureus isolates in hospital strains worldwide 
 
 
Figure 1.1: U.S. advertisement dating from the golden years of the ‘wonder drug’. 
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The discovery and initial success of penicillin initiated a massive hunt for new antimicrobial 
agents. Despite of the many antibiotics that have been discovered ever since, it time and again 
turns out that ‘once an antibiotic is proven to be effective and enters widespread human 
therapeutic use, its days are numbered’ (WALSH 2000). With the introduction of new 
antibiotics and the study of bacterial resistance mechanisms, it became apparent that there are 
many ways in which bacteria are able to acquire and transmit resistance. Cells can lower their 
permeability, antibiotics can be actively pumped out of cells and antibiotic targets can be 
modified. Yet another mechanism is the enzymatic breakdown of antibiotics. The most 
notorious antibiotic resistance enzymes are the ß-lactamases, which can break down ß-lactam 
antibiotics. These antibiotics and their mode of action will first be addressed here. 
 
ß-lactam antibiotics and their mode of action 
ß-lactam antibiotics are characterized by the presence of a ß-lactam ring in their molecular 
structure. They include penicillin and derivatives (e.g. ampicillin), cephalosporins (including 
cefotaxime, the antibiotic studied in this thesis), monobactams, carbapenems and ß-lactamase 
inhibitors. ß-lactam antibiotics act by interfering with bacterial cell wall synthesis. The 
antibiotics irreversibly bind to transpeptidases, enzymes that are involved in the cross-linking 
of the peptidoglycan layer of bacterial cell walls. The initial hypothesis, which is still often 
referred to, is that this results in instability of the cell wall and lysis under osmotic stress 
(TIPPER and STROMING 1965). However, the true mechanism is much more sophisticated and 
acts at several different levels. It was found that bacterial lysis is actually independent of the 
weakening of the cell wall and is mediated by triggering of the major autolytic enzyme as a 
result of the drug-target interaction (TOMASZ et al. 1970; TOMASZ and WAKS 1975). 
However, even without this enzymatically regulated lysis antibiotics were found to have a 
strong bactericidal effect, suggesting that lysis and lethality are two separate bactericidal 
mechanisms caused by these antibiotics (MOREILLON et al. 1990). Indeed, a bactericidal effect 
of ß-lactam antibiotics that is independent of drug-target interaction and involves induction of 
a common mechanism of cellular death has recently been described (KOHANSKI et al. 2007). 
All in all, it seems that ß-lactams both disrupt the delicate balance of cell wall metabolism 
(weakening the cell wall structure and at the same time inducing autolysis) and induce 
programmed cell death.  
 
Chapter 1 
 14 
Resistance to ß-lactam antibiotics 
There are various ways in which bacteria can become resistant to ß-lactam antibiotics. In 
Gram-negative bacteria, resistance can evolve by means of alteration of the permeability of 
the outer membrane or the active efflux of ß-lactam antibiotics from the periplasmic space. 
Some bacteria, e.g. the infamous MRSA, have developed changes in their transpeptidases that 
cause low affinity for ß-lactams (ZAPUN et al. 2008). However, the most common mechanism 
of resistance is the production of ß-lactamases, enzymes that catalyze hydrolysis of the ß-
lactam ring of ß-lactam antibiotics. A wide variety of these enzymes can be found in both 
gram-positive bacteria (where they are normally secreted) and gram-negative bacteria (where 
they are employed in the periplasmic space). This thesis deals with the natural and laboratory 
evolution of TEM-1, the most common of the ß-lactamases (BARLOW and HALL 2002). 
 
System studied 
TEM-1 ß-lactamase is one of the most notorious and widespread antibiotic resistance 
enzymes around. It was isolated as a plasmidic ampicillin resistance determinant in Greece in 
1963 and named after the patient (Temoneira) providing the first sample (DATTA and 
KONTOMICHALOU 1965). Following the introduction of 3
rd
 generation cephalosporins at the 
beginning of the 1980s, variants of the enzyme with subtle differences in their amino acid 
sequence were isolated. It had already been shown that a single amino acid substitution in a 
TEM-1 mutant obtained by in vitro mutagenesis could alter the catalytic activity (HALL and 
KNOWLES 1976) and it was therefore strongly suspected that the sequence alterations 
observed in clinical isolates could be a new mechanism of resistance (Bush 1989; Sougakoff 
et al. 1988). This was later confirmed using mutants created by site-directed mutagenesis 
(ZAFARALLA et al. 1992). Up until today, more than 150 derivatives of TEM-1 with aberrant 
amino acid sequences have been described (http://www.lahey.org/Studies/temtable.asp), and 
it is generally believed that they have evolved largely in response to selection imposed by the 
clinical use of more modern ß-lactam antibiotics (Barlow and Hall 2002; Medeiros 1997). An 
overview of the year of introduction of several ß-lactam antibiotics and the year in which a 
TEM-variant with increased resistance to this antibiotic was first isolated is shown in Figure 
1.2.  
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Figure 1.2: Overview of the year of clinical introduction of several ß-lactam antibiotics and the year 
in which the first TEM-variant conferring increased resistance to this antibiotic was isolated. 
 
Directed evolution 
The potential to use TEM-1 ß-lactamase as a model system for molecular evolution was 
recognized early on (HALL and KNOWLES 1976): 
 
‘To trace the evolutionary improvement of an enzyme in molecular terms and to watch the 
stepwise development of its catalytic apparatus, we need an enzyme susceptible to directed 
selective pressure towards an alternative catalytic function. So that mutational changes may 
be fully interpretable, the tertiary structure must be known. These criteria are fulfilled by the 
plasmid ß-lactamase from E. coli RTEM.’  
 
The study by Hall and Knowles (1976) is in fact one of the first examples of directed 
evolution, where enzymes encoded by a gene that has been diversified in vitro are subjected 
to selection for gain of function in vivo. In this case, whole E. coli cells containing a plasmid 
carrying TEM-1 were subjected to chemical mutagenesis and subsequently selected for 
increased resistance to cephalosporin C (to which TEM-1 has a low resistance). The mutant 
TEM variant that was picked up conferred an increased resistance to cephalosporin C and it 
was later found that this was due to a single amino acid substitution (HEALEY et al. 1989).  
The boom of different TEM-variants that were isolated in hospitals and clinics worldwide 
during the second half of the 1980s coincided with the rise of important techniques in 
molecular biology. Site-directed mutagenesis and easier sequencing methods greatly 
increased the knowledge of different TEM-variants and the effect of different substitutions on 
alteration of the resistance spectrum of the enzyme. Because of this and because of the ease of 
selecting for increased antibiotic resistance, TEM-1 was used as a genetic reporter in a study 
Chapter 1 
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on one of the most important inventions in enzyme engineering, DNA-shuffling (STEMMER 
1994). A combination of this technique with in vivo selection for increased resistance to 
cefotaxime (a third generation cephalosporin against which TEM-1 has a very low resistance) 
resulted in the isolation of a TEM-variant with a ~100,000-fold increased resistance to this 
antibiotic caused by a handful of substitutions. The potential to use directed evolution to study 
the evolutionary potential of TEM-1 for resistance to novel antibiotics was recognized soon 
after (VAKULENKO et al. 1998). In order to adapt the conditions of in vitro evolution to those 
encountered in vivo, an experimental system was set up that both mimicked the mutagenic 
spectrum of E. coli and used multiple selective pressures (BARLOW and HALL 2002). An 
overview of this method, which is extensively used in this thesis, is shown in Figure 1.3. 
 
 
Figure 1.3: Overview of the in vitro evolution method used in this thesis and developed by Barlow 
and Hall (2002). Clockwise from top; an antibiotic resistance gene is located on a plasmid carrying an 
additional selectable marker. The antibiotic resistance gene is amplified using a sloppy polymerase, 
resulting in a pool of amplicons with various amounts of mutations. Mutated amplicons are then 
placed back into the plasmid, which is transformed into E. coli cells. Transformant cells are grown 
overnight in order to expand the library and the next day a series of bottles containing broth with 
increasing amounts of the antibiotic to be studied is inoculated with these cells. They are then grown 
again overnight and the next day cells from the bottle with the highest concentration of antibiotic still 
permitting bacterial growth are plated on agar. The following day, a single colony can be isolated and 
the altered resistance allele can be sequenced and used again in subsequent rounds of evolution. 
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TEM-1 as a model system for molecular evolution 
TEM-1 ß-lactamase was one of the first antibiotic resistance enzymes for which it was 
demonstrated that amino acid substitutions could result in alteration of the resistance 
phenotype (HALL and KNOWLES 1976). Besides this, the clinical isolation of mutant TEM-
alleles as a result of the introduction of novel antibiotics at the beginning of the 1980s yielded 
a ‘free’ database of amino acid substitutions that were very likely to be involved in alteration 
of TEM-1’s catalytic properties. With this knowledge, TEM-1 has been used as a model 
system for the study of enzyme structure-function relationships, enzyme engineering, the in 
vitro evolution of antibiotic resistance and various fundamental evolutionary questions (Table 
1.1).  
 
Table 1.1: Important studies that have used TEM-1 ß-lactamase as a model system. 
 
Reference Topic 
Hall and Knowles (1976) Alteration of catalytic properties by in vivo mutagenesis 
Dalbadie-McFarland et al. (1982) Site directed mutagenesis for the study of protein function 
Schultz and Richards et al. (1986) Site-saturation mutagenesis 
Oliphant and Struhl (1989) Altering function by segment mutagenesis 
Palzkill and Botstein (1992) Structure probing by random replacement mutagenesis 
Stemmer (1994) DNA-shuffling 
Zaccolo and Gherardi (1999) High frequency random mutagenesis 
Blazquez et al. (2000) Effect of fluctuating ß-lactam pressure on in vivo evolution 
Barlow and Hall (2002) Reproduction of natural evolution by in vitro evolution 
Hayes et al. (2002) Optimization by computational and experimental screening 
Osuna et al. (2002) Regain of function after structural alteration 
Hall (2002) Reconstructing evolutionary pathways 
Wang et al. (2002) Stability and activity trade-offs 
Bershtein et al. (2006) Robustness-epistasis link 
Weinreich et al. (2006) Accessibility of evolutionary pathways  
Bershtein et al. (2008) Effect of neutral drift on evolvability 
 
The evolution of resistance to cefotaxime (a 3
rd
 generation cephalosporin) is by far the 
best-studied altered substrate specificity of TEM-1. Using DNA-shuffling, Stemmer (1994) 
isolated a mutant with a ~30,000-fold increased resistance to cefotaxime, apparently the result 
of six amino acid substitutions and a promoter mutation. Hall (2002), disregarding the 
Chapter 1 
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promoter mutation, tried to identify accessible evolutionary pathways to this six-fold mutant. 
Surprisingly, he found that only four of the six amino acid substitutions are needed to create 
an allele with even higher resistance to cefotaxime. Regarding the coding sequence, this 
mutant TEM-allele confers the highest cefotaxime resistance so far described. Weinreich and  
colleagues (2006) studied the accessibility of all trajectories leading to a quintuple mutant 
containing the four substitutions identified by Hall (2002) plus the promoter mutation found 
by Stemmer (1994). They found that, given that each mutation in such a trajectory must 
increase resistance, only a small fraction of al 120 possible trajectories leading to this mutant 
is accessible to Darwinian evolution, due to specific mutational interactions. These mutational 
interactions and the role they play in shaping the fitness landscape, an important metaphor in 
evolutionary dynamics, are discussed below. 
 
The fitness landscape 
The fitness landscape is a metaphor introduced by Wright (1932) to facilitate the discussion 
about mutation, selection and drift. The basic fitness landscape is a multi-dimensional graph 
mapping genotype to fitness. For illustrative purposes, often a three-dimensional picture is 
used with genotype space depicted in the xy-plane and fitness depicted along the z-axis. 
However, this simplistic metaphor is problematic, since it is impossible to depict all 
genotypes of an organism along two axes. Even for a single gene, although depicting the 
mutational neighbourhood at a distance of a single mutation might be possible, mutational 
neighbours that are two mutations away (let alone more) are virtually impossible to depict in 
an organized manner. The fitness landscape is thus a strong simplification of reality, but 
nevertheless it is a powerful metaphor for discussing evolutionary dynamics, as can be seen in 
the following example. 
Imagine the black ball in Figure 1.4a is an isogenic population of bacteria. This population 
is optimally adapted to its environment, so it resides on a fitness peak (here shown in just two 
dimensions). Any genetic change occurring in individuals of this population will either be 
neutral (causing the ball to move on the peak-plateau, but not in height) or result in a decrease 
of fitness, causing the population to move downhill. However, since individuals with lower 
fitness tend to be removed from the population by selection, the population will tend to 
remain on the peak. Now imagine that the environment of this bacterial population undergoes 
a sudden change (e.g. the population is exposed to an antibiotic). This will change the  
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a b
c d
 
Figure 1.4: Population dynamics on two-dimensional fitness landscapes (fitness is on the y-axis, 
genotype on the x-axis, the black dot indicates a population of organisms). (a) The population is at a 
fitness peak and because all mutations decrease fitness, selection keeps the population at this peak. (b) 
An environmental change (for example exposure to antibiotics in a bacterial population) causes the 
landscape to change and fitness decreases. (c) Mutations can now give rise to a better adapted 
genotype that can take over the population, because it reproduces more successfully. Repetition of this 
process results in an ‘adaptive walk’ to the top of the fitness peak. (d) The population is in a fitness 
valley in a multi-peaked or ‘rugged’ fitness landscape. Alternative solutions to the same problem, 
involving different mutational pathways, are now available.  
 
landscape radically; as the population is now no longer optimally adapted to its environment, 
it is all of a sudden at the foot of the hill (Figure 1.4b). Mechanisms to increase resistance 
exist, but the population simply has not had sufficient time to respond. Over the course of 
time, an individual with a single beneficial mutation may appear. Such an individual may pull 
the population upwards, since it can outcompete other individuals and may replace them 
eventually. In this way, step-by-step, the population can drag itself uphill again, until it is 
once again back at the fitness peak. Adaptive evolution is the motor behind this “hill 
climbing” and the process is also known as an “adaptive walk” (Figure 1.4c). An important 
assumption is that mutations occur one at a time and that an evolutionary trajectory must exist 
between the lower point and the peak, consisting of consecutive mutations that all increase 
fitness. 
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Now, the fitness landscape sketched above is extended by the addition of an extra fitness peak 
while the bacterial population is once again maladapted (Figure 1.4d, a so-called ‘rugged’ 
fitness landscape). The peaks surrounding the population can be seen as alternative solutions 
to the problem of survival (GAVRILETS 2004). Which peak will be ascended is largely a matter 
of chance when mutations occur and go to fixation one at a time. Because of this, the 
population does not necessarily end up at the highest peak. Adaptive evolution is ‘blind’ for 
the heights of the different peaks and simply forces the population upward along the steepest 
slope for which beneficial mutations are available. In this way, the population can end up at a 
suboptimal peak and selection will keep it at this peak. Escape from such a peak is only 
possible by genetic drift or by a change in the fitness landscape itself.  
A mechanism that shapes the fitness landscape is epistasis, i.e. the interaction between 
mutations in their effect on phenotype or fitness. Consider two genotypes, ab and AB, with 
low and high fitness respectively (Figure 1.5). Without epistasis, the fitness effect of mutation 
a → A is independent of which allele is present at the b/B locus and vice versa (Figure 1.5, 
left). With sign epistasis, the fitness effect of mutation a → A is dependent on which allele is 
present at the b/B locus: in the background of b, the fitness is decreased and in the 
background of B fitness is increased. This does not account for mutation b → B, which 
increases fitness in both backgrounds (Figure 1.5, middle). Under a special form of epistasis, 
called ‘reciprocal sign epistasis’ (POELWIJK et al. 2007), the sign of the fitness effect of both 
mutations a → A and b → B is dependent on which allele is present at the other locus (Figure 
1.5, right). In other words, when selection has to move from low fitness genotype ab to high 
fitness genotype AB, it has to cross a fitness valley, since both intermediate genotypes have 
an even lower fitness than ab. This type of sign epistasis causes constraints on protein 
evolution that give rise to multiple adaptive peaks (POELWIJK et al. 2007). 
 
 
 
 
 
 
 
Figure 1.5: Epistatic interactions between two loci with two alleles, a/A and b/B. The picture design is 
based on Weinreich et al. (2005). Left: no epistasis, fitness effect of a mutation is independent of its 
genetic background. Middle: sign epistasis, sign of fitness effect of mutation a → A depends on what 
allele is present at the b/B locus. Right: reciprocal sign epistasis, sign of fitness effect of mutation a → 
A depends on what allele is present at the b/B locus and vice versa. 
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Outline of this thesis 
This thesis deals with the in vitro and in vivo evolution of TEM-1 ß-lactamase. It is divided in 
two main parts; one that deals with fundamental questions about mutations and their 
interactions and one that deals with more practical questions about how antibiotic resistance 
enzymes evolve and to what extent laboratory techniques can be used to predict their 
evolutionary potential. 
 
Chapter 2: In this chapter the in vitro evolution of TEM-1 ß-lactamase for increased 
resistance to the antibiotic cefotaxime was studied with the aim to answer fundamental 
questions about mutation interaction and its effect on the fitness landscape. It is shown that 
whatever adaptive mutation for cefotaxime resistance appears first can influence the direction 
and eventual level of adaptation. A special kind of mutational interaction called sign epistasis 
is demonstrated to be at the basis of this adaptive contingency. 
 
Chapter 3: The potential to predict the natural evolution of antibiotic resistance genes using 
laboratory techniques is studied in this chapter. Substitutions found in all known laboratory 
studies in which the evolution of TEM-1 for increased or regained resistance to ß-lactam 
antibiotics were compared to a dataset that contains all variants of this gene that have been 
isolated in hospitals and clinics, with the aim to predict future resistant alleles that may be 
encountered in patients.  
 
Chapter 4: Here, genetic mechanisms underlying the evolution of TEM-variants are 
examined. Variation in known TEM-variants has typically been attributed to the occurrence 
of point mutations. Examination of both coding and silent mutations present in a dataset of 
natural TEM-isolates and the distribution of co-occurring TEM-alleles in clinical microbial 
populations indicates that recombination is an important additional factor in the evolution of 
plasmidic TEM-alleles. 
 
Chapter 5: Synonymous mutations present in clinical and laboratory TEM-isolates are more 
closely examined in this chapter. Although such mutations have long been thought to be 
functionally ‘silent’, evidence to the contrary has been accumulating. Evidence was found that 
at least one silent mutation found multiple independent times in laboratory isolates occurs 
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with a higher frequency than expected for a neutral mutation and is either the result of 
selection or a mutational hotspot. Another ‘silent’ mutation is shown to consistently increase 
resistance to cefotaxime compared to TEM-1. Indications exist that functional-yet-
synonymous mutations occur in clinical isolates as well. Putative mechanisms for the 
functionality of such mutations are discussed. 
 
Chapter 6: In the general discussion, I summarize the most important findings of this thesis 
and I elaborate on interesting areas for future research.   
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Abstract: The exact shape of the fitness landscape is of great importance for many questions 
in evolutionary biology.  Whether such landscapes are smooth (with a single optimum) or 
rugged (with many optima separated by fitness valleys) remains an open question. Sign 
epistasis, a special form of mutational interaction where the sign of the fitness effect of a 
mutation depends on the genetic background the mutation occurs in, can give rise to rugged 
fitness landscapes. Using directed evolution, the adaptive evolution of an antibiotic resistance 
gene towards recognition of a novel antibiotic was studied in twelve replicate lines during 
three rounds of mutagenesis and selection. It was found that multiple sign epistatic 
interactions between mutations are present which give rise to a rugged fitness landscape and 
constrain the adaptive trajectory to a limited number of mutational pathways. 
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2.1 Introduction 
 
The concept of a fitness landscape, i.e. the mapping from genotype to fitness (WRIGHT 1932), 
is an appealing and useful metaphor in evolutionary biology (COLEGRAVE and BUCKLING 
2005). The exact shape of the fitness landscape has important implications for evolutionary 
theory, including the origin and maintenance of sex and recombination (KONDRASHOV and 
KONDRASHOV 2001), the nature and extent of evolutionary constraint (WHITLOCK et al. 1995; 
CAMPS et al. 2007) and the evolution of diversity and speciation (WHITLOCK et al. 1995; 
GAVRILETS 2004). However, whether this shape is ‘smooth’ (single peaked) or ‘rugged’ 
(multi peaked) remains an open question (LUNZER et al. 2005).  
Wright (1932) pointed out that when the fitness effect of an allele present at one locus 
depends on which alleles are present at other loci (i.e. epistasis), such interactions can give the 
fitness landscape a rugged appearance with many local optima separated by fitness valleys. 
Fitness valleys, and hence ruggedness, are specifically caused by a special form of mutation 
interaction called ‘sign epistasis’, where the sign of the fitness effect of a mutation (i.e. 
positive or negative) depends on the genetic background in which it appears (WEINREICH et 
al. 2005).  For example, consider genotypes ab and AB with low and high fitness 
respectively. Whenever either or both intermediate genotypes aB and Ab have a fitness lower 
than ab, the interaction between the a/A and b/B loci is said to be ‘sign epistatic’, since the 
sign of the fitness effect of changing from ‘a’ to ‘A’ is dependent on the allele present at the 
b/B locus. Such interactions may constrain evolution towards the genotype of highest fitness 
and give rise to multiple peaks on the fitness landscape (WEINREICH et al. 2005). The type of 
sign epistasis that most severely imposes adaptive constraints occurs when both intermediate 
genotypes have lower fitness and is called ‘reciprocal sign epistasis’ (POELWIJK et al. 2007). 
Despite the appeal of the landscape metaphor, empirical information on real fitness 
landscapes is limited due to experimental limitations in obtaining fitness measurements of 
many known genotypes (COLEGRAVE and BUCKLING 2005). Nevertheless, recent 
experimental studies with simple systems, such as enzymes, viruses and bacteria, have begun 
to empirically explore the local fitness surface in a defined environment. Evolution 
experiments with bacteria (KORONA et al. 1994) and viruses (BURCH and CHAO 2000) have 
shown fitness divergence among replicate populations suggesting the approach of different 
peaks in a rugged fitness landscape. Other studies have reconstructed evolutionary pathways 
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from an ancestral to a particular evolved form of an enzyme or metabolic pathway by 
constructing all intermediate genotypes and measuring their fitness or enzymatic activity 
(LUNZER et al. 2005; MILLER et al. 2006; POELWIJK et al. 2006; WEINREICH et al. 2006). A 
general finding of these studies is that the fitness landscape shows many signs of ruggedness 
caused by sign epistatic interactions among the mutations involved. Although the presence of 
multiple peaks in a fitness landscape has been demonstrated experimentally (BURCH and 
CHAO 2000), the involvement of sign epistasis can only be inferred in this case due to lack of 
information about the underlying genetic changes.  
In the present study, we use directed evolution experiments with TEM-1 ß-lactamase in 
order to characterize this enzyme’s fitness landscape for the evolution of substrate specificity 
from ampicillin to cefotaxime (Ctx). Directed evolution (the creation of mutant enzymes in 
vitro, followed by selection in vivo) has been used to mimic the natural evolution of TEM-1 
(ORENCIA et al. 2001; BARLOW and HALL 2002) and to explore its evolutionary potential for 
hydrolysis of a range of ß-lactam antibiotics (VAKULENKO et al. 1998; VAKULENKO and 
GOLEMI 2002; BARLOW and HALL 2003). Besides, TEM-1 has been used as a genetic reporter 
exploring the potency of novel directed evolution techniques (STEMMER 1994; ZACCOLO and 
GHERARDI 1999; CAMPS et al. 2003; FUJII et al. 2004; KOPSIDAS et al. 2007). Most of these 
studies have used Ctx (a 3
rd
 generation cephalosporin that is poorly hydrolyzed by TEM-1) as 
selective agent, making this by far the best studied alteration of the enzyme’s substrate 
specificity. The allele encoding the most efficient enzyme that has been identified in these 
studies has a ~100.000-fold increased minimal inhibitory concentration (MIC) for Ctx and 
carries a single mutation in the promoter and four non-synonymous mutations in the coding 
region (HALL 2002). It has been shown, based on MIC assays, that only a small fraction of the 
evolutionary pathways leading to this quintuple mutant is accessible to Darwinian selection 
due to sign epistasis between the mutations involved (WEINREICH et al. 2006). Moreover, it 
was shown in the same study that the two most likely pathways of fixation are G238S > 
E104K > A42G > M182T and E104K > G238S > A42G > M182T (the promoter mutation is 
left out here since the promoter is not part of the mutagenized sequence in our experiments). 
An important assumption made in these predictions is that population size and mutation rates 
are sufficiently low to prevent the selection of more than one beneficial mutation at a time. It 
is conceivable that under conditions where more than one beneficial mutation is selected at 
once, some of the constraints caused by sign epistasis may be overcome. 
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Here, we seek to characterize the fitness landscape during the evolution of TEM-1 towards 
Ctx hydrolysis. The emphasis is on testing the prediction that sign epistasis can give rise to 
multiple adaptive peaks, the ascent of which depends on early substitutions which exclude 
later switching to alternative peaks. A previously developed in vitro evolution method 
(BARLOW and HALL 2002) is used, where replicate lines with varying mutation and 
recombination rates are selected to increase the ability to detect unique pathways by 
expanding the amount of sequence space covered. Three consecutive rounds of mutagenesis 
and selection resulted in the repetitive evolution of (part of) a previously described route to 
increased Ctx resistance (STEMMER 1994; ZACCOLO and GHERARDI 1999; ORENCIA et al. 
2001; HALL 2002). Next to this dominant route, several alternative pathways were observed 
that lack most of the substitutions of the main route. To assess whether these alternative 
routes represent separate peaks on the fitness landscape, early substitutions suspected to be 
responsible for blocking the main route to Ctx resistance were identified and built into TEM-
1. Three further rounds of directed evolution starting with these mutants show that the 
identified substitutions indeed block the dominant route towards Ctx resistance and lead to 
alternative peaks. Sign epistatic interactions are shown to be at the basis of this rugged 
empirical fitness landscape. 
 
2.2 Materials and methods 
 
Bacterial strains and plasmids: Escherichia coli strain DH5αE was used as the host for all 
plasmids. Plasmid pACSE3 (BARLOW and HALL 2002) was used as the vector for cloning and 
expressing TEM alleles.  
 
Media: LB-medium is 10g trypticase peptone, 5 g yeast extract and 10 g NaCl/ liter. LB-
tetracycline medium is LB-medium containing 15 mg tetracycline/ liter. Mueller Hinton 
(Merck) and Mueller Hinton II (BD) medium were prepared according to the manufacturers’ 
instructions. SOC medium is 20 g bacto-tryptone and 5 g yeast extract/ liter with 10 mM 
NaCl, 2.5 mM KCl, 10 mM MgCl2 and 20 mM glucose. Solid media contained 16 g agar/ 
liter. 
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Recombinant DNA methodology: Plasmids were prepared from overnight cultures grown in 
LB-tetracycline medium. Plasmids were purified using GenElute™ Plasmid Miniprep Kit 
(Sigma) according to the manufacturer’s instructions. TEM-1 was amplified from pBR322 
(BOLIVAR et al. 1977) using Pfu polymerase (Stratagene), sense primer P1 
(GGGGGGTCATGAGTATTCAACATTTCCGTGTCG) (BspHI site underlined) and 
antisense primer P2 (CCGAGCTCTTGGTCTGACAGTTACCAATGC) (SacI site 
underlined), and the following cycling-protocol; denaturation at 95° for 30 sec, annealing at 
61°C for 30 sec and extension at 72°C for 90 sec repeated for 30 cycles, followed by a single 
cycle of 72°C for 10 minutes. 
The resulting amplicon was digested with BspHI (New England Biolabs) and SacI (New 
England Biolabs). The pACSE3 plasmid was digested with the same restriction enzymes and 
dephosphorylated with Calf Intestinal Phosphatase (New England Biolabs). Digested 
amplicon and vector were purified using Sigma’s GenElute™ PCR Clean-up Kit, ligated 
using T4 DNA Ligase (New England Biolabs), and transformed into DH5αE by 
electroporation. 
 
Mutagenesis: Mutant TEM alleles were created by introducing random mutations into the 
TEM-1 allele using the Genemorph I and Genemorph II PCR Mutagenesis Kits (Stratagene) 
according to the manufacturer’s instructions. The primers used for the PCR were P3 
(TCATCCGGCTCGTATAATGTGGA) and P4 (ACTCTCTTCCGGGCGCTATCAT), which 
flank the multiple cloning site of pACSE3.  
The mutation rate in a Mutazyme-based error-prone PCR (ep-PCR) is determined by the 
number of duplications. As the yield of each PCR is approximately the same, higher mutation 
frequencies can be achieved by lowering the initial amount of template in the reaction. 
Conditions were set to introduce on average 2 (low mutation rate) or 6 (high mutation rate) 
mutations per amplicon per PCR.  
The resulting mutated amplicons were digested with BspHI and SacI restriction enzymes, 
ligated into pACSE3 and electroporated into DH5αE. After recovery for 90 min in SOC 
medium at 37°C, the cells were diluted in 500 ml LB-tetracycline medium. An aliquot was 
taken out of this directly after mixing and plated on LB-tetracycline to determine the library-
size, while the remainder of the culture was placed overnight at 37°C to expand the library. 
An aliquot of the expanded library was stored in 10% glycerol at -80°C. 
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Site-directed mutagenesis: Specific mutations were built into the TEM-1 gene using the 
QuickChange site-directed mutagenesis kit (Stratagene), according to the manufacturer’s 
instructions. 
 
Artificial recombination: Where used, recombination was introduced by digestion of the 
error-prone PCR-amplicons with SacI, BspHI and PvuI endonuclease. PvuI has a single 
recognition site halfway the TEM-1 sequence and digestion of the amplicons results in two 
fragments of approximately the same length. The truncated amplicons were subsequently 
restored to full-length sequences and placed in vector pACSE3 by a single ligation step as 
described previously. Because ligation is random this mimics a single recombination event at 
a fixed spot approximately halfway the TEM-1 gene, which was confirmed by pilot 
experiments using restriction markers.  
 
Expression of TEM alleles: Expression of cloned TEM alleles in pACSE3 is under control of 
the pTac promoter that is tightly regulated by the lac repressor that is encoded by the lacI 
gene on the plasmid. Expression of TEM alleles was induced by adding 50 µM isopropyl-ß-
D-thiogalactopyranoside (IPTG), a concentration that has previously been shown to mimic a 
natural expression level (BARLOW and HALL 2002). 
 
Selection for extended-spectrum TEM-alleles: A series of bottles containing 50 ml Mueller 
Hinton medium was inoculated with Ctx in two-fold increments (ranging from 0.125 µg/ ml 
(the MIC for TEM-1) to 1024 µg/ ml). Subsequently, each bottle was inoculated with a 
number of cells from the overnight-enriched library that was equivalent to 10 times the 
library-size. Cultures were incubated for 48 hours at 37°C. The culture that grew at the 
highest concentration of Ctx was plated on LB + Tet. Because of clonal fixation, a single 
genotype is expected to dominate this culture (BARLOW and HALL 2002). This was confirmed 
by sequencing of 10 clones from the bottle with the highest Ctx concentration that still 
permitted visible growth from a random selection series.  The next day a single colony was 
picked from this plate and grown overnight in LB + Tet. Plasmid from this overnight culture 
was subsequently isolated using the GenElute™ Plasmid Miniprep Kit (Sigma) and 
sequenced.  
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Sequencing: The TEM-allele was amplified from isolated plasmids using primers P3 and P4 
and BigDye™ (Perkin Elmer) or DYEnamic™ ET (AP-biotech) Terminator Cycle 
Sequencing kits according to the manufacturer’s instructions. 
 
Antibiotics and MIC-assay: The following ß-lactam antibiotics were used in this study: 
ampicillin, cefotaxime and tetracycline (all Sigma). Stock solutions were made in H2O 
(ampicillin), 0.1M NaPO4, pH 7.0 (Ctx) and 70% ethanol (tetracycline). 
MICs were determined from 150 µl cultures at a titre of 10
5
 cells/ ml in Mueller Hinton II 
medium containing 50 µm IPTG. Another 150 µl of twofold serial dilutions of antibiotic in 
MH II were added to this. MIC is defined as the lowest concentration of antibiotic that 
completely prevents visible growth. Cultures were grown for 24 hours at 37°C, after which 
MIC was determined by visual inspection. Prior to each MIC-assay, plasmid was isolated 
from all selected clones and transformed into isogenic E. coli DH5αE cells by electroporation 
in order to exclude any phenotypic variation in the bacteria.  
 
Statistical analysis: Because MIC values are measured on a discontinuous scale (using two-
fold increases of Ctx concentration), non-parametric tests were used to compare differences in 
evolved MIC values among treatments. Statistical analysis was done using SPSS, rel. 15.0.1.1 
(SPSS Inc., 2007).  
 
2.3 Results 
 
Exploring TEM-1’s evolutionary heterogeneity towards increased cefotaxime resistance 
We first performed an evolution experiment to explore the different mutational trajectories of 
TEM-1 towards increased Ctx resistance. Six independent error-prone PCRs were started each 
with a low mutation rate (LMR; ~2.0 mutations per amplicon) and a high mutation rate 
(HMR; ~6.1 mutations per amplicon). Three LMR and three HMR lines were subjected to 
recombination before selection while the remaining six lines were not allowed to recombine, 
resulting in four different treatments of three replicates each; (i) LMR no recombination (ii) 
LMR recombination (iii) HMR no recombination and (iv) HMR recombination. Each of the 
twelve mutagenized libraries was subsequently subjected to selection for increased resistance 
in a gradient of twofold increasing Ctx concentrations, and a random clone from the highest 
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Ctx concentration that allowed growth was selected for the next round of evolution. Three 
rounds of evolution were carried out. The average library-size over the whole experiment was 
~1.1 x 10
6
 transformants.  
Figure 2.1 shows the average log relative change in Ctx resistance for all lines per 
treatment over the three rounds of evolution. Three conclusions can be drawn from this 
pattern. First, evolution leads to substantial adaptation, with changes of more than three orders 
of magnitude in relative MIC. Second, mutation rate and recombination do not affect the final 
level of adaptation (mutation rate: Mann-Whitney U = 24, P = 0.295; recombination: U = 18, 
P = 1). Third, the MIC levels do not significantly increase from the second to the third round 
of evolution (Sign test comparing MIC between round 2 and 3, P = 0.754; comparison of MIC 
between round 1 and 2, P < 0.001), suggesting that most lines approach a fitness peak.  
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Figure 2.1:  Average relative log change in cefotaxime resistance over the three evolutionary rounds. 
 
The amino acid substitutions encountered in all twelve lines after the different rounds of 
evolution are shown in Table 2.1, together with the MIC values for all genotypes (see Figure 
2.3 for the location, in the three-dimensional structure of TEM-1, of amino acid residues at 
which substitutions were observed with high frequency). Seven of the twelve lines seem to 
follow a preferred mutational pathway involving substitutions E104K, M182T and G238S 
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(from here on referred to as the ‘G238S-based pathway’). The combination of these three 
substitutions has been reported as the evolutionary end-point in several other directed 
evolution studies on increased Ctx resistance of TEM-1 (ZACCOLO and GHERARDI 1999; 
ORENCIA et al. 2001; KOPSIDAS et al. 2007).  
Five lines deviate from this pattern in that they lack one or two of the three substitutions 
present in the G238S-based pathway. The MIC levels of these lines are significantly lower 
than those of the seven lines that do contain the three substitutions (Mann-Whitney U = 0, P = 
0.002), suggesting that they approach one or more peaks of lower fitness than the G238S-
based pathway. We were interested whether sign epistatic interactions between early 
substitutions present in these lines and substitutions from the G238S-based pathway could be 
responsible for the observed deviations in mutational pathways and whether such 
substitutions could lead evolution to alternative adaptive peaks. We focussed on the three 
lines that contain only one of the three substitutions of the G238S-based pathway (lines 3, 4 
and 7 in Table 2.1) and screened their first round alleles for candidate substitutions with 
such properties. Since lines 3 and 4 are the only ones lacking substitution G238S, we 
suspected that they harbour a substitution with a sign epistatic interaction with G238S. 
Substitution R164S, present in line 3, is expected to show such a sign epistatic interaction 
with G238S (ZACCOLO and GHERARDI 1999; GIAKKOUPI et al. 2000). At the same time, this 
substitution confers a considerable increased resistance when present alone (ZACCOLO and 
GHERARDI 1999) and therefore it might function as the first substitution of a putative 
alternative mutational pathway. In experimental line 4, substitution A237T is considered to be 
the most likely candidate, because the substitution (i) is physically close to G238S (ii) 
frequently occurs in clinical isolates and (iii) has never been found in combination with 
G238S in clinical isolates (http://www.lahey.org/studies/temtable.asp). A237T confers both a 
slightly increased MIC (GIAKKOUPI et al. 2001) and increased Kcat/ Km values for Ctx 
(CANTU et al. 1997) suggesting that this substitution is individually accessible to selection. 
We constructed the single mutants A237T and G238S as well as the double mutant A237T/ 
G238S. A comparison of the MICs of TEM-1 (0.0625 µg Ctx/ ml), the single mutants A237T 
(0.125 µg/ ml) and G238S (1.0 µg/ ml) and the double mutant A237T/ G238S (0.125 µg/ ml), 
suggests that A237T has a sign epistatic interaction with G238S while being individually 
adaptive. Like R164S, this substitution might therefore be a starting substitution of an 
alternative mutational pathway. 
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Table 2.1: Amino acid substitutions in evolved TEM alleles. Substitutions fixed after the first round 
are in bold, those fixed after the second round are in italic and those fixed after the third round are 
underlined. 
a Position in the coding sequence, numbering according to Sutcliffe (1978). 
b Substitutions are shown as the TEM-1 amino acid according to the IUPAC single-letter code (left), the position 
in the protein as numbered in Ambler et al. (1991) (middle), and the mutant amino acid (right). A dash at the 
position of the mutant amino acid indicates a (new) stop-codon. 
c The mutation causing this substitution disappeared after the second round of evolution and selection 
d The mutation causing this substitution disappeared after the third round of evolution and selection 
e Median value across three replicates 
 
 
Like line 3 and 4, line 7 deviates from the other lines in that it lacks both E104K and M182T. 
Because substitution G238S is present in line 7 in the first round of evolution, another first-
round substitution must have been responsible for the deviating mutational pathway of this 
line. Of the two possible substitutions (A184V and R191H), we expected that A184V was 
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adaptive in the TEM-1 background carrying G238S, because we observed this combination 
after a single round of evolution in two pilot experiments before. To investigate whether the 
single mutants R164S and A237T or the double mutant A184V/ G238S would prevent the 
(other) substitutions of the G238S-based pathway from occurring, we constructed TEM-1 
alleles carrying these substitutions and subjected them to three rounds of ep-PCR and 
selection for increased Ctx resistance with fivefold replication. The mutation rate was set to 
introduce on average ~2 mutations per amplicon per ep-PCR and extra recombination was 
omitted this time. The average library-size was ~5.9 x 10
4
 for the libraries of mutant R164S, 
~6.9 x 10
4
 for the libraries of mutant A237T and ~1.0 x 10
5
 for the libraries of double mutant 
A184V/ G238S. The average mutation rate was 2.23 (± 0.0) (R164S), 2.23 (± 0.0) (A237T) 
and 2.51 (±0.22) (A184V/ G238S). The amino acid substitutions and MIC-values recorded 
after each round of evolution and selection can be found in Tables 2.2 (R164S and A237T 
mutants) and 2.3 (A184V/ G238S double mutant). 
 
MIC levels 
Figure 2.2 shows the changes in mean MIC values for each of the three constructed mutants 
together with those of the seven lines following the G238S-based pathway of the previous 
experiment. Two conclusions can be drawn from these changes in MIC.  First, after an initial 
rise (Sign test comparing all 15 lines for first two rounds, P = 0.001), MIC values level off 
(Sign test, P = 0.453), suggesting that they approach an adaptive peak. Second, despite their 
head start, the final resistance reached by these lines is significantly lower than that reached 
by the G238S-based lines of the previous experiment (R164S lines: Mann-Whitney U = 35, P 
= 0.002; A237T lines: U = 35, P = 0.002; A184V/G238S lines: U = 35, P = 0.002). The final 
MIC values do not vary significantly among the three types of lines (Kruskal-Wallis statistic = 
3.404, P = 0.182), although the difference between the 10 single-substitution and the five 
double-substitution lines approaches significance (U = 10.5, P = 0.065).  This suggests that 
evolution leads to one or more peaks that differ from the peak approached by the G238S-
based lines.  To verify whether these lines follow adaptive trajectories different from the 
G238S-based trajectories and leading to different local peaks, we then looked at the 
mutational pathways involved for each of the three constructed mutants. 
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R164S mutant 
The absence of M182T and G238S in all five, and E104K in four of the five lines containing 
R164S (see Table 2.2) strongly suggests that R164S hampers the selection of these 
substitutions involved in the G238S-based pathway. The substitutions present in the final 
genotypes of the R164S mutant differ almost completely from the substitutions observed in 
the seven lines following the G238S-based pathway in the first experiment. The repeated 
observation in independent lines suggests that substitutions A237T, E240K, R241H and 
I173V are unique adaptive mutations in this background.  
 
A237T mutant 
None of the five lines carrying A237T acquires substitution G238S, while only in one line 
E104K is found after three rounds of evolution. However, different from the R164S 
background, M182T is found in four lines. A general pattern in all lines is that they contain 
substitutions in the functionally important Ω-loop (positions 161-179) after the initial round of 
evolution. Most of the substitutions again differ from the ones encountered in the lines 
following the G238S-based mutational pathway (see Table 2.1). Therefore, while the 
pathways observed here show some overlap with the G238S-based pathway and particularly 
with the R164S-based pathways (see Table 2.2) they also involve substitutions that are unique 
to this genetic background.  
 
A184V/ G238S double mutant 
Contrary to what was expected, E104K appears in three of the lines carrying A184V/ G238S. 
Substitution M182T remains absent in all experimental lines, indicating that this substitution 
has become selectively neutral or deleterious in the background of A184V and G238S, 
perhaps because A184V is functionally similar to M182T. When line 7 from Table 2.1 is 
included, three parallel changes can be observed next to E104K; I208M, E240K and T265M, 
none of which were observed in the seven lines following the G238S-based pathway (see 
Table 2.1). Therefore, although some mutations are shared with the G238S-based pathway, 
the mutational pathways followed by this background seem to lead to one or more adaptive 
peaks that are different from the one approached by the G238S-based pathway. 
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Table 2.2: Amino acid substitutions in evolved, mutant TEM-alleles containing R164S (left) and 
A237T (right). Substitutions present at the start of the experiment are in normal text and shaded, 
substitutions fixed after the first round are in bold, those fixed after the second round are in italic and 
those fixed after the third round are underlined. 
 
Amino acid substitutionb 
D
N
A
 s
it
ea
  
  
  
  
M
u
ta
ti
o
n
 
1 2 3 4 5 1 2 3 4 5 
22 G > A     V10I      
65 T > G F24C          
74 C > T          P27L 
107 A > G  D38G         
110 A > G       Q39R    
257 A > T    Q88L       
284 A > T     Y97F      
294 T > G  N100K         
304 G > A    E104K      E104K 
366 T > G S124R          
379 A > T    M129L       
482 A > T        D163V   
484 C > T      R164Cc     
484 C > A R164S R164S R164S R164S R164S  R164S    
485 G > A      C164Y    R164H 
487 T > G        W165G   
500 T > C         L169P  
511 A > G I173V  I173V        
512 T > C       I173T    
517 A > T          N175Y 
533 C > G  T180S         
539 T > C      M182T  M182T M182T M182T 
544 G > A    A184T       
557 C > T   T188I        
568 A > G          K192E 
570 A > T       K192N    
583 G > A E197K          
596 T > C    L201P   L201P    
640 G > A    V216I     V216I  
643 G > T        A217S   
665 C > T    A224V  A224V  A224V   
697 T > A S235T          
703 G > A  A237T A237T  A237T A237T A237T A237T A237T A237T 
709 G > A E240K E240K E240K  E240K  E240K    
713 G > A  R241H   R241H      
730 A > G    I247V       
737 C > T    A249V       
756 G > T   K256N        
782 C > T  T265M         
788 G > T    G267V       
790 A > G     S268G      
821 A > G    Q278R       
859 T > A end291K          
            
Round  MIC valued 
1  4 8 4 16 8 4 32 1 8 4 
2  16 64 32 16 64 32 32 8 8 64 
3  16 32 32 16 128 64 32 16 16 64 
 
a Position in the coding sequence, numbering according to Sutcliffe (1978) 
b Substitutions are shown as the TEM-1 amino acid according to the IUPAC single-letter code (left), the position 
in the protein as numbered in Ambler et al. (1991) (middle), and the mutant amino acid (right) 
c Changed into 164Y after the third round of evolution and selection 
d Median value across three replicates in µg Ctx/ ml 
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Table 2.3: Amino acid substitutions in evolved, mutant TEM-alleles containing A184V and G238S. 
Substitutions present at the start of the experiment are in normal text and shaded, substitutions fixed 
after the first round are in bold, those fixed after the second round are in italic and those fixed after the 
third round are underlined.  
 
  Amino acid substitutionb 
DNA sitea Mutation 1 2 3 4 5 
315 A > T     D38V 
317 C > A    Q39K  
327 C > G    A42G  
345 A > T E48V     
347 C > A     L49M 
512 G > A E104K E104K   E104K 
534 A > T  K111M    
660 A > G  H153R    
661 C > G   H153Q   
725 A > G     N175D 
753 C > T A184V A184V A184V A184V A184V 
826 A > G  I208M I208M   
839 G > C   A213P   
914 G > A G238S G238S G238S G238S G238S 
917 G > A   E240K E240K  
990 C > T   T265M   
       
Round  MIC valuesc 
1  32 32 8 64 8 
2  64 128 8 128 32 
3  32 128 128 128 32 
 
a Position in the coding sequence, numbering according to Sutcliffe (1978) 
b Substitutions are shown as the TEM-1 amino acid according to the IUPAC single-letter code (left), the position 
in the protein as numbered in Ambler et al. (1991) (middle), and the mutant amino acid (right) 
c Median value across three replicates in µg Ctx/ ml 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.2: Average relative log change in cefotaxime resistance over the three evolutionary rounds 
for the seven E104K/ M182T/ G238S containing lines from table 2.1 and the mutants containing 
R164S, A237T and A184V/ G238S. 
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2.4 Discussion 
 
The exact shape of the fitness landscape has important implications for many questions in 
evolutionary biology, including the causes of evolutionary constraints, the evolution of 
diversity and speciation, and the evolutionary significance of sex and recombination. Here we 
showed that, using in vitro evolution, the fitness landscape of TEM-1 ß-lactamase is rugged 
for adaptation to a novel antibiotic. We found that while most experimental lines acquire three 
amino acid substitutions leading to a high level of resistance, some lines acquire other 
substitutions and reach lower levels of adaptation. When we introduced some of the early 
substitutions observed in the lines with exceptional substitutions and selected these alleles for 
increased resistance, the three substitutions of the preferred pathway were avoided in most 
cases. These results therefore indicate that sign epistatic interactions between early mutations 
that individually increase resistance can make evolution contingent upon early substitutions, 
which can drive evolution towards different adaptive peaks. Which peak is approached 
depends on the epistatic properties of early substitutions. We found that escape from local 
peaks was not possible, despite our high mutation rate which allowed multiple mutations to 
fix in a single round of evolution.  Finally, we showed that not only the first, but also later 
substitutions are involved in negative interactions with subsequent mutations. 
 
What exactly is the highest fitness peak of TEM-1 for increased cefotaxime resistance? 
As indicated before, the main difference between the most Ctx resistant mutants identified in 
this study and the most Ctx resistant mutant known from literature (which was identified by 
DNA-shuffling (STEMMER 1994) and subsequent step-by-step reconstruction of evolutionary 
intermediates (HALL 2002)) is the absence of substitution A42G in our study. According to 
literature, addition of A42G to an E104K/ M128T/ G238S background should increase Ctx 
MIC levels 8- to 32-fold (HALL 2002; WEINREICH et al. 2006). However, the A42G 
substitution does not occur in the background of these three substitutions in our experiments 
and even a single round of ep-PCR and selection using the triple mutant E104K/ M182T/ 
G238S as template in fivefold replicate did not yield this substitution. Apart from the DNA-
shuffling experiment by Stemmer (1994), none of the experimental or directed evolution 
studies on increased Ctx resistance of TEM-1 has identified the fourfold mutant containing 
A42G, though several studies have identified the E104K/ M182T/ G238S triple mutant that 
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was frequently encountered in our experiments (ZACCOLO and GHERARDI 1999; ORENCIA et 
al. 2001; KOPSIDAS et al. 2007).  All in all, it seems that in our experimental setup and in that 
of most others, the peak for Ctx resistance is the E104K/ M182T/ G238S triple mutant. 
Although minor adaptive substitutions may be added in this background (notice the parallel 
changes at residues 10 and 19 in the background of the triple mutants in Table 2.1 for 
example), they do not seem to noticeably increase Ctx resistance and therefore it seems 
reasonable to assume that E104K/ M182T/ G238S is approximately the evolutionary endpoint 
when selecting for increased Ctx resistance.  
 
Height of the alternative fitness peaks 
The MIC levels reached by both the R164S and A237T mutants (~32 µg/ ml) are considerably 
lower than those of the E104K/ M182T/ G238S-containing mutants in experiment I (~256 µg/ 
ml). This indicates that whatever substitution is selected first can not only force evolution 
onto different evolutionary trajectories, but also lead evolution to lower fitness peaks. 
Interestingly, clinical isolates of R164S/ A237T/ E240K (TEM-5) and E104K/ M182T/ 
G238S (TEM-52) exist. Although no direct comparison has been made between these two 
alleles, TEM-5 has been compared to TEM-3 (Q39K/ E104K/ G238S) in an isogenic E. coli 
background (BRADFORD and SANDERS 1995). Since Q39K is generally assumed to be neutral 
(KNOX 1995), TEM-3 is comparable to the E104K/ G238S double mutant and despite the fact 
that this mutant does not contain M182T, its MIC for Ctx is already much higher than that of 
the R164S/ A237T/ E240K mutant (32 vs 4 µg/ ml) (BRADFORD and SANDERS 1995). This 
strengthens our conclusion that the adaptive peak for Ctx resistance reached by the G238S-
based route is considerably higher than those reached by the R164S- and A237T-based routes.  
 
Accessibility of the alternative pathways 
In nature, mutations most probably go to fixation one at a time, assuming that the time to 
fixation for a particular mutation is much lower than the time between the occurrence of 
successive mutations (GILLESPIE 1984). This is in contrast with our experimental setup where 
often two or three mutations go to fixation at the same time. In the presence of sign epistatic 
interactions between these mutations (for example when two mutations have a neutral or 
negative effect on fitness when individually present, but a positive effect when combined) this 
could uncover pathways that are not accessible to standard ‘one-by-one’ selection. Previous 
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analysis has shown that the G238S-based pathway, which was repeatedly found in our initial 
experiment, is accessible to Darwinian selection, although the order in which mutations 
appear is severely constrained (WEINREICH et al. 2006). Below, we briefly address the 
accessibility of the general pathway found for the R164S mutant, illustrated by data on 
evolutionary intermediates of this pathway that have previously been described.  
Substitution R164S is known to increase Ctx resistance when present in the TEM-1 
background (SOWEK et al. 1991; BLAZQUEZ et al. 1998; ZACCOLO and GHERARDI 1999; 
WANG et al. 2002), although the effect is less strong than that of G238S. It is known that 
addition of either E104K, M182T, A237T or E240K can further increase Ctx resistance in an 
R164S background (BLAZQUEZ et al. 1998; ZACCOLO and GHERARDI 1999). In agreement 
with this, E104K and E240K are observed in the background of R164S after the first round of 
evolution (once and four times respectively). Addition of A237T to either of these double 
mutants is also known to increase Ctx resistance (BLAZQUEZ et al. 1998; GIAKKOUPI et al. 
2001) and is observed in three of the four experimental lines containing R164S and E240K. 
Although we stress that more adaptive substitutions are present in our experiments (e.g. 
substitutions R241H and T265M appear independently in multiple lines), it is unknown 
whether these substitutions are part of accessible evolutionary pathways. Similar evidence for 
accessible evolutionary pathways in the A237T- and A184V/ G238S-based routes exists, on 
which we will not further elaborate here.  
 
R164S- and A237T-based pathways; one or two fitness peaks? 
When comparing the sequence data of the R164S- and A237T-based evolutionary trajectories 
towards increased Ctx resistance (Table 2.3) it is clear that the substitutions do not exclude 
each other; A237T appears in the background of R164S three times, while R164S appears in 
the background of A237T once (notice that in the background of A237T, two alternative 
substitutions occur at residue 164 as well). Therefore, it seems reasonable to ask the question 
whether the R164S- and A237T-based pathways ascend a single adaptive peak. Experimental 
line 2 of the A237T mutant (Table 2.3) contains several of the substitutions observed in the 
experiment with the R164S mutant (R164S, E240K), which suggests that a similar peak is 
reached while only the sequence of mutational events differs. However, the substitutions 
found in the other experimental lines of mutant A237T differ markedly from those reported 
for the R164S-based genotypes. For example, they all contain M182T which is absent in the 
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R164S-mutant lines.  In fact, even if we consider the alternative substitutions at residue 164 
(lines 1 and 5) equal to R164S, experimental lines 3 and 4 still show totally different 
mutations in the Ω-loop. After three rounds of evolution, these experimental lines show a 
considerable increase in MIC, but the substitutions they contain are completely different from 
those observed for the R164S-based pathway. This suggests that more than one accessible 
A237T-based pathway towards increased Ctx resistance exists for TEM-1. 
 
More constraints on TEM-1 evolution 
Clear indications for yet another constraint at the level of the second mutation (as found in the 
experiment on the A184V/ G238S mutant) exist. In the dataset of the R164S-mutant, four 
experimental lines fix E240K after the first round of evolution. Experimental line 4 however, 
contains E104K after the first round but lacks E240K even after the third round. This is 
consistent with the previous observation that, even though both E104K and E240K enhance 
Ctx resistance in the background of R164S, the triple mutant E104K/ R164S/ E240K has a 
lower MIC for Ctx than both double-mutants E104K/ R164S and R164S/ E240K (SOWEK et 
al. 1991). Since the additional substitutions gathered by line 4 differ greatly from those 
observed in the other four experimental lines, this seems to be a clear example of yet another 
constraint on evolution, caused by a sign epistatic interaction, this time at the level of the 
second substitution. 
 
Clinical relevance 
Here, we have focussed exclusively on the evolution of TEM-1 for increased Ctx resistance. 
In the ‘natural’ setting of TEM-1 and its derivatives, hospitals and clinics worldwide, many 
more antibiotic pressures are encountered (MEDEIROS 1997). The great variability in 
mutational trajectories observed in our experiments creates the possibility that in a setting 
with variable ß-lactam pressure different mutants may be successful due to their different 
pleiotropic effects with respect to various antibiotics. For example, even though the triple 
mutant E104K/ M182T/ G238S confers the highest Ctx resistance encountered here, it may 
show much less of an increase or even a decrease in resistance when challenged with a 
different ß-lactam. Conversely, the triple-mutant R164S/ A237T/ E240K, though seemingly 
stuck at a suboptimal peak concerning Ctx resistance, may ‘beat’ the E104K/ M182T/ G238S 
mutant when it concerns another ß-lactam. Such pleiotropic effects are nicely illustrated by 
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the side-by-side comparison of the resistance spectra of the R164S and G238S mutants; while 
G238S indeed gives a higher increase in MIC for Ctx, the situation is reversed for ceftazidime 
(another 3
rd
 generation cephalosporin) (GIAKKOUPI et al. 2000). Thus, temporal and spatial 
variation in the application of antibiotics may change the fate of TEM alleles with suboptimal 
adaptation to Ctx.  
 
A structural explanation for the sign epistatic interaction between R164S and G238S 
A previous analysis of the interaction between R164S and G238S (ZACCOLO and GHERARDI 
1999) revealed that addition of R164S decreased the MIC for Ctx in a series of backgrounds 
containing G238S, while vice versa the addition of G238S appeared to be neutral in all these 
backgrounds except in the background of R164S itself (Table 2.4). These data suggest that 
R164S, presumably because it is translated first, dominates the folding of ß-lactamase, 
thereby neutralizing the effect of G238S.  
 
Table 2.4: Effect of addition of R164S and G238S to various genetic backgrounds. Data reproduced 
from Zaccolo and Gherardi (1999). Additional data from Giakkoupi et al. (2000) are in parentheses. 
 
   Relative increase in MIC compared to genotype reported on the left 
   Addition of R164S Addition of G238S 
TEM-1   20 (17) 78 (33) 
E104K   4 16 
R164S    -4 (-8) 
M182T   625 1250 
G238S   -16 (-17)  
E104K R164S   0 
E104K G238S  -32  
M182T R164S   0 
M182T G238S  -2  
E104K R164S M182T  0 
E104K M182T G238S -32  
 
Detailed analysis of the effect of various substitutions at residue 238 on kinetic parameters for 
different antibiotics indicates that the most likely effect of G238S is alteration of the active 
site configuration by repositioning of the Ω-loop. The larger Ser-238 side chain can be 
positioned towards the Ω-loop as a result of a new hydrogen bond of Ser-238 to Asn-170, 
causing perturbation of the loop and of the deacylation residue Glu-166 (CANTU and 
PALZKILL 1998). The most widely accepted explanation for the structural effect of R164S also 
involves perturbation of the Ω-loop and Asn-170; X-ray crystallography of a mutant TEM 
containing E104K, R164S and M182T has revealed that substitution R164S introduces a  
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Figure 2.3: Three-dimensional structure of TEM-1 ß-lactamase (PDB-code: 1BTL) with a cefotaxime 
molecule modelled in the binding site. Some important amino acid residues mentioned in the text have 
been indicated. The active site residue at position 70 has also been indicated. Residue numbering 
according to Ambler et al. (1991). 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
Figure 2.4: Left: the three-dimensional structure of TEM-1 ß-lactamase (PDB-code: 1BTL) with in 
black the Ω-loop of a TEM-mutant containing substitution R164S (PDB-code: 1JWZ, this mutant 
contains E104K and M182T additionally). Right: a magnification of the boxed area of the left figure 
showing the two Ω-loops and the repositioning of the asparagine at residue 170 compared to the 
glycine at residue 238. Residue numbering according to Ambler et al. (1991). 
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packing defect in the Ω-loop, due to loss of hydrogen bonds to Glu-171 and Asp-179 (Figure 
2.4). As a result, Asn-170 flips by almost 180° and fills the cavity created by substitution of 
the large Arg-164 by the smaller Ser. In turn, the small 310 helix (168-170) unwinds and 
leaves a cavity in the active site, which is thought to create space for the more bulky oxyimino 
side chains of third generation cephalosporins like Ctx (WANG et al. 2002). These 
observations provide an explanation for the negative epistatic interaction between R164S and 
G238S; if the structural changes brought about by substitutions of Gly-238 are not only the 
result of steric hindrance between Ser-238 and the Ω-loop, but also depend on formation of a 
new hydrogen bond between this residue and Asn-170 on the Ω-loop in order to stabilize the 
new configuration (as suggested in Cantu and Palzkill 1998), substitution G238S may lose its 
effect when the position of the Ω-loop and Asn-170 has already been altered by another 
substitution like R164S. This could either be due to loss of the stabilizing hydrogen bond 
between Ser-238 and Asn-170 as a result of repositioning of the Ω-loop, or because this loop 
is repositioned in such a way by R164S that substitution G238S no longer results in steric 
conflict.  
 
In conclusion, we have shown that sign epistatic interactions can give rise to multiple peaks of 
different height in the fitness landscape of a single gene, which poses constraints on the 
mutational pathways followed by replicate lines. These interactions do not only occur at the 
level of the first substitution, but can also occur later on. The fact that such interactions do not 
seem to be rare suggests that the ruggedness of the fitness landscape is pervasive. A rugged 
fitness landscape has so far only been demonstrated using experimental evolution of a phage 
(BURCH and CHAO 2000), but indirect evidence exists indicating that ruggedness may be a 
more general feature of fitness landscapes (KORONA et al. 1994; ROZEN 2008). Although we 
can not extrapolate our findings to the level of organisms, contrary to the aforementioned 
studies, we can make a clear link between genotype and phenotype and in this way 
demonstrate that sign epistatic interactions are responsible for the observed ruggedness of the 
fitness landscape. 
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Abstract: TEM-1 ß-lactamase is one of the most notorious and widespread antibiotic 
resistance determinants around. It confers resistance to penicillins and early cephalosporins 
and has shown an astonishing functional plasticity in response to the introduction of novel 
drugs derived from these antibiotics. Ever since its discovery in the 1960s, over 150 variants 
of TEM-1 - differing in their amino acid sequence and often in their resistance phenotype - 
have been isolated in hospitals and clinics worldwide. Next to this well-documented ‘natural’ 
evolution, the in vitro evolution of TEM-1 has been the focus of attention of many 
experimental and directed evolution studies. In this review we compare the substitutions 
found in clinical TEM-isolates to those found in laboratory studies in order to address the 
question to what extent the evolution of antibiotic resistance can be repeated or even predicted 
under laboratory conditions. We find that laboratory evolution has very accurately repeated 
the natural evolution of TEM-1 at many residues, and we present a list of substitutions found 
frequently in experimental isolates that have not (yet) been found in clinical isolates, but may 
predict their future evolution. 
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3.1 Introduction 
 
The TEM ß-lactamases are among the best-studied antibiotic resistance enzymes around. 
They are the main cause of bacterial resistance to penicillins, cephalosporins and related 
antibiotics and they are found at high frequencies in hospitals and clinics around the world 
(MEDEIROS 1997; MATAGNE et al. 1998). TEM-1, the ancestor of this family, was first 
isolated from penicillin-resistant bacteria in the 1960s (DATTA and KONTOMICHALOU 1965). 
In response to the introduction of new antibiotics, TEM-1 has given rise to over 150 
descendants ever since. All of these descendants differ in amino acid sequence and in most 
cases they also differ in resistance phenotype (the degree of resistance to different antibiotics). 
While TEM-1 only confers resistance to penicillins and early cephalosporins, the resistance 
spectrum of the TEM-family of ß-lactamases has fanned out to 2
nd
 and 3
rd
 generation 
cephalosporins, monobactams and penicillin-inhibitor combinations. Typically, within three 
years after the introduction of a new antibiotic, TEM-1 descendants have evolved the ability 
to hydrolyze the new drug (MEDEIROS 1997).  
The detailed description of the natural evolution of TEM-alleles combined with the 
experimental ease of selecting for increased antibiotic resistance has made TEM-1 an 
interesting tool for directed evolution studies, where it has been used to explore the potential 
of novel in vitro evolution methods for protein engineering (STEMMER 1994; ZACCOLO and 
GHERARDI 1999; LONG-MCGIE et al. 2000; CAMPS et al. 2003; FUJII et al. 2004; KOPSIDAS et 
al. 2007). The remarkable results of the first directed evolution experiment on TEM-1 
(STEMMER 1994) did not go unnoticed, and the potential of using in vitro evolution to repeat 
or even predict the natural evolution of TEM-1 was recognized soon after (VAKULENKO et al. 
1998). At a later stage, in vitro evolution protocols were further fine-tuned in order to mimic 
natural evolution more accurately (BARLOW and HALL 2002). 
A question that remains is to what extent laboratory evolution can repeat or predict the 
natural evolution of antibiotic resistance. One of the main problems in addressing this 
question is that, contrary to the controlled conditions in the laboratory, the exact selective 
conditions in nature are almost always unknown. In recent years however, the spectrum of 
selective agents used in experimental studies has broadened to such an extent that a direct 
comparison between clinical and laboratory isolates of TEM-alleles seems legitimate (see 
Table 3.2). Moreover, both the number of clinically isolated TEM-alleles described and the 
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amount of data on the laboratory evolution of TEM-1 has grown enormously.  
Here, we compare the amino acid substitutions found in all known clinical TEM-isolates to 
those found in 17 different laboratory experiments that have looked at the directed or 
experimental evolution of TEM-1. We analyze to what extent laboratory evolution can be 
used to repeat the natural evolution of TEM-1 ß-lactamase. In addition, we also try to identify 
substitutions that are frequently encountered in laboratory isolates but that have not been 
identified in clinical isolates, in order to predict substitutions that might be encountered in 
clinical isolates yet to be identified. Since a lot of substitutions occur in just a few clinical 
isolates and since their effect is often unknown, we also use both datasets to make an 
inventory of exactly which substitutions are involved the in extension of the resistance 
phenotype of TEM-1.   
 
Terminology 
TEM-variants that differ in their amino acid sequence are referred to as ‘TEM-alleles’ here, 
although this does not necessarily imply a difference in resistance phenotype. We use the term 
‘clinical isolates’ to describe the ~150 different TEM-alleles that have been isolated from 
patients in hospitals and clinics worldwide. Since the variation present in clinical isolates of 
TEM-alleles is the direct result of genetic drift and natural selection for resistance to (novel) 
antibiotics, we here use the term ‘natural evolution’ to describe the process by which these 
clinical isolates have arisen. Mutant TEM-alleles have also been identified in studies that 
mimic this process under laboratory conditions, for which we here use the term ‘laboratory 
evolution’. We distinguish two types of laboratory evolution; ‘experimental evolution’ (which 
uses in vivo evolution by growing bacteria carrying TEM-1 in the presence of increasing 
amounts of antibiotics) and ‘directed evolution’ (which relies on in vitro mutagenesis 
techniques to create variation in TEM-1 and subsequently subjects the mutant alleles to in 
vivo selection). Specific substitutions are here referred to by the TEM-1 amino acid according 
to the IUPAC single-letter code, the number of the amino acid residue (AMBLER et al. 1991) 
and the respective mutant amino acid (e.g.; ‘G238S’ indicates that the glycine residue at 
position 238 was substituted for a serine residue).  
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Data included 
Clinical isolates 
The data on clinical TEM-isolates were collected from the Lahey database 
(http://www.lahey.org/studies/temtable.asp, as updated on June 10
th
 2008), which contains an 
up to date list of the amino acid substitutions present in all known (~150) clinical TEM-
isolates with a unique amino acid sequence. Two alleles (TEM-41 and TEM-69) were left out 
of the analysis since their sequences have been withdrawn. Three other alleles (TEM-116, 157 
and 162) contain substitutions V84I and A184V, which have been introduced into TEM-1 by 
site directed mutagenesis in order to remove restriction sites (SHORT et al. 1988; CHAIBI et al. 
1997). The TEM-allele that contains both substitutions has been identified as a contamination 
in Taq-polymerase (KONCAN et al. 2007). Both substitutions were therefore ignored in the 
analysis, but other substitutions occurring in their background in TEM-157 and TEM-162 
have been included.  
 
Laboratory isolates 
The data of seventeen laboratory studies have been included in this review (Table 3.1), and 
they are divided in four different categories: (i) twelve studies selecting for increased 
resistance to one or more ß-lactam antibiotics, (ii) two studies selecting for increased 
resistance to a ß-lactam - inhibitor combination, (iii) one study selecting for retention of 
ampicillin resistance and regain of this resistance after the introduction of a single deleterious 
mutation and (iv) two studies selecting for restored ampicillin resistance after structural 
perturbation.  
Not all studies have used TEM-1 as the starting point of evolution and selection. Some of 
the studies have used the previously described TEM-variant that contains substitutions V84I 
and A184V. Reverse substitutions at these amino acid residues have been ignored in this case. 
One study has partially used TEM-variants containing a single adaptive substitution (Salverda 
and de Visser unpublished), while another study partially used a TEM-variant containing 
a single maladaptive substitution(BERSHTEIN et al. 2008). In both cases, these substitutions 
were not counted. The two structural perturbation studies differ from the other studies 
analyzed here in that they first used circular permutation (OSUNA et al. 2002) and N-terminal 
truncation (HECKY and MULLER 2005) to create crippled TEM-1 variants that had lost their 
native ampicillin resistance. Directed evolution was subsequently used to select for 
 
 Table 3.1: Laboratory studies included.  
 
Reference # Alleles 
a 
Selective agent(s) 
b 
Experimental technique 
    
Antibiotic resistance    
Stemmer 1994 1 Ctx  Directed evolution; DNA-shuffling 
Zaccolo and Gherardi 1999 7 Ctx  Directed evolution; high-frequency random mutagenesis 
Long-McGie et al. 2000 2 Ctx  Experimental evolution; phagemid in hypermutator E. coli strains KH1366 and VS03 
Blazquez et al. 2000 18 Caz, Amx  Experimental evolution; E. coli strain K12 
Orencia et al. 2001 1 Ctx  Directed evolution; hypermutator E. coli combined with DNA-shuffling  
Barlow and Hall 2002 9 Caz, Ctx, Cxm, Atm c  Directed evolution; error-prone PCR (Mutazyme I) 
Barlow and Hall 2003 8 Fep  Directed evolution; error-prone PCR (Mutazyme I) 
Camps et al. 2003 2 Atm  Directed evolution; in vivo error-prone DNA-replication 
Fujii et al. 2004 3 Caz  Directed evolution; error-prone Rolling Circle Amplification 
Holloway et al. 2007 4 Amp, Ctx  Experimental evolution; E. coli strain W3110 
Kopsidas et al. 2007 1 Ctx  Directed evolution; error-prone RNA-replication 
Salverda et al. unpublished 64 Ctx  Directed evolution; error-prone PCR (Mutazyme I & II) 
    
Antibiotic-inhibitor resistance    
Vakulenko et al. 1998 1 Amp, Clavulanate d Directed evolution; error-prone PCR (MgCl2- and MnCl2-based) 
Vakulenko and Golemi 2002 1 Caz, Clavulanate d Directed evolution; error-prone PCR (MgCl2- and MnCl2-based) followed by DNA-
shuffling 
    
Retention and regain of  resistance    
Bershtein et al. 2008 2 Amp  Directed evolution; error-prone PCR (wobble base analogues) 
    
Structural perturbation    
Osuna et al. 2002 2 Amp  Directed evolution; DNA-shuffling 
Hecky and Müller 2005 1 Amp  Directed evolution; DNA-shuffling followed by error-prone PCR (MgCl2- and MnCl2-
based) 
 
a Number of independent alleles present in the respective study (see text).  
b Abbreviations used; Amx, amoxicillin; Atm, aztreonam; Caz, ceftazidime; Ctx, cefotaxime; Cxm, cefuroxime;  Fep, cefepime. 
c In addition to resistance to these drugs, mutated alleles were submitted to selection for retention of resistance to ampicillin, pipericillin and cephalotin. 
d ß-lactam inhibitor. 
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substitutions restoring this resistance. Structural perturbation followed by directed evolution 
is an efficient way of analyzing thermostability and finding thermo-stabilizing mutations 
(HECKY and MULLER 2005). Since protein evolution is considered to be prone to activity-
stability tradeoffs, stabilizing mutations are thought to play an important role by 
compensating the destabilizing effects of primary mutations that increase activity but decrease 
stability (DePristo et al. 2005). In TEM-1, such interactions have been demonstrated for 
mutations that increase cefotaxime resistance (WANG et al. 2002). Therefore, despite the fact 
that the structural perturbation studies have used TEM-variants with a rather aberrant amino 
acid sequence, we consider it informative to include these studies in the review presented 
here, as they posses the potential to localize a class of mutations that clearly plays an 
important role in the evolution of TEM-1 mediated antibiotic resistance.  
Most of the studies analyzed here use truly independent libraries (directed evolution) or 
selection lines (experimental evolution), and therefore substitutions found in different 
libraries or lines can be considered independent. However, in some directed evolution studies 
a single pool of mutagenized amplicons was screened by plating transformants on selective 
agar immediately after transformation, thus preventing competition between clones. As a 
consequence, the isolated clones, though differing in the exact substitutions they carry, are not 
independent products of evolution, since a substitution present in two clones can originate 
from one and the same mutational event. Therefore, substitutions were scored only once, no 
matter how many different clones were found to contain a particular substitution in such 
studies (VAKULENKO et al. 1998; ZACCOLO and GHERARDI 1999; OSUNA et al. 2002; HECKY 
and MULLER 2005; BERSHTEIN et al. 2008). Finally, whenever genotypes were characterized 
after each cycle of evolution and selection in an experiment, substitutions absent in the final 
genotype but present in a genotype characterized after one of the preceding cycles were 
included in the dataset.  
 
Clinical and laboratory selection-spectra 
The majority of clinical TEM-isolates that have been phenotypically characterized are so-
called ‘extended spectrum ß-lactamases’, meaning that they have evolved the ability to break 
down more modern ß-lactam antibiotics or ß-lactam - inhibitor combinations, to which TEM-
1 is highly sensitive. The exact selection regimes that have preceded the appearance of these 
alleles are almost always unknown. The antibiotics used in the 17 experimental studies 
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reviewed here include several modern cephalosporins, a monobactam and two ß-lactam - 
inhibitor combinations (ampicillin - clavulanate and ceftazidime - clavulanate). An overview 
of the antibiotics and inhibitors used in the laboratory studies is given in Table 3.2.  
 
Table 3.2: Antibiotics used in laboratory studies and their classification. 
 
ß-lactam family ß-lactam sub-family ß-lactams used in laboratory studies
 
Penicillins Narrow spectrum - 
 Narrow spectrum penicillinase-resistant - 
 Narrow spectrum ß-lactamase-resistant - 
 Moderate spectrum Ampicillin , amoxicillin  
 Broad spectrum - 
 Extended spectrum Pipericillin 
   
Cephalosporins First generation Cephalotin 
 Second generation Cefuroxime  
 Third generation Cefotaxime, ceftazidime  
 Fourth generation Cefepime  
   
Carbapenems - - 
   
Monobactams  - Aztreonam  
   
ß-lactamase inhibitors - Clavulanate  
 
3.2 Results and discussion 
 
The primary objective of this study is to analyze to what extent laboratory evolution can 
identify amino acid substitutions found in clinical isolates of TEM-alleles that are known to 
contribute to an extended resistance phenotype. Three factors hamper the straightforward 
comparison of amino acid substitutions found in nature and experiments.  
First, the functional significance of alternative amino acid substitutions at the same 
position is unclear. Whenever substitutions at a certain amino acid residue occur both in 
nature and in experiments but the exact substitutions differ between the two, it is important to 
know whether or not this implies a functional difference. Laboratory evolution shows that 
various alternative substitutions at the same position can be selected when a single selective 
agent is used, indicating that alternative substitutions can have qualitatively similar 
phenotypic effects (BARLOW and HALL 2003; FUJII et al. 2004). On the other hand, a detailed 
phenotypic analysis of all possible substitutions at two amino acid residues in TEM-1 shows 
that alternative substitutions at one and the same locus can have quantitatively different 
effects on the degree of resistance (VAKULENKO et al. 1995; VAKULENKO et al. 1999). 
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However, since we have found no evidence for alternative substitutions at the same amino 
acid residue that have a completely different effect on resistance phenotype, we here assume 
that such alternative substitutions are functionally equivalent. The primary focus will 
therefore be on amino acid residues, while the specific substitutions at these residues will be 
addressed secondarily. 
Second, it is not clear whether all substitutions that can be found in the dataset of clinical 
isolates have arisen by natural selection. The majority of randomly introduced substitutions in 
the TEM-1 background is thought to be functionally neutral (PALZKILL and BOTSTEIN 1992; 
HUANG et al. 1996) and such neutral substitutions could occasionally end up in clinical 
isolates by genetic hitchhiking (BAQUERO et al. 1998). Despite the fact that most of the 
clinical TEM-isolates have been phenotypically characterized, the contribution of individual 
amino acid substitutions to the resistance phenotype is often unknown and as a consequence it 
can be unclear whether substitutions have truly arisen by selection.  
Third, methodological errors have led to the erroneous report of novel substitutions in the 
past and it can not be excluded that some unnoticed errors persist in the dataset of clinical 
isolates.  
 
An overview of the number of times substitutions have been found at different positions 
within the TEM-1 amino acid sequence in the datasets of clinical and laboratory isolates is 
shown in Figure 3.1. In total, 73 different substitutions were recorded at 50 different amino 
acid residues in clinical isolates while 245 different substitutions were recorded at 135 
amino acid residues in laboratory isolates (see supplementary Table 3.1). 
It is clear from Figure 3.1 that for a substantial fraction of the amino acid residues at which 
substitutions have been recorded in clinical isolates only one or two substitutions have been 
found, rendering these substitutions the suspicion of being adaptively neutral. The analysis of 
the 50 amino acid residues harbouring substitutions in clinical isolates is therefore split up in 
two main parts. We first analyze the group of 18 residues at which substitutions with a 
demonstrated effect on resistance phenotype have been found, i.e. increased catalytic 
efficiency values or MICs compared to TEM-1 (the location of these residues in the three- 
dimensional structure of TEM-1 is shown in Figure 3.2a). Based on the type of effect on 
resistance phenotype, we have split this group in three subgroups of residues harbouring 
(i) substitutions with an effect on ß-lactam resistance, (ii) substitutions with an effect on 
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Figure 3.1: Occurrence of substitutions in clinical and laboratory isolates of TEM ß-lactamase. The 
amino acid numbering according to Ambler (1991) is on the x-axis (note that residues 1, 2, 239 and 
253 do not exist in this numbering-scheme). Structural features of the enzyme according to Jelsch et 
al. (1993) are shown below these numbers (H = α-helix, S = ß-sheet). Substitutions occurring more 
than ten times in either of the two datasets are shown as occurring ten times here (see supplementary 
table 3.1 for exact frequencies). 
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resistance to ß-lactamase inhibitors and (iii) substitutions with an effect on both. Second, we 
analyze the group of 32 residues at which substitutions with unknown effect on resistance 
phenotype have been recorded in clinical isolates. Since several of these residues have been 
substituted in a single clinical isolate only, indicating that the respective substitutions might 
be functionally neutral (or erroneously reported), we have split this group up in two 
subgroups of residues substituted in (i) multiple clinical isolates and (ii) a single clinical 
isolate.     
 
Substitutions with demonstrated effect on resistance phenotype 
Most of the amino acid residues belonging to this group harbour substitutions that are found 
at high frequency in the dataset of clinical isolates and whose effect on resistance phenotype 
has been extensively studied (see Table 3.3 for an overview). While most of these 
substitutions play a role in extension of the resistance spectrum to more modern ß-lactam 
antibiotics, some have been shown to play a specific role in resistance to ß-lactamase 
inhibitors (drugs that bind to but do not hydrolyze ß-lactamases and that are often 
administered in combination with ß-lactam antibiotics). A third group of substitutions confers 
a more general effect and can increase resistance to both ß-lactams and inhibitors. We analyze 
to what extent these three types of substitutions were identified in laboratory isolates below. 
 
Substitutions involved in extension of the ß-lactam resistance spectrum 
Exactly which amino acid substitutions are involved in extension of the resistance spectrum 
of TEM-1 and how such substitutions influence the structure, function and stability of the 
enzyme has been intensively studied (KNOX 1995). Almost all substitutions that have been 
found with high frequency in clinical isolates and that have been shown to be involved in 
increasing resistance to more modern ß-lactam antibiotics (E104K, R164C, R164H, R164S, 
A237T, G238S and E240K) were identified in multiple experimental studies at high 
frequency (see Table 3.3). The only exception is substitution Q39K. This substitution has long 
been thought to be an example of neutral variation present in the TEM-1 background, though 
it was later shown to slightly but consistently increase the minimal inhibitory concentration 
(MIC) of ceftazidime and aztreonam (BLAZQUEZ et al. 1995), while it enlarges the catalytic 
efficiency values of a whole series of related antibiotics (CHAIBI  et al.  1996).  
Q39K is present in 32 clinical isolates and in a single experimental isolate that was identified 
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Figure 3.2:  Three dimensional structures of TEM-1 ß-lactamase (PDB-code: 1BTL). (A) Amino acid 
residues at which substitutions with a demonstrated effect on resistance phenotype have been found 
(listed in Table 3.3). (B) Amino acid residues at which substitutions are found with high frequency in 
experimental isolates but not in clinical isolates (listed in Table 3.6).  
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Table 3.3: The 18 amino acid residues at which substitutions with a demonstrated effect on resistance 
phenotype have been recorded in clinical isolates. Substitutions found at these residues in clinical and 
laboratory isolates are also shown. 
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39 Q39K 32 1  182 M182K 0 1 
 Q39R 0 2   M182L 0 1 
51 L51P 1 0   M182R 0 1 
 L51I 0 1   M182T 21 26 
 L51F 0 2   M182V 0 1 
69 M69I 4 0  237 A237G 1 0 
 M69L 12 1   A237T 8 6 
 M69V 19 0   A237S 0 2 
104 E104K 42 36  238 G238D 1 0 
 E104A 0 2   G238N 1 0 
 E104G 0 2   G238S 32 57 
 E104V 0 1   G238A 0 3 
130 S130G 3 1  240 E240K 25 13 
164 R164C 4 2   E240R 1 0 
 R164H 18 15   E240V 1 1 
 R164S 26 21   E240G 0 4 
 R164G 0 2  244 R244G 1 0 
 R164N 0 1   R244H 3 0 
 R164Y 0 1   R244L 1 0 
165 W165C 1 0   R244C 4 1 
 W165R 3 0   R244S 6 1 
 W165G 0 1  268 S268G 2 7 
173 I173V 1 12   S268N 0 1 
 I173L 0 1   S268T 0 1 
 I173R 0 1  275 R275A 2 0 
 I173T 0 2   R275L 3 1 
175 N175I 1 0   R275Q 4 1 
 N175D 0 5  276 N276D 12 3 
 N175Y 0 1   N276R 1 0 
179 D179E 1 0   N276S 1 1 
 D179G 0 4      
 D179Y 0 1      
 
 
after selection for increased cefotaxime resistance (Salverda and de Visser unpublished), 
while an alternative substitution at this position (Q39R) was recorded in the same experiment 
(Salverda and de Visser unpublished). The low frequency of TEM-2 (which differs from 
TEM-1 by the presence Q39K only) in clinical E. coli isolates compared to the frequent 
presence of Q39K in extended-spectrum TEM-alleles has lead to the suggestion that Q39K 
might provide host strains with better survival at low concentrations of certain cephalosporins 
or monobactams, thus increasing the possibility of acquisition of new substitutions 
(BLAZQUEZ et al. 1995). This effect might explain the low frequency of occurrence of this 
substitution in experimental studies where, due to more stringent selective conditions and 
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higher mutation rates (when directed evolution is involved), substitutions with large effects 
tend to dominate.  
What remains to be discussed are substitutions at four amino acid residues that have been 
shown to be involved in extending the resistance spectrum of TEM-1, but that nevertheless 
occur at low frequency in clinical isolates. These substitutions and substitutions found at these 
residues in laboratory isolates are discussed below.  
 
L51P 
Reversion of substitution L51P in the genetic background of the only clinical isolate it occurs 
in (TEM-60) was found to decrease both activity towards certain antibiotics and enzyme-
stability, which lead to the conclusion that the substitution plays a role in both activity and 
stability of the enzyme (CAPORALE et al. 2004). Alternative substitutions L51F and L51I have 
been found in experiments twice (Osuna et al. 2002; Salverda and de Visser unpublished) and 
once (OSUNA et al. 2002), respectively. It is interesting that two of the three alternative 
substitutions found at this position in experiments were identified in one of the structural 
perturbation studies, where they persisted in the clones characterized after multiple rounds of 
mutagenesis and selection (OSUNA et al. 2002). This suggests that L51F and L51I affect 
enzyme stability and are thus functionally synonymous to L51P. Interestingly, a wide variety 
of substitutions has been found at the adjacent residue 52 as well and it seems that these 
substitutions are also involved in increasing enzyme stability (HECKY and MULLER 2005; 
BERSHTEIN et al. 2008).   
 
I173V 
This substitution was found in two in vitro evolution studies (BARLOW and HALL 2002; 
BARLOW and HALL 2003) prior to the report of the first and only clinical isolate carrying this 
substitution (ZARNAYOVA et al. 2005). Interestingly, the substitution was later identified in 
two more experimental studies (Fujii et al. 2004; Salverda and de Visser unpublished), 
resulting in a total of 11 independent observations in laboratory studies. Alternative 
substitutions I173R (OSUNA et al. 2002) and I173T (Barlow and Hall 2002; Salverda and de 
Visser unpublished) were identified once and twice in experiments, respectively.  
The effect of I173V on resistance phenotype was already extensively tested after its 
identification in laboratory experiments, and although a number of ß-lactam antibiotics were 
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screened, the substitution was found to only increase resistance to the fourth generation 
cephalosporin cefepime (BARLOW and HALL 2003). The substitution was later identified in 
experimental studies using ceftazidime (FUJII et al. 2004) and cefotaxime (Salverda and de 
Visser unpublished) as sole selective agents, indicating a broader phenotypic effect. 
Therefore, this substitution may be expected to appear in future clinical isolates.   
 
N175I 
Despite the presence of N175I in a single clinical isolate only (TEM-138), the substitution is 
thought to be involved in increased ceftazidime resistance (CHOUCHANI et al. 2006). In 
experimental studies, alternative substitutions N175Y and N175D were found once and five 
times, respectively, the latter in three different studies (Barlow and Hall 2003; Bershtein et al. 
2008; Salverda and de Visser unpublished). Although the exact mechanism remains obscure, 
the high frequency at which these substitutions occur strongly suggests that substitutions at 
position 175 are involved in extending the resistance phenotype. The Ω-loop on which N175 
is present is involved in the formation of the active site pocket (JELSCH et al. 1993) and 
numerous substitutions within this loop are known to alter resistance phenotype. Substitutions 
at this residue could therefore appear in future clinical isolates.   
 
D179E 
Substitution D179E, reported in a single clinical isolate (TEM-126), was found to improve the 
catalytic efficiency against ceftazidime (DELMAS et al. 2005). Although D179E was not found 
in experiments, alternative substitutions D179G (Blazquez et al. 2000; Fujii et al. 2004; 
Salverda and de Visser unpublished) and D179Y (BLAZQUEZ et al. 2000) were found at this 
position. Because of its anchoring function in the Ω-loop, substitutions of residue 179 have 
been extensively studied. It was found that both D179G and D179Y increase the MIC for 
ceftazidime 16-fold (VAKULENKO et al. 1995). In agreement with this, D179G and D179Y 
were recorded in laboratory studies that use ceftazidime as selective agent (BLAZQUEZ et al. 
2000; FUJII et al. 2004). Interestingly, although no effect on cefotaxime resistance could be 
measured for a mutant created in vitro (VAKULENKO et al. 1999), substitution D179G was 
isolated twice in an experiment that used cefotaxime as single selective agent (SALVERDA and 
DE VISSER unpublished), indicating that the effect on resistance phenotype might be broader 
than previously assumed.  
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A detailed study of the effect of all possible amino acid substitutions at this residue on 
resistance phenotype shows that although nearly all substitutions increase ceftazidime 
resistance, at the same time they almost all dramatically worsen resistance to ampicillin 
(VAKULENKO et al. 1995). Indeed, in a laboratory evolution experiment focussing on 
fluctuating ß-lactam pressure, substitutions D179G and D179Y were only found in the 
absence of fluctuating selection-pressure (BLAZQUEZ et al. 2000). Pleiotropic effects of 
substitutions at this residue might thus have prevented their appearance in clinical isolates so 
far. 
 
Substitutions involved in inhibitor resistance 
Substitutions at residues 69, 130, 165, 244, 275 and 276 have been shown to play an exclusive 
role in inhibitor resistance (CHAIBI et al. 1999) and are found at high frequency in the dataset 
of clinical isolates. Substitutions at residues 69, 130, 244 and 276 were also identified in an 
experimental study selecting for increased resistance to the ß-lactam - inhibitor combination 
ampicillin - clavulanate (VAKULENKO et al. 1998). The only other experimental study of 
inhibitor resistance used a combination of ceftazidime - clavulanate and also identified the 
most frequently found substitution at residue 276 (VAKULENKO and GOLEMI 2002). There is 
evidence for the involvement of substitutions at the remaining two residues (165 and 275) in 
increasing the resistance to inactivation by clavulanate, although the effects are small 
(LENFANT et al. 1993; CHAIBI et al. 1999; FIETT et al. 2000). This might explain why 
substitutions at these residues have not been found in the two experimental studies that have 
used clavulanate as a selective agent. Substitutions at residues 165 and 275 have been found 
in other experiments, but under selection regimes without inhibitors; W165G was found in a 
study selecting for increased cefotaxime resistance (Salverda and de Visser unpublished) 
while R275L and R275Q were both found in one of the structural perturbation studies 
(OSUNA et al. 2002), suggesting that substitutions at these residues are able to increase 
resistance to novel antibiotics and inhibitors at the same time. 
 
Amino acid residues harbouring substitutions involved in both ß-lactam and inhibitor 
resistance 
Substitutions M182T and S268G have been shown to increase resistance to both ß-lactams 
and ß-lactam – inhibitor combinations (HUANG and PALZKILL 1997; VAKULENKO and GOLEMI 
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2002). Typical for these modulating substitutions is that their effect is only apparent in the 
background of other substitutions that affect resistance phenotype. Substitution M182T, 
present in 21 clinical isolates, was found in the majority of the experimental studies. 
Substitution S268G is far less common among clinical isolates (present only in TEM-49 and 
TEM-136). This substitution was found in four different experimental studies, three using 
cefotaxime as selective agent (Holloway et al. 2007; Kopsidas et al. 2007; Salverda and de 
Visser unpublished) and one using a combination of ceftazidime and clavulanate 
(VAKULENKO and GOLEMI 2002). In agreement with evidence from mutant TEM-variants 
with and without this substitution, this indicates that the substitution plays a role in increased 
resistance to both ß-lactams and inhibitors and may very well have a similar mode of action as 
that described for M182T (HUANG and PALZKILL 1997; SIDERAKI et al. 2001; WANG et al. 
2002).  
 
Substitutions with unknown or no effect on resistance phenotype 
There are 32 residues in clinical isolates at which substitutions have been identified that either 
have not been tested for their effect on resistance phenotype or that failed to give any 
measurable results when tested. For 11 of these residues, substitutions were identified in 
multiple clinical isolates (Table 3.4), while for the remaining 21 residues a substitution was 
found in a single clinical isolate only (Table 3.5). We analyze to what extent clinical and 
laboratory data overlap for both groups in order to identify to what extent laboratory data 
support adaptive effects of substitutions found at these residues.  
 
Substitutions found in multiple clinical isolates 
At eleven amino acid residues, multiple substitutions without known effect on resistance 
phenotype have been identified in clinical isolates. They are discussed below one by one. 
 
Q6K  
This substitution, located in the signal sequence (residue 3-25), was found in four different 
clinical isolates (TEM-87, 92, 123 and 124). In experiments an alternative substitution (Q6R) 
has been identified in a single sequenced clone (BARLOW and HALL 2002).  
Although it has been extensively tested, no phenotypic effect of Q6K has been described 
(PERILLI et al. 2002). It has been argued that since the positively charged amino-terminal 
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region of the signal peptide plays an important role in efficient protein secretion across the 
cytoplasmic membrane (INOUYE et al. 1982), substitution of the polar glutamine residue at 
position 6 for a positively charged lysine residue could result in an effect on resistance 
phenotype (PERILLI et al. 2002). Interestingly, the alternative substitution Q6R that was found 
in a single experiment (BARLOW and HALL 2002) would result in a similar effect.  
 
L21F 
Substitution L21F, again present in the signal sequence, was found in as many as 21 clinical 
TEM-alleles. An alternative substitution, L21I, has been reported in a single allele (TEM-67) 
as well as in a single experimental study (Salverda and de Visser unpublished). Substitution 
L21P was identified three times in two other experimental studies (ZACCOLO and GHERARDI 
1999; BERSHTEIN et al. 2008).  
Because of its location in the signal sequence, substitution L21F has been speculated to be 
functionally neutral (SOUGAKOFF et al. 1989). Nevertheless, the frequent occurrence of L21F 
in clinical isolates as well as the presence of alternative substitutions at the same position in a 
clinical isolate and in four experimentally isolated alleles strongly suggests a phenotypic 
effect. This is supported by the observation that the substitution occurs in an otherwise 
unaltered TEM-1 background in TEM-117, excluding genetic hitchhiking as a factor that may 
have contributed to the frequent occurrence of the substitution. Furthermore, L21F occurs 
both in the background of substitutions known to be involved in extension of the resistance 
spectrum and in the background of substitutions involved in inhibitor resistance, indicating a 
general effect of the substitution (e.g. at the level of protein expression), which would be 
expected for substitutions with functional effect in the signal peptide. Although the exact 
effect remains to be identified, it seems that substitutions at this residue can alter resistance 
phenotype. 
 
E28D and E28K 
Both substitutions have been found in a single clinical isolate (TEM-150 and TEM-162 
respectively). No substitutions were recorded at this residue in experiments and it therefore 
remains unclear whether the substitutions found in the two clinical isolates confer an adaptive 
advantage.  
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Table 3.4: The 11 amino acid residues at which substitutions with unknown effect on resistance 
phenotype have been found in multiple clinical isolates. Substitutions found at these residues in 
clinical and laboratory isolates are also shown. 
 
Table 3.5: The 21 amino acid residues at which a substitution has been found in a single clinical 
isolate only. Substitutions found at these residues in laboratory isolates are also shown. 
 
 
G92D 
This substitution was found in two clinical isolates (TEM-57 and TEM-66). It has been 
recorded in experiments once (Salverda and de Visser unpublished), as has the alternative 
substitution G92S (STEMMER 1994).  
Effects of G92D on resistance spectrum or enzyme kinetics have been tested but were not 
found (BONNET et al. 1999). The recovery of two substitutions at residue 92 in two laboratory 
studies provides some evidence that substitutions at this position can contribute to an altered 
resistance phenotype.  
 
Amino acid 
residue 
Substitution # clinical 
isolates 
# 
laboratory 
isolates  
Amino acid 
residue 
Substitution # clinical 
isolates 
# 
laboratory 
isolates 
6 Q6K 4 0  153 H153R 3 6 
 Q6R 0 1   H153D 0 1 
21 L21F 21 0   H153L 0 1 
 L21I 1 1   H153Q 0 1 
 L21P 0 3   H153Y 0 1 
28 E28D 1 0  163 D163G 1 0 
 E28K 1 0   D163H 1 0 
92 G92D 2 1   D163V 0 1 
 G92S 0 1  196 G196D 1 0 
100 N100S 2 0   G196S 1 1 
 N100G 0 1  265 T265M 20 12 
 N100K 0 1   T265A 0 2 
127 I127V 2 0  280 A280V 2 0 
      A280T 0 1 
Amino acid 
residue 
Substitution # clinical 
isolates 
# 
laboratory 
isolates  
Amino acid 
residue 
Substitution # clinical 
isolates 
# 
laboratory 
isolates 
16 F16L 1 0  114 T114P 1 0 
 F16C 0 1   T114A 0 1 
34 K34E 1 0   T114M 0 1 
35 D35P 1 0  115 D115G 1 0 
 D35A 0 1  124 S124N 1 1 
38 D38N 1 1   S124G 0 2 
 D38G 0 1   S124R 0 2 
 D38V 0 1  145 P145A 1 0 
 D38Y 0 1   P145L 0 1 
42 A42V 1 0   P145Q 0 1 
 A42G 0 6  157 D157E 1 0 
49 L49M 1 3  158 H158N 1 0 
 L49V 0 1   H158Y 0 1 
64 E64K 1 0  204 R204Q 1 0 
80 V80E 1 0  218 G218E 1 0 
 V80I 0 1  221 L221M 1 0 
102 L102V 1 0  224 A224V 1 7 
 L102M 0 1  262 V262I 1 0 
     284 A284G 1 0 
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N100S 
This substitution was only found in two very recently identified clinical isolates (TEM-157 
and TEM-162). Alternative substitutions N100G and N100K have both been found in 
experiments once (Bershtein et al. 2008; Salverda and de Visser unpublished). It remains 
unclear whether or not substitutions at this residue confer an adaptive advantage.  
 
I127V 
Substitution I127V has been identified in two clinical isolates (TEM-80 and TEM-81). In both 
cases the substitution is present together with substitutions involved in inhibitor resistance 
(M69L and N276D in TEM-80 and M69L in TEM-81). No substitutions were recorded at this 
position in experiments.  
The precise effect of I127V is unknown, although it has been found to increase Km values 
(and therefore decrease affinity) for a number of substrates compared to TEM-1 (ARPIN et al. 
2002). The absence of substitution I127V in experimental studies may therefore either lie in 
the neutrality of this substitution or, considering the fact that it was found in inhibitor resistant 
backgrounds, in the limited scope of experimental studies that focus on inhibitor resistance.  
 
H153R 
This substitution was recorded in three clinical isolates (TEM-21, TEM-56 and TEM-112), 
always in the background of substitutions involved in extended cephalosporin resistance. No 
phenotypic effect of the substitution has been described. In experiments, this substitution was 
found in two studies selecting for increased cefotaxime resistance (Kopsidas et al. 2007; 
Salverda and de Visser unpublished), in a study on the retention and regain of ampicillin 
resistance (BERSHTEIN et al. 2008) and in both structural perturbation studies (OSUNA et al. 
2002; HECKY and MULLER 2005), clearly suggesting that the substitution confers a selectable 
advantage. The presence of H153R in both structural perturbation studies and the fact that it 
has only been observed in the background of other substitutions in clinical and laboratory 
isolates may indicate that the substitution compensates for the pleiotropic effects of other 
adaptive substitutions. Alternative substitutions H153D, H153L, H153Q and H153Y have 
been recorded in experiments as well, suggesting that a variety of substitutions at this position 
can result in selectable effects. 
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D163G and D163H 
These substitutions were found in TEM-96 and TEM-87 respectively. No phenotypic effect of 
these substitutions has ever been described, although there are indications that D163G might 
increase resistance to ceftazidime (PALZKILL et al. 1994). A single substitution at the same 
position (D163V) was found in an experiment selecting for increased cefotaxime resistance 
(Salverda and de Visser unpublished).  
Residue 163 is located in the Ω-loop, which is involved in the formation of the active site 
pocket. The identification of substitutions at this position, both in clinical isolates and in 
experiments, suggests that perturbation of the Ω-loop at this position might alter the native 
resistance phenotype of TEM-1. In fact, it has been shown that simultaneous substitution of 
residue 161 and 163 can result in increased resistance to ceftazidime (PALZKILL et al. 1994). 
 
G196D and G196S 
Substitutions G196D and G196S were found in TEM-88 and TEM-108 respectively. In 
experiments, G196S was found once (Salverda and de Visser unpublished). Concerning 
G196D, no differences in kinetic properties were found when TEM-88 was compared to 
TEM-52, which lacks G196D but is otherwise identical (PAI et al. 2001). In a mutagenesis 
study, it was shown that a variety of substitutions at residue 196 are tolerated (HUANG et al. 
1996), leading to the speculation that G196D is functionally silent (PAI et al. 2001). No 
further information is available on substitution G196S, except that it occurs in an unusual 
allele that also contains substitutions V80E and N276S that are not found in any other TEM-
allele described. With only a single substitution recorded at residue 196 in experiments, it 
remains unclear whether or not substitutions at this position can alter resistance phenotype. 
 
T265M 
Although found in 21 different clinical TEM-isolates and extensively tested, no effect on 
enzyme catalysis or expression was found for this substitution (HUANG et al. 1994). However, 
since the substitution has been identified no less than twelve times in five independent 
experimental studies, it is clear that it does confer an adaptive advantage. The fact that T265M 
is frequently encountered in one of the two structural perturbation studies (HECKY and 
MULLER 2005) suggests that the substitution has an effect on enzyme stability rather than 
enzyme activity, which is in agreement with its location far away from the active site. This is 
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also in agreement with the fact that T265M has only been found in the background of other 
substitutions involved in both ß-lactam or inhibitor resistance. All in all, it seems that 
substitution T265M is a suppressor of defects introduced by other substitutions, with a mode 
of action similar to that of M182T (HUANG and PALZKILL 1997; SIDERAKI et al. 2001; WANG 
et al. 2002). 
 
A280V 
This obscure substitution has been described in two clinical isolates (TEM-101 and TEM-
104). No phenotypic effect has been described and although a single alternative substitution 
(A280T) was found in one of the structural perturbation studies (OSUNA et al. 2002), it 
remains unclear whether or not any of these substitutions confers a selective advantage. Note 
that in the sequence of both clinical isolates substitution A280V is caused by a double point 
mutation (the codon changes from ‘GCT’ to ‘GTC’).  
 
Substitution found in a single clinical isolate 
As mentioned before, there are 21 amino acid residues that have been altered in a single 
clinical isolate only and of which no phenotypic effect is known (see Table 3.5). At nine of 
the 21 residues, no substitutions were found in experiments and at five other residues a single 
alternative substitution was found in experiments, which we do not regard as sufficient 
evidence to support a putative adaptive advantage. At the remaining seven residues, multiple 
substitutions were found in experiments, suggesting a role of substitutions at these positions 
in extending resistance phenotype. The substitutions found at these positions in clinical and in 
experimental isolates are discussed in detail below.  
 
D38N 
This substitution was identified in TEM-162 and its effect on resistance phenotype is 
unknown. The substitution was found in a single experimental study on increased cefotaxime 
resistance (Salverda and de Visser unpublished) in which two alternative substitutions (D38G 
and D38V) were identified as well, while D38Y was found in yet another study (BARLOW and 
HALL 2003). Thus, indications exist that substitutions of this amino acid can confer a 
selectable advantage. 
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A42V 
No effect on resistance phenotype was found for A42V in TEM-42, the only clinical isolate 
containing this substitution (MUGNIER et al. 1996). An alternative substitution (A42G) was 
identified in as many as six different experimental studies. The A42G substitution has been 
particularly well studied as, combined with substitutions E104K, M182T and G238S, it gives 
rise to the TEM-derivative with the highest cefotaxime resistance described so far (HALL 
2002). Interestingly, all of the later studies that have used selection for increased cefotaxime 
resistance were able to identify the triple mutant E104K/ M182T/ G238S (ZACCOLO and 
GHERARDI 1999; LONG-MCGIE et al. 2000; ORENCIA et al. 2001; KOPSIDAS et al. 2007; 
SALVERDA and DE VISSER unpublished), but none of them identified the quadruple mutant 
containing A42G. Detailed MIC analyses of different combinations of the four substitutions 
however indicates that addition of A42G to the triple mutant should greatly increase 
cefotaxime resistance (HALL 2002; WEINREICH et al. 2006).  
The identification of A42G in studies with various selective conditions (antibiotics, 
inhibitors and structural perturbation), its location (far away from the active site and binding 
pocket), and the fact that the substitution has no effect on resistance in a TEM-1 background 
(HALL 2002) suggest that this substitution has a modulating effect comparable to that of 
M182T. Whether substitution A42V that is found in a single clinical isolate confers a similar 
effect remains unclear. 
 
L49M 
Substitution L49M was found in TEM-139. The allele was found in isolates originating from 
several Bulgarian clinics, and since it was phenotypically indistinguishable from TEM-3 
(from which it differs by L49M only) it has been suggested to have no clinical relevance 
(SCHNEIDER et al. 2007). L49M was identified three times in a single experimental study, 
while an alternative substitution (L49V) was found in the same study (Salverda and de Visser 
unpublished). The identification of L49M in three independent experiments within a single 
study indicates that the substitution is likely to have an effect on resistance phenotype.  
 
T114P 
This substitution was found in TEM-146. Alternative substitutions T114A (BERSHTEIN et al. 
2008) and T114M (Salverda and de Visser unpublished) have both been found in a single 
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experimental isolate. It is unclear whether and to what extent substitutions at this position can 
alter the level or spectrum of resistance.   
 
S124N 
TEM-105 is the only clinical TEM-isolate known to carry substitution S124N, with no other 
substitutions present in its background. No information is available on the phenotypic effect 
of the substitution, although the fact that it occurs all by itself could imply some effect on 
extended spectrum activity. 
Substitution S124N was found in experiments once, while alternative substitutions S124G 
and S124R were both found twice (Bershtein et al. 2008; Salverda and de Visser 
unpublished), indicating that substitutions at this residue may have effects on resistance 
phenotype, possibly by secondary, stabilizing effects.  
 
P145A 
The only clinical isolate containing P145A (TEM-95) was found to have a resistance 
phenotype similar to TEM-1 (BRINAS et al. 2002). Alternative substitutions P145L and 
P145Q were both identified once in an experiment selecting for increased cefotaxime 
resistance (Salverda and de Visser unpublished), indicating that substitutions at this position 
may be involved in extension of the resistance phenotype. 
 
A224V 
This substitution is present in a single TEM-allele only (TEM-147) and no phenotypic effect 
of the substitution has been described. In experiments, the substitution was found in studies 
using cefepime (BARLOW and HALL 2003) and cefotaxime (Salverda and de Visser 
unpublished) as selective agents. Furthermore, the substitution was recorded in all of the 
clones that were sequenced after the final round of mutagenesis and selection in one of the 
structural perturbation studies (HECKY and MULLER 2005), while it was also present in one of 
the clones analyzed in the other structural perturbation study (OSUNA et al. 2002). The 
presence of A224V in both structural perturbation studies strongly suggests a stabilizing 
effect. Both the position of residue 224 (on the small helix H10 just after the second hinge-
region) and the fact that substitution A224V has never been found by itself in clinical or 
experimental isolates are in agreement with this conclusion. The substitution may be expected 
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to appear in future clinical TEM-isolates, due to its possible modulating function (similar to 
that of M182T). 
 
Table 3.6: Amino acid substitutions found at high frequency in laboratory isolates that have not been 
found (or that are found at very low frequency) in clinical isolates. 
  
Structure a AA b Substitution Clinical 
isolates 
Laboratory 
isolates 
 Structure a AA b Substitution Clinical 
isolates 
Laboratory 
isolates 
Signal 
peptide 
10 V10I 0 6  Ω-loop 173 I173L 0 1 
 19 F19C 0 2    I173R 0 1 
  F19I 0 1    I173T 0 2 
  F19L 0 2    I173V 1 12 
  F19V 0 1   175 N175D 0 5 
H1 31 V31A 0 3    N175I 1 0 
Turn H1/ S1 42 A42G 0 6    N175Y 0 1 
  A42V 1 0   179 D179E 1 0 
S1 47 I47V 0 4    D179G 0 4 
 49 L49M 1 3    D179Y 0 1 
  L49V 0 1  H8 184 A184V (3) c 4 
Turn S1/ S2 52 N52D 0 3    A184T 0 1 
  N52H 0 1  H9 201 L201I 0 1 
  N52S 0 3    L201P 0 4 
  N52T 0 2    L201Q 0 1 
  N52Y 0 1    L201R 0 1 
Hinge I 63 E63A 0 1   208 I208K 0 1 
  E63D 0 1    I208L 0 1 
  E63G 0 1    I208M 0 5 
  E63K 0 2    I208T 0 1 
H3/ Loop 111 K111E 0 1    I208V 0 2 
  K111M 0 2  H10/ Hinge II 224 A224V 1 7 
  K111Q 0 2  Turn S3/ S4 241 R241H 0 4 
  K111R 0 3  S4 247 I247V 0 3 
  K111T 0 2   249 A249V 0 3 
H4 120 R120E 0 1  Turn S4/ S5 254 D254G 0 3 
  R120G 0 5    D254H 0 1 
  R120S 0 2    D254N 0 2 
H6 147 E147A 0 1  Turn S5/ H11 268 S268G 2 7 
  E147G 0 2    S268N 0 1 
  E147K 0 2    S268T 0 1 
Loop 155 M155I 0 4  H11 288 K288E 0 2 
        K288Q 0 1 
        K288R 0 2 
        K288T 0 1 
 
a 
Structure of the part of TEM-1 the respective amino acid residue is localized in according to Jelsch et 
al. (1993). 
b 
Amino acid residue number. 
c 
Present in three clinical isolates, but together with V84I and therefore not the result of natural 
selection (see text). 
 
Prediction of substitutions that may be encountered in future clinical isolates 
Amino acid residues at which no substitutions have been found in clinical isolates, but at 
which multiple substitutions have been recorded in experiments are of special interest, since 
they may reveal the evolutionary potential of TEM-1 that has not been used by natural 
selection yet. In order to make a conservative (albeit somewhat arbitrary) estimate of this 
group of substitutions, we here consider a particular substitution to have arisen by selection 
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whenever it was found more than twice in laboratory isolates and we consider an amino acid 
residue to be under selection whenever more than four substitutions have been found at a 
single residue in laboratory isolates. The results of this analysis are shown in Table 3.6. Data 
on amino acid residues at which less than three substitutions were found in clinical isolates 
but at which substitutions were recorded with high frequency in experiments have been added 
to this table for completeness. An overview of the location of all amino acid residues in the 
three-dimensional structure of TEM-1 is shown in Figure 3.2b. 
 
3.3 Conclusions 
 
Summarizing, we have made an inventory of all amino acid substitutions present in the ~150 
unique clinical TEM-isolates that have so far been described and in a collection of 17 
laboratory studies on the experimental and directed evolution of TEM-mediated antibiotic 
resistance. Since we have reasons to believe that alternative substitutions at one and the same 
amino acid residue are, at least qualitatively, equivalent, we have focussed primarily on the 50 
amino acid residues at which substitutions have been found in clinical isolates. Within this 
group, we have first analyzed the 18 residues at which substitutions have been found that have 
been shown to contribute to an extension of the resistance phenotype. Substitutions at residues 
104, 164, 182, 237, 238 and 240, all frequently encountered in clinical isolates, are typically 
associated with resistance to extended-spectrum ß-lactams (Knox 1995). Laboratory evolution 
studies identified substitutions at all these residues, and, moreover, they correctly identified 
the substitutions at these positions that were found in multiple clinical isolates (E104K, 
R164C, R164H, R164S, M182T, A237T, G238S and E240K). In addition, several 
substitutions have been described that occur in a single clinical isolate only, but that 
nevertheless do confer an increased resistance to one or more ß-lactams (L51P, I173V, N175I, 
D179E). Again, laboratory evolution identified multiple substitutions at all of these residues, 
while in the case of I173V it also identified the correct substitution.  
Substitutions at residues 69, 130, 165, 244, 275 and 276 are associated with inhibitor 
resistance (YANG et al. 1999). Although laboratory evolution again identified substitutions at 
all these residues, in this case the identification of specific amino acid substitutions was not 
perfect. Amino acid substitutions M69I, M69L, M69V, S130G, W165R, R244C, R244H, 
R244S, R275A, R275L, R275Q and N276D have all been found in multiple clinical isolates. 
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Laboratory evolution failed to find M69I, M69V, W165R, R244H and R275A, while R275L 
and R275Q were only found in one of the structural perturbation studies (OSUNA et al. 2002) 
where they may serve a different function. The two studies on ß-lactam - inhibitor 
combinations used the same inhibitor (clavulanate) and both isolated clones after a single 
round of mutagenesis and selection only. The resulting limited quantitative and qualitative 
scope of these studies is likely to explain the limited identification of substitutions involved in 
inhibitor resistance. Yet, even with this very limited scope, the two studies identified 
substitutions at four of the six residues associated with inhibitor resistance.  
Besides the accurate identification of almost all substitutions known to be involved in 
increased resistance to extended-spectrum ß-lactams and inhibitors, a large number of 
substitutions present in multiple clinical isolates exists that have no known individual 
phenotypic effect. Most of these substitutions occur in a limited number of clinical isolates, 
but two of them occur in at least 20 different isolates (L21F and T265M). Interestingly, L21F 
has not been identified in laboratory studies, although three alternative substitutions were 
found at this residue. It seems that the failure to detect an effect of this substitution on 
resistance phenotype coincides with the failure to detect the same substitution in laboratory 
evolution experiments.  
The case is different for substitution T265M, which has been identified in four different 
laboratory studies, strongly suggesting that, contrary to the results of extensive testing 
(HUANG et al. 1994), this substitution does alter resistance phenotype. The fact that this 
substitution is one of the most frequently encountered substitutions in one of the two 
structural perturbation studies (HECKY and MULLER 2005) indicates that it may have an effect 
on enzyme stability rather than enzyme activity, which is in agreement with the observation 
that the substitution is located far away from the active site (HUANG et al. 1994). This is also 
in agreement with the fact that in clinical isolates T265M occurs in the background of 
substitutions involved in both ß-lactam and inhibitor resistance. All in all, it seems that 
substitution T265M is a suppressor of defects introduced by other substitutions, with a mode 
of action similar to that of M182T (HUANG and PALZKILL 1997; SIDERAKI et al. 2001; WANG 
et al. 2002).  
Next to tracing substitutions involved in altering the resistance phenotype of TEM-1, 
independent laboratory studies have identified a number of substitutions that have not been 
recorded in the clinical isolates so far described. The predictions that can be inferred from 
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laboratory studies concern substitutions in the signal peptide, in structurally important groups 
in or near the binding pocket, and away from the binding pocket that probably suppress 
disadvantageous effects of other substitutions. These substitutions illustrate the remarkable 
plasticity of TEM-1. In a number of cases, especially where it concerns substitutions in the Ω-
loop, pleiotropic effects of substitutions might be responsible; such substitutions tend to 
surface in laboratory studies under the selective pressure of a single antibiotic, while in a 
clinical setting where often more antibiotics are used at the same time their selective 
advantage vanishes.  For example, almost all of the 19 possible substitutions at residue 179 
increase resistance to ceftazidime compared to TEM-1, but at the same time all these 
substitutions result in a dramatic decrease of resistance to ampicillin (VAKULENKO et al. 
1995). Similarly, it has been found that exposing bacteria carrying a plasmidic TEM-1 to the 
alternating pressure of two ß-lactams eventually yields substitutions that are frequently found 
in clinical isolates, while continued exposure to only one of these antibiotics resulted in the 
identification of substitutions not previously found in clinical isolates (BLAZQUEZ et al. 2000). 
The selective pressures applied in the different laboratory studies can be distinguished in 
conditions scanning for a better fit (increased antibiotic resistance), scanning for a worse fit 
(increased antibiotic - inhibitor resistance) and scanning for a regained fit (structural 
perturbation). Combining these three experimental approaches seems especially promising, as 
it provides a thorough scan of the evolutionary potential as well as robustness of an antibiotic 
resistance gene while at the same time it characterizes the substitutions involved.         
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Abstract: The TEM ß-lactamases are among the most widely dispersed and frequently 
encountered resistance determinants in clinical microbial populations. There are currently 
~160 variants of the TEM ß-lactamase that vary in amino acid sequence. Typically, the 
variation among TEMs has been attributed to the occurrence of point mutations. Therefore 
recombination has not been considered an important or regularly occurring process among 
TEM-alleles. We present evidence for recombination that is based on phylogenetic 
interpretation of the occurrence of silent mutations in clinical isolates of TEM variants. We 
also show that the distribution of co-occurring TEM-alleles in clinical microbial populations 
is consistent with the regular occurrence of recombination among TEM-alleles. Our findings 
indicate that recombination has had an important effect on the sequence evolution and 
population distribution of TEM-alleles. 
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4.1 Introduction 
 
The TEM ß-lactamases are one of the best-studied families of resistance determinants. They 
are encountered throughout the world at high frequency among clinical microbial populations, 
and they confer resistance to the heavily used ß-lactam antimicrobials (PATERSON and 
BONOMO 2005).  The progenitor of this family, TEM-1 was first isolated in 1963 as a 
plasmidic penicillin resistance determinant (DATTA and KONTOMICHALOU 1965).  Since that 
time, TEM-1 has given rise to ~160 variants (http://www.lahey.org/Studies/temtable.asp) that 
differ in amino acid sequence and that often differ in the phenotype they confer (PATERSON 
and BONOMO 2005).  The TEM enzymes have exhibited considerable functional plasticity and 
are able to confer resistance to most ß-lactams. Extended spectrum TEMs (ESBLs) confer 
resistance to penicillins, 2
nd
 and 3
rd
 generation cephalosporins, and monobactams while 
inhibitor resistant TEMs confer resistance to penicillins and penicillin / inhibitor combinations 
(HELFAND et al. 2003; PATERSON and BONOMO 2005).  The functional plasticity of the TEMs 
and the numerous publications documenting the evolution of the TEMs has made them an 
ideal model system for studying molecular evolution, phenotypic trade-offs and evolutionary 
potential.  The TEMs are also an ideal model for studying evolutionary and population 
processes in microbes because of numerous hospital surveillance studies, which have 
documented their frequencies and distributions.  Despite the numerous studies of TEM 
molecular evolution, there are few reports of sequence evolution occurring through 
homologous recombination (BARANIAK et al. 2005) of TEM-alleles.  Therefore, 
recombination is not generally considered as a mechanism of importance in the evolution of 
TEM-alleles. 
Recent evidence that recombination occurs regularly among plasmidic qnr resistance 
alleles indicates that recombination may be a regular occurrence among allelic variants of 
plasmidic resistance genes (Baquirin and Barlow 2007 (submitted)).  Typically, 
recombination in microbes is studied in the chromosome with respect to clonality and 
parasexual exchange (MILKMAN 1997; KRAFT et al. 2006).  Recombination of plasmidic DNA 
has also been studied with respect to increasing the stability of artificial plasmidic constructs 
(CASALI 2003).  Occasional incidences of recombination among plasmidic alleles have been 
reported, however the occurrence of recombination among plasmids is not generally 
considered a process that has important consequences upon microbial populations (BARANIAK 
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et al. 2005).  We have used the extensive data available about the synonymous variation and 
population distribution of plasmidic TEM-alleles to study the occurrence and the effects of 
recombination among TEM-alleles. 
 
4.2 Materials and methods 
 
Phylogenetic reconstruction: A maximum likelihood phylogeny of TEM-alleles was 
generated with Phyml v2.4.5 using a general time reversible substitution matrix, a discrete 
gamma model with 4 categories and an estimated shape parameter of 0.338.  The proportion 
of invariant sites was estimated as 0.448.  The tree was rooted using a blaSHV-2 allele as the 
outgroup.  A summary of that phylogeny is shown in Figure 4.1. 
 
Analysis of silent mutations: There are 253 silent sites within TEM-alleles. In our 
phylogeny, 61 silent mutations occurred throughout the TEM phylogeny.  Among all TEM-
alleles, there is an average of 0.2411 silent mutations per silent site. This mean was used to 
compute the expected number of times that mutations would occur at a single site according 
to the Poisson distribution (Table 4.1).  The observed number of times that point mutations 
occurred at each site was inferred from the phylogeny and the observed and expected values 
were compared using a G-test. 
 
Population analysis: Data were compiled from ten surveillance studies (DECRE et al. 2004; 
KIM et al. 2004; KRUGER et al. 2004; LAVIGNE et al. 2004; BARANIAK et al. 2005; BRINAS et 
al. 2005; HO et al. 2005a; HO et al. 2005b; SCHLESINGER et al. 2005; TASLI and BAHAR 2005) 
in which bacteria exhibiting the extended-spectrum ß-lactamase (ESBL) phenotype were 
screened by isoelectric focusing or sequence analysis to identify genes conferring the ESBL 
phenotype.  While the entire data set includes frequencies of Class A, Class C and Class D ß-
lactamases, our analysis included only Class A ß-lactamases.  The entire aggregated dataset 
used for this analysis contained 291 strains.  Of those, 163 strains expressed a single Class A 
enzyme, 102 strains expressed two Class A enzymes, 25 strains expressed more than two 
Class A enzymes, and one strain expressed no Class A enzymes.  The 25 strains 
that expressed more than two Class A enzymes were excluded from the analysis because 
sample size was insufficient for significant statistical analysis. 
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Figure 4.1: The occurrence of synonymous mutations in TEM-alleles. Top panel: phylogeny showing 
order of descent of alleles in which the silent mutations t226c, a346g, t604g, t682c, and g925a arose. 
Chi square likelihood ratios showing the confidence of the node are shown at each node where a 
synonymous mutation occurred. Lower panel: pathways of silent mutation occurrence in TEM-alleles. 
This diagram shows the order in which synonymous mutations arose. The nodes of the phylogeny at 
which synonymous mutations arose are represented with boxes.  Inside each box is a list of the 
mutations that occur at the node. 
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Three families of Class A enzymes were identified among the isolates included in this 
analysis: TEM, SHV, and CTX-M.  The frequency of each family was computed among all 
isolates included in the analysis.  The frequencies of each family were then multiplied to 
predict the frequency of co-occurring alleles from the Class A families. Chi square analysis 
was used to compute the probability that the co-occurrence of alleles results from their 
frequencies in populations. 
 
Table 4.1: Probability* that observed distribution of silent variation resulted from spontaneous point 
mutations. 
 
Number of mutations Poisson probability Expected number of sites Observed number of sites 
0 0.7858 198.8074 235 
1 0.18945 47.93085 10 
2 2.28x10
-2
 5.77852 1 
3 1.80 x10
-3
 0.4554 1 
4 1.10 x10
-4
 0.02783 0 
5 5.34 x10
-6
 0.00134976 1 
6 2.14 x10
-7
 5.4243 x10
-5 
2 
7 7.39 x10
-9
 1.8684 x10
-6 
1 
8 2.23 x10
-10
 5.6318 x10
-8 
0 
9 5.96 x10
-12
 1.5084 x10
-9 
0 
10 1.44 x10
-13
 3.6432 x10
-11 
1 
11 3.15 x10
-15
 7.972 x10
-13 
0 
12 6.33 x10
-17
 1.6017 x10
-14 
1 
 
*χ
2
 p-value = 6.82 x10 
-45
 
 
4.3 Results and Discussion 
 
We analyzed the silent variation of TEM-alleles to determine whether recombination is 
detectable.  Silent mutations usually occur randomly and they usually are not subject to 
selection. Therefore, independent occurrences of silent mutations that result from spontaneous 
point mutations should be Poisson distributed.  Non-synonymous variation was excluded from 
our analysis because some recurrent amino acid replacement could be selected for as a means 
of adapting to new substrates and could therefore appear to arise more often than expected by 
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chance alone, while silent mutations are essentially neutral and their occurrence is expected to 
be random. 
The allele TEM-1b is the ancestor of the TEM-alleles and was used as a reference 
sequence for identifying silent mutations.  There are six silent mutations that occur repeatedly 
among TEM-alleles.  They are t226c, a346g, t436c, t604g, t682c, g925a.  The allele TEM-1b 
is the ancestor of the TEM-alleles and was used as a reference sequence for identifying silent 
mutations.  The order in which those mutations arose is presented in Figure 4.1.  Chi square 
likelihood ratio testing supports this order of occurrence as all nodes at which these mutations 
occurred had likelihood ratios of > .98.  The mutation t226c arose twice and could have 
resulted either from independent point mutations or transfer of the mutation by recombination 
into an additional TEM lineage. 
By inferring the order in which silent mutations have occurred among TEM-alleles, it is 
also possible to infer combinations of mutations that are inconsistent with sequential 
acquisition of point mutations and that are more likely to occur through a recombination 
event.  The silent mutations found in the TEM-68 allele would have required two 
simultaneous reversion mutations at sites 226 and 346 of a TEM-1f descendent, but they are 
consistent with a single recombination event between an allele descended directly from TEM-
1b and another descended from TEM-1f.  Assuming that a single recombination event is more 
likely than two simultaneous reversions, the silent mutations found in the TEM-68 allele 
provide evidence that recombination within the TEM-alleles does occur. 
The pattern of mutations observed in 32 additional TEM-alleles could be explained either 
by recombination or by mutation/reversion of a single site among the six sites listed 
previously.  For any single TEM allele, it would be impossible to distinguish whether 
recombination or the occurrence of a point mutation led to the pattern of silent mutations.  
However, when the entire phylogeny is taken into consideration, it becomes possible to detect 
whether the occurrence of silent mutations is consistent with spontaneous point mutations. 
The occurrence of point mutations is consistent with the Poisson distribution because point 
mutations occur randomly and infrequently.  A total of 61 silent mutations occurred 
throughout the TEM phylogeny.  There are 253 silent sites within TEM-alleles.  Among all 
TEM-alleles, there is an average of 0.2411 silent mutations per silent site.  This mean was 
used to compute the expected number of times that mutations would occur at a single site 
according to the Poisson distribution (Table 4.1).  The observed number of times that point 
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mutations occurred at each site was inferred from the phylogeny and the observed and 
expected values were compared using a G-test.  The observed and expected distributions of 
point mutations were significantly different (p=6.82 x 10
-45
) which indicates that the observed 
pattern of silent mutations is not consistent with the occurrence of spontaneous point 
mutations.  To eliminate the possibility that the difference may be an artifact caused by under-
sampling silent mutations due to biases against reporting TEM-alleles that contain only silent 
variation, the mean number of silent mutations per silent site used for computing the expected 
values was increased by an order of magnitude. This resulted in the observed pattern of silent 
mutations becoming even less likely to have occurred by silent point mutations (p=2.04 x 10
-
219
).  These results indicate that the pattern of silent variation among TEM-alleles cannot be 
explained by spontaneous point mutations.  The most reasonable alternative is that 
recombination is responsible for the seemingly independent occurrence of pre-existing point 
mutations among independent lineages of the TEM-alleles.  These results show that 
recombination has occurred regularly among TEM-alleles. 
To determine the amount of variation in TEM-alleles that has resulted from recombination, 
we estimated the frequency of alleles that have arisen by spontaneous point mutations and the 
frequency of those that have arisen by recombination.  There are 61 independent occurrences 
of silent mutations that occur at 18 sites in the TEM gene.  There are 7 sites at which 49 of the 
61 silent mutations occur (Table 4.1).  The difference between the expected and observed 
number of occurrences of mutations at those sites exceeds two orders of magnitude.  By 
assuming that all variation at those sites, except for the first mutation, arose by recombination 
we can infer that 42 mutations or 69% of silent variation resulted from recombination 
occurring between variant TEM-alleles.  It is reasonable to assume that recombination has 
also resulted in disseminating non-synonymous variation among the TEM-alleles and that a 
similar proportion of amino acid substitutions may have likewise resulted from 
recombination.  Conservatively, we can conclude that recombination contributes as much to 
variation as does mutation. 
Phylogenetic evidence indicates that recombination occurs regularly among TEM-alleles.  
Therefore, recombination may result in other detectable patterns among microbial populations 
that carry TEM-alleles.  If two TEM-alleles co-occur on a single plasmid and are oriented in 
the same direction, a single recombination event between them will remove one allele from 
the plasmid and one will remain.  Depending on the recombination site, the remaining allele 
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may be a chimera derived from the two alleles that previously co-occurred.  If the co-
occurring TEM-alleles are oriented in opposite directions, a single recombination event 
between them will result in the rotation of the DNA segment between the recombination sites.  
Assuming that TEM-alleles orientation is random and that there is an equal probability of 
either orientation, and that recombination occurs regularly among TEM-alleles, one would 
predict that approximately half of all co-occurrences of TEM-alleles would be subject to 
elimination by recombination. 
To test this expectation, we compiled data from ten surveillance studies (DECRE et al. 
2004; KIM et al. 2004; KRUGER et al. 2004; LAVIGNE et al. 2004; BARANIAK et al. 2005; 
BRINAS et al. 2005; HO et al. 2005a; HO et al. 2005b; SCHLESINGER et al. 2005; TASLI and 
BAHAR 2005) in which bacteria exhibiting the extended-spectrum ß-lactamase (ESBL) 
phenotype were screened by isoelectric focusing or sequence analysis to  identify genes 
conferring the ESBL phenotype.  Three families of Class A enzymes were identified among 
the isolates included in this analysis.  They are the TEM, SHV, and CTX-M families.  The 
frequency of each family was computed among all isolates included in the analysis.  The 
frequencies of each family were then multiplied to predict the frequency of co-occurring 
alleles from the Class A families.  Chi square analysis of the co-occurrence of Class A ß-
lactamases revealed that the observed frequencies of co-occurring alleles from a single family 
are significantly lower than expected and that the frequencies of co-occurring alleles from 
different families are significantly higher than expected (p=1.64 x 10 
-7
) (Table 4.2).  These 
results indicate suppression of two allelic variants from one family co-occurring in a single 
strain.  This result rejects the hypothesis that the co-occurrences of Class A ß-lactamases 
depends upon their frequencies in microbial populations and indicates that recombination 
affects both sequence evolution and population distributions of TEM-alleles. We predicted 
that ~55 isolates should co-express two TEM enzymes and found that only 31 (56.4%) did.  
This finding is consistent with random orientation of co-occurring TEM-alleles and removal 
of a TEM allele when the co-occurring alleles are oriented in the same direction. 
It is interesting to note that in the aggregated bacterial population used for this study, the 
TEM-1 protein was the most frequently recovered Class A ß-lactamase, despite the fact that 
inclusion in the aggregated dataset was based on resistance to extended spectrum ß-lactams. 
The frequent expression of TEM-1 in clinical bacterial populations and the less than expected 
frequency of co-occurring TEMs in bacterial isolates suggests that there may be an advantage 
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Table 4.2: Probability** that co-expression of Class-A ß-lactamases results from their frequencies in 
bacterial populations. 
 
 Observed number of occurrences Expected number of occurrences 
Single TEM 140  
Single CTX-M 15  
Single SHV 8  
TEM + TEM 31 55.21 
CTX-M + CTX-M 0 1.04 
SHV + SHV 0 2.73 
TEM + CTX-M 19 15.13 
TEM + SHV 49 24.54 
SHV + CTX-M 3 3.36 
 
**χ2 p-value = 1.64 x 10 
-7 
 
for bacteria that express TEM-1 rather than an extended spectrum TEM enzyme.  It has been 
shown that expression of TEM-1 confers a fitness advantage relative to strains expressing 
extended spectrum TEMs when bacteria are exposed to ampicillin (MROCZKOWSKA and 
BARLOW 2008). In a recent report of antimicrobial consumption in European countries, 
penicillin consumption consistently exceeded cephalosporin consumption. This pattern of 
antimicrobial consumption supports the explanation that the prevalence of TEM-1 expression 
in microbial populations has resulted from a selective advantage conferred by TEM-1. 
These results further indicate that the combined effects of selection and recombination may 
actually suppress the occurrence of extended spectrum TEMs in microbial populations.  By 
suppressing the co-occurrence of multiple TEM-alleles in a bacterial strain, recombination 
causes strains to carry, in general, only one TEM allele.  A selective advantage of strains 
expressing TEM-1 over strains expressing extended-spectrum TEMs may cause the strains 
that express TEM-1 to dominate clinical microbial populations (MROCZKOWSKA and BARLOW 
2008). Although extended spectrum TEMs are frequently encountered, none have been 
encountered as frequently as TEM-1 (DECRE et al. 2004; KIM et al. 2004; KRUGER et al. 
2004; LAVIGNE et al. 2004; BARANIAK et al. 2005; BRINAS et al. 2005; HO et al. 2005a; HO et 
al. 2005b; SCHLESINGER et al. 2005; TASLI and BAHAR 2005). While cephalosporin resistance 
is common, it is not as common as penicillin resistance.  It is possible that resistance to 
cephalosporins has been somewhat inhibited by the combined effects of selection and 
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recombination.  It is likewise possible that an increased understanding of these effects may 
lead to novel strategies to extend the useful period of antimicrobials. 
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Abstract: Silent or synonymous mutations have long been thought to be functionally and 
adaptively neutral. However, several mechanisms that can cause synonymous mutations to 
have functional effects have recently been identified. The availability of many antibiotic 
resistance genes from clinical isolates and the ease with which they can be used in laboratory 
experiments offer an excellent opportunity for studying the adaptive significance of silent 
mutations. Here, we examine synonymous mutations present in clinical isolates of the 
antibiotic resistance gene TEM-1, as well as synonymous mutations present in laboratory 
isolates of this gene that were isolated after directed evolution for increased resistance to the 
antibiotic cefotaxime. It was found that among laboratory isolates at least one synonymous 
mutation occurs at a frequency that is too high to be explained by mere chance, while another 
mutation conferred a direct adaptive benefit at low cefotaxime concentrations. Among clinical 
TEM-isolates, indications exist that similar functional-yet-synonymous mutations may be 
present. Putative mechanisms underlying the adaptive benefit are explored using information 
on mRNA stability and codon usage. 
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5.1 Introduction 
 
Owing to the redundancy of the genetic code, most amino acids are encoded by more than one 
codon (a triplet of nucleotides). Codons encoding the same amino acid are called 
synonymous, because they use a different ‘word’ (the nucleotides) to deliver exactly the same 
‘message’ (the amino acid encoded). Synonymous mutations are also known as ‘silent’ 
mutations, because of the once widely accepted notion that mutations cannot alter gene 
function or phenotype when they do not change the amino acid sequence (ANFINSEN 1973). 
However, in the past decades evidence has accumulated that silent mutations are not 
necessarily functionally silent; silent mutations have been found to cause functional effects by 
affecting translation efficiency, splicing, miRNA binding, mRNA folding and translational 
timing (PARMLEY and HURST 2007).  
The evolution of antibiotic resistance genes offers an excellent opportunity for tracing and 
studying functional-yet-silent mutations, since both the natural and in vitro evolution of some 
of these genes in response to challenges with novel antibiotics has been recorded in great 
detail. Here, we study the silent mutations present in two datasets, one of clinical isolates and 
one of laboratory isolates of the TEM family of antibiotic resistance genes. 
TEM-1 is one of the best studied and widespread antibiotic resistance genes around. It 
encodes the enzyme TEM-1 ß-lactamase, which confers resistance to most ß-lactam 
antibiotics like penicillins and early cephalosporins (MATAGNE et al. 1998). Mutations in the 
gene can expand this resistance spectrum to more modern cephalosporins, monobactams and 
penicillin/ inhibitor combinations. It is generally thought that the many different TEM-alleles 
that have been isolated in the past decades are the result of increased and novel antibiotic 
pressures (BARLOW and HALL 2002). Since the first TEM-allele was isolated in 1963 (DATTA 
and KONTOMICHALOU 1965), more than 160 TEM-alleles have been identified, each with a 
unique amino acid sequence. TEM-1 has also been used to predict the evolution of antibiotic 
resistance in the laboratory (VAKULENKO et al. 1998; BARLOW and HALL 2002; BARLOW and 
HALL 2003).  
We have sequenced 65 TEM-alleles isolated in separate experiments of in vitro 
mutagenesis followed by in vivo selection for increased resistance to the antibiotic cefotaxime 
(Salverda and de Visser unpublished). Next to a large number of nonsynonymous mutations, 
85 silent mutations were identified in this dataset. Several of these silent mutations were 
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found in two, three or even four independently evolved alleles, suggesting that they may have 
been selected. Here, we provide direct experimental evidence that at least one of these 
frequently occurring silent mutations increases resistance to cefotaxime. We also present 
statistical evidence that another silent mutation with beneficial effect is present in our dataset. 
Apart from this, we have analysed the silent variation present in 175 unique clinical isolates 
of TEM-alleles and we find indications that at least some of these silent mutations could also 
have been selected for their improved functional effects.   
 
5.2 Materials and methods 
 
Clinical dataset: Sequence data of 175 clinical isolates of TEM that differ in their nucleotide 
sequence were gathered using the references in the online database of clinically isolated 
TEM-variants (http://www.lahey.org/studies/temtable.asp) and GenBank.  
 
Experimental dataset: The experimental dataset consists of the sequences of 65 TEM-alleles 
isolated after in vitro mutagenesis of TEM-1 followed by in vivo selection for increased 
cefotaxime resistance. The exact experimental procedures used in these experiments are 
explained in detail below. It is important to note that all these alleles have been isolated under 
identical mutagenic and selective conditions, which are detailed below. 
 
Bacterial strains and plasmids: Escherichia coli strain DH5αE (Invitrogen) was used as the 
host for all plasmids. Plasmid pACSE3 (BARLOW and HALL 2002) was used as the vector for 
cloning and expressing TEM alleles.  
 
Media: LB-broth is 10g trypticase peptone, 5 g yeast extract and 10 g NaCl/ litre. LB-Tet 
medium is LB-broth containing 15 mg tetracycline/ litre. Mueller Hinton broth (Merck) was 
prepared according to the manufacturer’s instructions. SOC medium is 20 g bacto-tryptone 
and 5 g yeast extract/ litre with 10 mM NaCl, 2.5 mM KCl, 10 mM MgCl2 and 20 mM 
glucose. Solid media contained 16 g agar/ litre. 
 
Mutagenesis: TEM-1 alleles were mutagenized using the Genemorph I and Genemorph II 
PCR Mutagenesis Kits (Stratagene) according to the manufacturer’s instructions. Primers P3 
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(TCATCCGGCTCGTATAATGTGGA) and P4 (ACTCTCTTCCGGGCGCTATCAT), were 
used for PCR. Mutated amplicons were digested with BspHI and SacI restriction enzymes, 
ligated into plasmid pACSE3 (BARLOW and HALL 2002) and electroporated into Escherichia 
coli strain DH5αE. After recovery for 90 min in SOC medium at 37°C, the cells were diluted 
in 500 ml LB-tetracycline broth. An aliquot was taken out of this directly after mixing and 
plated out on LB-tetracycline to determine the library-size, while the remainder of the culture 
was placed overnight at 37°C to expand the library.  
 
Selection for extended-spectrum TEM-alleles: A series of bottles containing 50 ml Mueller 
Hinton broth was inoculated with 50 mM IPTG and cefotaxime in two-fold increments 
(ranging from 0.125 µg/ ml, the minimal inhibitory concentration of TEM-1, to 1024 µg/ ml). 
Subsequently, each bottle was inoculated with a number of cells from the overnight-enriched 
library that was equivalent to 10 times the library-size. Cultures were incubated for 48 hours 
at 37°C. The culture that grew at the highest concentration of cefotaxime was plated on LB + 
Tet to select for maintenance of the plasmid, which contains a Tet
r
 gene. A single genotype is 
expected to dominate this culture (BARLOW and HALL 2002). The next day a single colony 
was picked from this plate and grown overnight in LB + Tet. Plasmid from this overnight 
culture was subsequently isolated using the GenElute™ Plasmid Miniprep Kit (Sigma) and 
sequenced.  
 
Sequencing: The TEM-allele was amplified from isolated plasmids using primers P3 and P4 
and BigDye™ (Perkin Elmer) or DYEnamic™ ET (AP-biotech) Terminator Cycle 
Sequencing kits according to the manufacturer’s instructions. 
 
Antibiotics and MIC-assay: The antibiotics cefotaxime (Ctx) and tetracycline (both Sigma) 
were used in this study. Stock solutions were made in 0.1M NaPO4, pH 7.0 (cefotaxime) and 
70% ethanol (tetracycline). Minimal inhibitory concentrations (MICs, defined here as the 
lowest concentration of antibiotic that completely inhibits visual bacterial growth after 24 
hours) were determined from overnight cultures diluted to a titre of 10
5
 cells/ ml in Mueller 
Hinton II broth containing 50 µm IPTG (to cause expression of TEM by inactivation of the 
lacI-repressor). Aliquots of 150 µl of this diluted culture were added to twofold serial 
dilutions of cefotaxime in 150 µl Mueller Hinton II in 96-well microtitre plates. In order to 
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increase accuracy, we used starting concentrations of 0.250 and 0.187 µg Ctx/ ml and diluted 
with twofold steps from there. The culture used as inoculum was also suitably diluted and 
plated on LB + Tet in order to check the true inoculum. MIC is defined as the lowest 
concentration of antibiotic that completely prevents visible growth. Once inoculated, cultures 
were grown for 24 hours at 37°C, after which MIC was determined by visual inspection. Prior 
to the MIC assay both alleles tested (TEM-1 and the silent mutant N175*) were placed into an 
isogenic vector background in order to exclude possible variation at the level of the plasmid. 
Both plasmids were then transformed into isogenic E. coli DH5αE cells by electroporation in 
order to exclude phenotypic variation in the host.  
 
Annotation of mutations: Silent mutations in the TEM-allele are described by the respective 
nucleotide in the TEM-1 sequence, the number of the nucleotide according to Sutcliffe (1978) 
and the nucleotide in the respective mutant sequence. Amino acid numbering is according to 
Ambler (1991). In the text, some silent mutations are described by the amino acid involved. 
The mutation is then indicated by a single letter indicating the amino acid according to the 
IUPAC single letter code, the number of the respective amino acid according to Ambler 
(1991) and an asterix (indicating that the amino acid has not changed). 
 
5.3 Results & discussion 
  
Several mechanisms that can cause functional effects of silent mutations have been 
demonstrated in the past two decades (PARMLEY and HURST 2007). Two mechanisms that 
apply both to prokaryotes and eukaryotes have been particularly well documented in recent 
years; effects on mRNA secondary structure (NACKLEY et al. 2006) and on enzyme folding 
(KIMCHI-SARFATY et al. 2007). Below, we will first statistically analyse the dataset of 
experimentally obtained silent mutations in TEM-1 in order to address the question whether 
the frequency of occurrence of some of the silent mutations found is higher than expected 
under a uniform distribution. Subsequently, we directly measure the resistance of a mutant 
TEM-allele that differs from TEM-1 by a single silent mutation. Finally, we analyse the 
datasets of silent mutations in clinical and experimental isolates from the perspective of the 
two main mechanisms for functional effects of silent mutations described so far; mRNA 
secondary structure and enzyme folding. 
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Statistical arguments for the adaptive significance of silent mutations 
A total of 85 silent mutations were found in the dataset of TEM-alleles isolated after directed 
evolution for increased cefotaxime resistance (Table 5.1). Within this dataset, three mutations 
(T141*, A150* and N175*) were found three times and one (H153*) was found four times. 
Since there are 616 silent mutations possible in the TEM-1 coding sequence (Table 5.1), it 
was suspected that the chances of finding the same silent mutation three or four times would 
be extremely low when ‘drawing’ 85 times (the number of silent mutations found in the total 
dataset) with replacement. 
 
Table 5.1: Characterization of the 85 silent mutations found in the experimental dataset. 
 
Number of times found   Number of possible silent 
mutations in TEM-1 
1 2 3 4 Total 
Transitions       
A → G, T → C 165 26 0 1 0 29 
G → A, C → T 126 15 2 2 1 29 
       
Transversions       
A → T, T → A 96 8 2 0 0 12 
A → C, T → G 93 2 0 0 0 2 
G → C, C → G 63 1 0 0 0 1 
G → T, C → A 73 10 1 0 0 12 
       
Total 616 62 5 3 1 85 
 
 
We investigated whether mutations found with high frequency in the experimental dataset 
occur more often than would be expected under randomness and independency model 
assumptions. We first focus on the most frequently found silent mutation (H153*, found in 
four independently evolved alleles) which is caused by a GC → AT transition. By focusing at 
the specific transition, we eliminate the mutational spectrum of the error-prone polymerase as 
a factor that can affect the frequency of occurrence of certain mutations. In total, 29 such 
transitions were found in the experimental dataset (the ‘balls’ in the statistical model below), 
while there are 126 different positions in the TEM-1 coding sequence where such a silent 
transition can be located (the ‘bins’ in our model).  
 
An appropriate mathematical-statistical model is the following. Given are N = 126 bins and n 
= 29 balls.  
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The null-hypothesis H0: ‘balls are thrown independently and each bin has a constant 
probability of 1/126 of being hit’ is tested against the alternative hypothesis  
 
H1: ‘bins having been hit in the process already have a higher probability to be hit again’.  
 
As a test statistic, we choose M with M the maximum number of hits taken over all bins. 
Under H1, high outcomes of M have a higher probability than under H0, so the rejection 
region is to be chosen right-hand sided. The experimental dataset and the corresponding 
Expected numbers under the null-hypothesis based on Binomial calculations, are as follows. 
 
Number of hits 0 1 2 3 4 ≥5 
Number of bins 106 15 2 2 1 0 
Expected number of 
bins under H0 
100.0035 23.2008 2.5985 0.1871 0.0097 0.0004 
  
Outcome of the test statistic therefore is M = 4. In accordance with the right-hand sided 
rejection region, the significance of the test is P0 (M ≥ 4), where P0 is the probability under the 
null-hypothesis. If the significance is sufficiently small, the null-hypothesis can be rejected. 
Let Hij be the event that bin i is hit in attempt j (i = 1, 2, .., 126; j = 1, 2, .., 29). Let Ai be the 
event that bin i is hit more than or equal to 4 times. From elementary probability theory and 
symmetry arguments we have 
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which supplies sufficient evidence to reject the null-hypothesis in favour of the alternative 
hypothesis. The conclusion therefore is that this silent mutation occurs too frequently to be 
explained by random chance if we assume a uniform distribution of chances.  
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Second dataset 
The story is different for the remaining substitution that occurs three times (A150*), since this 
mutations is caused by another transition (AT → GC). The experimental dataset is in this case 
as follows. 
 
Number of hits 0 1 2 3 ≥4 
Number of bins 138 26 0 1 0 
Expected number of 
bins under H0 
138.3315 24.4611 2.0881 0.1146 0.0047 
 
Using the same formulas as described above for N = 165, n = 29 and M = 3, we find P0 (M ≥ 
3) ≈ 0.134. We conclude that this mutation does not occur at a frequency that is high enough 
to reject H0. Overall, the only silent mutation that occurs more frequently than expected under 
a Binomial distribution is H153*. It thus seems that this silent mutation either confers some 
selective advantage or is the result of the presence of a mutational hotspot. 
 
MIC measurement of a TEM-1 variant containing a single silent mutation 
Next to the statistical arguments presented above, our idea that some of the silent mutations 
might in fact increase antibiotic resistance was strengthened by an observation in the 
experiments; one of the silent mutations that was found three times (N175*), was identified as 
the sole mutation present in a TEM allele that had been isolated after a single round of error-
prone PCR and selection at a cefotaxime concentration higher than TEM-1’s MIC. Based on 
this observation, we measured the MIC of four different clones of both TEM-1 and the silent 
mutant N175* with threefold replication, after having replaced both alleles in the naïve vector 
background and transformation into isogenic bacteria (Table 5.2). The MIC of the N175* 
mutant turned out to be significantly higher than that of TEM-1 (Mann-Whitney U = 3.50, P < 
0.001), indicating a selective benefit of this silent mutation.  
Next, we analyse the silent mutations found in clinical isolates and those found with high 
frequency in experiments in order to test the possible contribution of two of the main 
mechanisms that can cause functional effects, i.e. mRNA folding and protein folding.   
 
Analysis of mRNA secondary structure 
There is strong evidence that silent mutations can affect protein translation efficiency by 
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Table 5.2: MICs of overnight cultures of four different clones of TEM-1 and a silent variant of TEM-
1 differing by a single silent mutation (N175*). 
  
Allele Clone MIC
a 
TEM-1 1 0.031 
 2 0.047 
 3 0.031 
 4 0.047 
N175* 1 0.063 
 2 0.094 
 3 0.063 
 4 0.094 
 
a 
Median value across three replicates. 
 
altering the secondary structure of the mRNA (NACKLEY et al. 2006). For instance, it has 
been demonstrated that in the specific case of TEM-1 the replacement of a stretch of 24 
codons by their synonymous counterparts most frequently used in E. coli results in an 
increased mRNA half-life (DEANA et al. 1996). We have predicted the mRNA secondary 
structures of all known clinically isolated silent variants of TEM-1 (TEM-1b, c, d, e, f , g and 
an additional variant here named TEM-1-II) and of the four silent variants of TEM-1 that 
contain one of the silent mutations found with high frequency in the experimental dataset 
(T141*, A150*, H153* and N175*), using the Mfold (MATHEWS et al. 1999; ZUKER 2003) 
and Vienna (HOFACKER et al. 1994) programs (Table 5.3). Just a few of the clinically isolated 
TEM-variants have a Gibbs free energy (∆G) that is consistently lower than that of TEM-1 
(TEM-1d, TEM-1f and TEM-1-II), indicating that they may form a more stable mRNA 
secondary structure. There are no experimental isolates that have a consistently lower ∆G 
than TEM-1 (although A150* has a much lower ∆G than TEM-1 according to Mfold). The 
inconsistency of the outcome of the two methods used makes it hard to draw clear 
conclusions from these data. We therefore can neither support nor reject the hypothesis that 
adaptive effects of these silent mutations are the result of changes in mRNA stability. 
Measurements on mRNA half-life (DEANA et al. 1996) could provide more reliable data, but 
are beyond the scope of this study.  
 
Putative effects on enzyme folding 
Location of silent mutations in clinically and experimentally isolated TEM-alleles 
It has been noted that rare codons are found more frequently than expected in parts of the 
sequence that encodes turns, loops and linker regions of proteins (KOMAR et al. 1999). It has 
been suggested that, since such regions are more slowly translated, they may serve as 
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interpunctuations separating different folding events (PURVIS et al. 1987). Therefore, if the 
silent mutations found in clinical and experimental isolates have functional effects, they may 
be found more often than expected in these regions.  
 
Table 5.3: Silent variation in clinically isolated silent variants of TEM-1 and changes in Gibbs free 
energy (∆G) of the respective mRNAs relative to TEM-1. The ∆∆G of the four silent mutations found 
with high frequency in experimental isolates is shown below.  
Allele Occurrence Silent mutation 
∆∆G (relative to 
TEM-1) 
  c226t a346g c436t g604t t682c c913t g925a Mfold Vienna 
TEM-1 14        0 0 
TEM-1b 29 X  X X    1.12 -1.43 
TEM-1c 6   X     -0.11 0.19 
TEM-1d 1   X   X  -3.85 -0.21 
TEM-1e 1 X X X X    1.12 -1.43 
TEM-1f 61  X X  X  X -0.45 -1.27 
TEM-1g 10   X X    2.6 0.47 
TEM-1-II 3 X  X     -1.59 -.143 
           
T141* 3        -2.28 1.39 
A150* 3        -4.35 -0.01 
H153* 4        0 0 
N175* 3        0 0 
 
 
To test this, we first analysed the distribution of silent mutations in clinical TEM-isolates. 
Using the references in the Lahey-database and GenBank, we collected 175 unique TEM 
nucleotide sequences (belonging to 150 unique amino acid sequences). The location of the 
silent mutations found in these sequences is shown in Figure 5.1 and the details of all 
mutations depicted in this figure can be found in Table 5.4. Before analysing the distribution 
of these silent mutations over the various structural regions, we first corrected the data for the 
number of silent mutations possible per nucleotide and for the spectrum of spontaneous 
mutations in E. coli (BARLOW and HALL 2002). We found no evidence that silent mutations 
are more or less common then expected in the signal sequence (χ
2
 = 2.00, df = 1, P = 0.16), α-
helices (χ
2
 = 1.12, df = 1, P = 0.29), ß-sheets (χ
2
 = 1.14, df = 1, P = 0.28), or the remaining 
turns, loops and hinges (χ
2
 = 0.07, df = 1, P = 0.80). Furthermore, the distribution over these 
four different regions of TEM-1 combined does not differ significantly from what would be 
expected under a uniform distribution (χ
2
 = 3.78, df = 3, P = 0.29). Concluding, we find no 
evidence that the location of the silent mutations found in the dataset of clinical isolates is 
clustered in specific structural regions within TEM-1. 
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Figure 5.1: Location of silent mutations in TEM-1, as found in clinical isolates (asterices) and 
directed evolution studies (black triangles). Scale is the amino acid numbering according to Ambler 
(1991). Structural features like α-helices (grey) and ß-sheets (dotted) have been indicated according to 
Jelsch et al. (1993) and some additional structural features of TEM-1 are shown in text below. 
Nucleotide substitutions occurring in variants of TEM-1 that only contain silent mutations have been 
indicated by dotted arrows, the substitutions indicated by the respective nucleotide in TEM-1, the 
numbering according to Sutcliffe (1978) and the nucleotide in the mutant sequence. 
 
The location of the four silent mutations found more than twice in the experimental dataset is 
shown in Figure 5.1 (black triangles). All four mutations occur in or in the vicinity of the 
structurally important Ω-loop (Figure 5.2). Because of the surprisingly short distance between 
the four mutations, we approximated the chance of finding a maximum distance of 34 amino 
acids when drawing four times with replacement from 273 possible locations (the total 
number of amino acids in TEM-1 minus the ones that cannot harbour silent mutations). 
Drawing ~10,000 sets as described before indicated that this chance is extremely low 
(~0.007), suggesting that the mutations indeed cluster together in a specific region of the 
TEM-allele. It is known that the exact positioning of the Ω-loop in and around which these 
mutations occur (see Figure 5.2) is of crucial importance for TEM-1 activity. On the one hand 
repositioning of this loop due to nonsynonymous mutations is known to increase TEM-1’s 
resistance to several novel antibiotics (KNOX 1995). On he other hand, the Ω-loop contains 
several highly conserved amino acids and is relatively sensitive to nonsynonymous mutations 
when selection for ampicillin resistance is maintained (PALZKILL and BOTSTEIN 1992). It may 
therefore well be that the silent mutations found in the experimental dataset influence protein 
folding and thereby the position of the Ω-loop, as will be explained below.   
 
 
Codon usage in the 15-codon neighbourhood of the experimental silent mutations 
It has been hypothesised that protein folding is affected by the in vivo translation rate (PURVIS 
et al. 1987). Since translation kinetics are influenced by both the synonymous codon usage 
3
***** ** * * * * *
100 200 290
* * * *** *
Hinge I Hinge IIΩ-loopSignal peptide
*
c226t a346g c436t g604t t682c c913t g925a
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bias and the availability of cognate tRNAs of a specific organism, regions of rare synonymous 
codons might be translated more slowly (KOMAR and JAENICKE 1995). In turn, protein folding 
is thought to be a co-translational process and it has been suggested that alteration of the 
translation kinetics can influence protein folding (KOMAR et al. 1999). Recent empirical work 
showing that silent mutations can indeed affect protein folding supports this hypothesis and it 
was suggested that the silent mutations involved may contribute to the formation of clusters of 
rare codons that alter the timing of co-translational folding (KIMCHI-SARFATY et al. 2007). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.2: Location of the four silent mutations found with high frequency in experimental isolates in 
the 3d structure of TEM-1 (PDB-code: 1BTL). The Ω-loop is shown in black and a cefotaxime 
molecule (grey sticks) has been modelled in the binding pocket. 
 
In E. coli, known to have a strong codon bias and a level of cognate tRNAs that is directly 
proportional to codon usage (IKEMURA 1981), rare codons are at the same time slowly 
translated codons (KOMAR et al. 1999). Thus, in E. coli, the main host of clinical TEM-alleles 
and the host of the TEM-alleles in our experimental dataset, mutations that alter a codon to a 
synonymous but rare codon might affect protein folding according to the model proposed by 
Kimchi-Sarfaty et al. (2007). We have analysed the codon usage in TEM-1 and in the codons 
altered by the silent mutations in the clinical and experimental datasets using two different 
codon preference criteria for E. coli. Ikemura (1981) used tRNA concentrations and the 
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efficiency of codon-anticodon interactions to describe a set of non-optimal codons. Because 
this set does not cover all amino acids, we also identified rare codons by looking at the codon 
usage in very highly expressed genes in E. coli (SHARP and LI 1986). The pattern of codon 
usage in very highly expressed genes can reveal which of the alternative synonymous codons 
for an amino acid are the most and the least efficient, since it has been shown that the strong 
codon usage bias in these genes is directly proportional to the level of cognate tRNAs 
(IKEMURA 1981).  
The codon changes caused by synonymous mutations found in clinical isolates and by the 
four synonymous mutations found with high frequency in experimental isolates are shown in 
Table 5.4. The consequences of these changes regarding the two codon preference criteria 
described above are shown in the same table. Although most synonymous mutations in 
clinical isolates are towards less optimal or less frequent codons it is hard to draw conclusions 
from this observation, as it is unknown whether TEM-1 is the ‘ancestral’ sequence. There are 
seven variants of TEM-1 that only differ at synonymous sites and judging from the high 
frequency at which some of these mutations occur in the 175 clinical isolates analysed here, 
this actually seems unlikely. Our lack of information of the evolutionary relationships of the 
TEM alleles therefore complicates conclusions about the mechanism underlying a possible 
adaptive benefit of these silent mutations. 
 The four synonymous mutations found more than twice in experimental isolates all change 
their codon to the least optimal (with one exception where criteria do not apply) or least 
frequent one (Table 5.4). We have analysed the 15-codon neighbourhood of these four 
synonymous mutations (in analogy to Kimchi-Sarfaty et al.) using the codon preference 
criteria defined by Ikemura (1981) and the Relative Synonymous Codon Usage values 
(RSCU, i.e. the number of codons observed for a specific amino acid divided by the number 
of codons expected under a uniform distribution) of very highly expressed genes of E. coli 
(SHARP and LI 1987) (Table 5.5). All four silent mutations lower the RSCU value of their 
codon to the lowest possible value, while three of the four change the codon to the least 
preferred according to the Ikemura-criteria (the fourth codon change is not characterised by 
these criteria). In addition, all four mutations are surrounded by a large number of rare codons 
according to both methods of analysis, an image similar to that found by Kimchi-Sarfaty et al. 
(2007), which indicates that the mutations might be involved in the formation of clusters of 
rare codons. 
  
Table 5.4: Silent mutations found in clinical isolates and silent mutations found with high frequency in directed evolution studies.  
 
 Silent 
mutation
a 
Amino 
acid 
Change Occurrence Change according to Ikemura
b 
Change according to Sharp & Li
c 
     Before After Before After 
Clinical isolates c226t F8 ttc > ttt 42 Optimal Least optimal 1.54* 0.46** 
 t229a R9 cgt > cga 1 Optimal Least optimal 4.38* 0.02** 
 t241a I13 att > ata 1 Sub-optimal Least optimal 0.47 0.01** 
 g292t L30 ctg > ctt 1 Optimal Least optimal 5.33* 0.23 
 a346g E48 gaa > gag 90 Optimal Least optimal 1.59* 0.41** 
 c370t I56 atc > att 3 Optimal Sub-optimal 2.53* 0.47 
 c436t G78 ggc > ggt 149 Optimal Optimal 1.65 2.28** 
 g469a E89 gag > gaa 2 Least optimal Optimal 0.41** 1.59* 
 g604t A134 gcg > gct 50 Optimal Optimal 0.80 1.88* 
 g625a T141 acg > aca 4 Least optimal Least optimal 0.19 0.14** 
 t682c T160 act > acc 89 Optimal Optimal 1.80 1.87* 
 a856g G218 gga > ggg 1 Least optimal Sub-optimal 0.02** 0.04 
 c863t L221 ctg > ttg 1 Optimal Least optimal 5.33* 0.11 
 g871t S223 tcg > tct 1 - - 0.04** 2.57* 
 t907a S235 tct > tca 1 - - 2.57* 0.20 
 c913t A237 gcc > gct 1 Optimal Optimal 0.23** 1.88* 
 g925a G242 ggg > gga 74 Sub-optimal Least optimal 0.04 0.02** 
 c970t S258 tcc > tct 1 - - 1.91 2.57* 
 c985t I263 atc > att 1 Optimal Sub-optimal 2.53* 0.47 
 g1003a Q269 cag > caa 1 Optimal Sub-optimal 1.78* 0.22** 
 t1009g T271 act > acg 1 Optimal Least optimal 1.80 0.19 
         
Experimental isolates g625a T141 acg > aca 3 Least optimal Least optimal 0.19 0.14** 
 t652c A150 gct > gcc 3 Optimal Least optimal 1.88* 0.23** 
 t661c H153 cac > cat 4 - - 1.55* 0.45** 
 c727t N175 aac > aat 3 Optimal Least optimal 1.90* 0.10** 
a Mutations in bold are present in one of the seven silent variants of TEM-1. All mutations shown are relative to the TEM-1 sequence (SUTCLIFFE 1978). 
b Codon preference principles for E. coli as defined by Ikemura (1981); dash indicates that the criteria are not applicable 
c Relative Synonymous Codon Usage (RSCU; observed frequency of codon/ expected frequency of codon when all codons for a particular amino acid are used equally) 
of highly expressed proteins in E. coli according to Sharp & Li (1987); dark shade indicates that the change is towards a lower RSCU value, * highest RSCU ** lowest 
RSCU
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Table 5.5: RSCU values of the 15-codon neighborhood around the four silent mutations found with high frequency in the experimental data. For each 
codon the maximal (‘max’) and actual (‘act’) RSCU are shown, in analogy to the supplemental data of Kimchi-Sarfaty et al. (2007). The four silent 
mutations are boxed and the codon before (left) and after (right) the silent mutation is shown.  
 
AA
a 
A A N L L L T T141 I G G P K E L  
Codon
b 
GCG GCC AAC TTA CTT CTG ACA ACG ACA ATC GGA GGA CCG AAG GAG CTA  
Max 1.88 1.88 1.90 5.33 5.33 5.33 1.87 1.87  2.53 2.28 2.28 3.29 1.60 1.59 5.33  
Act
c 
0.80 0.23 1.90 0.11 0.23 5.33 0.14 0.19 0.14 2.53 0.02 0.02 3.29 0.40 0.41 0.04  
                  
AA
a 
G G P K E L T A150 F L H N M G D H 
Codon
b 
GGA GGA CCG AAG GAG CTA ACC GCT GCC TTT TTG CAC* AAC ATG GGG GAT* CAT* 
Max 2.28 2.28 3.29 1.60 1.59 5.33 1.87 1.88  1.54 5.33 1.55 1.90  X
d 
2.28 1.40 1.55 
Act
c 
0.02 0.02 3.29 0.40 0.41 0.04 1.87 1.88 0.23 0.46 0.11 1.55 1.90  X
d 
0.04 0.61 0.45 
                  
AA
a 
K E L T A F L H153 N M G D H V T R 
Codon
b 
AAG GAG CTA ACC GCT TTT TTG CAC* CAT* AAC ATG GGG GAT* CAT* GTA ACT CGC 
Max 1.60 1.59 5.33 1.87 1.88 1.54 5.33 1.55  1.90  X
d 
2.28 1.40 1.55 2.24 1.87 4.38 
Act
c 
0.40 0.41 0.04 1.87 1.88 0.46 0.11 1.55 0.45 1.90  X
d 
0.04 0.61 0.45 1.11 1.80 1.56 
                  
AA
a 
E L N E A I P N175 D E R D T T M P 
Codon
b 
GAG CTG AAT GAA GCC ATA CCA AAC AAT GAC* GAG CGT GAC* ACC ACG ATG CCT 
Max 1.59 5.33 1.90 1.59 1.88 2.53 3.29 1.90  1.40 1.59 4.48 1.40 1.87 1.87  X
d 
3.29 
Act
c 
0.41 5.33 0.10 1.59 0.23 0.01 0.44 1.90 0.10 1.40 0.41 4.48 1.40 1.87 0.19  X
d 
0.23 
a Amino acid (according to the IUPAC single letter code) 
b Shade indicates that the codon used is not the most preferred according to Ikemura (1981). Dark shade indicates least preferred codons. Asterix indicates that no 
preference data are available for the respective codon. 
c Shade indicates that the codon used is not the most common one according to the RSCU values of Sharp and Li (1987). Dark shade indicates lowest RSCU value. 
d No RSCU value, since amino acid is encoded by a single codon only. 
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Since the Ω-loop is of high functional importance for TEM-1 and since the silent mutation 
found three times in this loop in experiments (N175*) was found to increase MIC levels, we 
have focussed on the codon usage in this loop and its border-regions in the same way as 
described above (Table 5.6). It is clear that the codon switch caused by the silent mutation at 
amino acid position 175 contributes to the formation of a rather large cluster of rare codons 
located around the C-terminal end of the Ω-loop. When this results in a local decrease in the 
speed of translation it may influence the folding of the Ω-loop, and in that way affect the MIC 
for cefotaxime, as was found for the mutant TEM-allele containing only this silent mutation.  
 
Silent variation in signal sequence of natural isolates 
Secretory signal sequences of E. coli are rich in non-optimal codons and it was hypothesised 
that this could facilitate targeting of secretory proteins by allowing interaction of the nascent 
signal peptide with the cell membrane prior to translocation (BURNS and BEACHAM 1985; 
POWER et al. 2004). It has also been shown that the codon composition of the signal sequence 
of TEM-1 (amino acids 3 to 25) can alter enzyme expression: when 13 non-optimal codons 
(according to the criteria of Ikemura 1981) in this region were replaced by optimal ones, a 
fourfold reduction in resistance to ampicillin was measured that was independent of plasmid 
copy number or mRNA levels (ZALUCKI et al. 2008). When this ill-performing mutant was 
subsequently allowed to revert its first six optimised codons using degenerate primers, the 
nine isolated colonies with increased resistance levels all contained reversions to non-optimal 
codons. Stimulated by these findings, we have analyzed the codon changes caused by silent 
mutations in the signal peptide region of clinical isolates of TEM-1. Again, we used two 
different methodologies to estimate codon preference in E. coli for comparison (IKEMURA 
1981; SHARP and LI 1987). We found that the three silent mutations identified in the signal 
peptide of clinical TEM-isolates change the respective codons to the least optimal ones 
according to both datasets (Table 5.7 and 5.8). 
Interestingly, it seems that non-optimal codons in the N-terminal half of the signal 
sequence are especially important to maintain ß-lactamase expression (ZALUCKI et al. 2008). 
All three silent mutations found in clinical isolates are in this region and they all change a 
(sub)optimal variants that only contain silent mutations (TEM-1b, TEM-1e and TEM-1-II) 
and is ubiquitous among clinically isolated TEM-alleles. We therefore speculate that in E. coli 
such a mutation could have a subtle but yet unnoticed effect on ß-lactamase expression. 
  
Table 5.6: Codon usage in the Ω-loop. The change in codon caused by the silent mutation at amino acid position 175 has been boxed. 
a Structure according to Jelsch et al. (1993); note that a small α-helix is present between 168-170 
b According to the IUPAC single letter code 
c Codon preference according to the principles defined by Ikemura (1981); shade indicates codon is not the most preferred codon, dark shade indicates least preferred 
codons. Asterix indicates that no preference criteria are available. 
d Codon preference according to the RSCU values of Sharp and Li (1987); shade indicates that the codon used is not the most common one, dark shade indicates the 
least common codons. 
e Amino acid encoded by a single codon. 
 
Table 5.7: Distribution of optimal (white) and non-optimal codons (shaded) in the signal sequence of TEM-1, according to the codon preference table of 
Ikemura (1981) (darkest shade indicating least preferred codons) and the codon distribution in very highly expressed proteins of E. coli as described by 
Sharp and Li (1987) (darkest shade indicating codons with lowest RSCU values). The codon-changes caused by the three silent mutations that can be 
found in clinical isolates (in amino acids 8, 9 and 13) are given next to the respective wild-type codon and in each case both have been boxed. Codons 
where criteria don’t apply are indicated with an asterix.   
 
Position 3 4 5 6 7 8  9  10 11 12 13  14 15 16 17 18 19 20 21 22 23 24 25 
AA M S I Q H F  R  V A L I  P F F A A F C L P V F A 
Codon ATG AGT ATT CAA CAT TTC TTT CGT CGA GTC GCC CTT ATT ATA CCC TTT TTT GCG GCA TTT TGC CTT CCT GTT TTT GCT 
Ikemura * *   *                *      
Sharp *                          
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Table 5.8: Details of silent mutations found in the signal peptide region of TEM-1 in clinical and 
experimental isolates. 
 
 Amino acid Silent mutation # isolates Changea Changeb 
    From: To: From: To: 
Clinical 
isolates 
F8 c226t 44 Optimal Least-
optimal 
1.54* 0.46** 
 R9 t229a 1 Optimal Least-
optimal 
4.38* 0.02** 
 I13 t241a 1 Sub-
optimal 
Least-
optimal 
0.47 0.01** 
        
Experimental 
isolates 
I5 t217a 1 Sub-
optimal 
Least-
optimal 
0.47 0.01** 
 Q6 g220a 1 Optimal Least-
optimal 
1.78* 0.22** 
 R9 t229a 2 Optimal Least-
optimal 
4.38* 0.02** 
 I13 t241c 1 Sub-
optimal 
Optimal 0.47 2.53* 
 A17 g253a 1 Optimal Optimal 0.80 1.10 
 
a According to codon usage preference as defined by Ikemura (1981).  
b Relative Synonymous Codon Usage (RSCU) values based on the codon usage in very highly expressed proteins 
of E. coli according to Sharp and Li (1987); * = highest RSCU-value and ** = lowest RSCU-values.  
 
Furthermore, the silent mutation in the amino acid at position nine (which changes the most 
preferred and most common codon ‘CGT’ for arginine to the least preferred and least 
common codon ‘CGA’) was not only found in a clinical isolate, but in two experimental 
isolates as well (Table 5.3). Although it is not possible do distinguish this event from mere 
chance (see our statistical arguments given above), both the location and the nature of this 
silent mutation are at least suspicious. 
 
Concluding, we provide both direct and indirect empirical evidence for functional effects of 
silent mutations in a common antibiotic resistance gene. We show that one of the silent 
mutations found with high frequency in an experimental dataset increases resistance to a new 
antibiotic relative to the wild type enzyme. Another silent mutation was found with such a 
high frequency that the chance that it resulted from genetic drift was estimated to be 
extremely low under the assumption of a Binomial distribution of chances. Furthermore, we 
have reasons to believe that silent variation present in the signal sequence of clinical isolates 
of TEM-alleles is not selectively neutral. Because of this evidence, we think it is important 
that both nonsynonymous and synonymous mutations are reported when sequence data on 
antibiotic resistance genes are reported in order to obtain a better overview of putative 
functional effects of silent mutations. Since antibiotic resistance genes often strongly affect 
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the fitness of their host and are subject to lateral transfer (OCHMAN et al. 2000), which can 
alter the concentration of tRNAs in their environment, they might provide an excellent system 
for the detection and study of functional effects of synonymous mutations. 
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General discussion 
Merijn Salverda 
 
The enzyme studied in this thesis, TEM-1 ß-lactamase, confers resistance to ß-lactam 
antibiotics and is one of the best studied antibiotic resistance enzymes around. The remarkable 
phenotypic plasticity of TEM-1, that gradually became apparent as a result of the introduction 
of more modern ß-lactam antibiotics from the beginning of the 1980s onwards, makes it an 
ideal enzyme for the study of molecular evolution. Consequently, TEM-1 has been used as a 
model system for the study of protein structure-function relationships, directed evolution 
protocols and the prediction of antibiotic resistance. Elaborating on the detailed knowledge of 
both the natural and laboratory evolution of TEM-1, the molecular evolution of this notorious 
antibiotic resistance gene was studied in this thesis. This has resulted in a more detailed 
knowledge about the mechanisms shaping the evolution of TEM-1, such as recombination and 
the nature and interaction of adaptive mutations.   
 
The use of TEM-1 as a model system for the study of epistasis and the fitness landscape 
In Chapter 2, the fitness landscape of TEM-1 was studied using directed evolution. The 
evolutionary potential to adapt to increasing concentrations of cefotaxime, an antibiotic to 
which TEM-1 confers only marginal resistance, was studied using in vitro evolution. 
Deviations from the predominant mutational pathway observed in an initial experiment led to 
the identification of two mutations (causing substitutions R164S and A237T) that had putative 
sign epistatic interactions with the initial mutation of the predominant mutational pathway to 
high resistance (G238S). Directed evolution starting with both single mutants indeed indicates 
that they give rise to one or possibly more alternative mutational pathways. Evidence that 
such interactions do not only play a role at the level of the first mutation in such pathways 
was also found. 
It has been shown that, while sign epistasis can create ridges and valleys in the pathways 
that together constitute a fitness landscape (WEINREICH et al. 2005), a special form of sign 
epistasis named ‘reciprocal sign epistasis’ (where the effect of a mutation at one locus 
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depends on what mutation is present at another locus and vice versa) is a necessary condition 
for the occurrence of multiple peaks isolated by neighbouring genotypes of lower fitness 
(POELWIJK 2008). Such reciprocal sign epistasis is found between substitutions R164S and 
G238S: the double mutant carrying both substitutions has a MIC that is considerably lower 
than that of both single mutants and barely higher than that of TEM-1. In this respect, it 
would be interesting to see what solutions adaptive evolution ‘finds’ when the R164S/ G238S 
double mutant is subjected to in vitro evolution. It is already known that adaptive evolution in 
the background of this double mutant is possible by addition of substitution E104K or M182T 
(ZACCOLO and GHERARDI 1999), but it is unknown where this evolutionary trajectory goes 
and whether at some point back mutation S164R or S238G is the only way ‘up’. The same 
questions apply to the evolutionary fate of the A237T/ G238S double mutant.  
 
The comparison of natural and laboratory evolution 
Considering laboratory evolution in vivo (experimental evolution) and in vitro (directed 
evolution), TEM-1 ß-lactamase is by far the best studied antibiotic resistance enzyme around. 
In Chapter 3, the amino acid substitutions identified in 17 laboratory evolution studies on 
TEM-1 mediated antibiotic resistance (the majority focussing at the evolutionary potential for 
increased resistance to a variety of antibiotics that TEM-1 itself is susceptible to) were 
compared to those found in a dataset containing all known clinically isolated TEM-variants 
identified so far. This proved that laboratory evolution is highly successful and accurate in 
identifying the variation found in clinical TEM-alleles. Additionally, side-by-side comparison 
of laboratory studies resulted in the identification of amino acid substitutions that seem to 
constitute a selective benefit but that have nevertheless not (yet) been reported in clinical 
isolates. Time will tell whether these substitutions are part of sequence space not yet tapped 
by natural selection or whether they are laboratory artefacts that are not likely to appear in a 
clinical setting. 
The big question is of course, even when the evolution of antibiotic resistance genes is 
largely predictable in the laboratory, to what extent predictive laboratory evolution can be 
exploited in the design and use of novel antibiotics. For one thing, a priori knowledge about 
the evolutionary potential of antibiotic resistance genes and detailed characterization of the 
pleiotropic effects of the different mutations involved may result in knowledge about which 
drug combinations to apply when a predicted mutant is identified in nature.  
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The effect of recombination and other variables influencing evolutionary dynamics in 
vivo 
In Chapter 4, several lines of evidence are presented indicating that recombination has had an 
important effect on the sequence evolution of TEM-alleles. In order to address the question 
whether recombination has adaptive significance from a theoretical point of view, both 
mutation rate and population size also have to be taken into account, because recombination 
can only be effective in populations that are sufficiently polymorphic. 
There are reasons to believe that the in vivo mutation rate of TEM-alleles is higher than 
that of most bacterial strains. The frequency of hypermutable strains of E. coli is higher 
among clinical strains carrying TEM-alleles than for clinical strains not carrying TEM-alleles 
(BAQUERO et al. 2005). Since a association between hypermutable strains and acquisition of 
antibiotic resistance has been demonstrated (OLIVER et al. 2000), these results suggest that 
TEM-alleles might be subject to increased mutation rates in vivo. This could be connected to 
the finding that ß-lactam mediated inhibition of cell wall synthesis can induce an error prone 
DNA polymerase in E. coli, resulting in an increased mutation rate and a mutator phenotype 
(Perez-Capilla et al. 2005; Tompkins et al. 2003). The chemicals used to fight bacteria might 
thus enhance the rate of antibiotic resistance acquisition.  
The mutation rate in E. coli per base pair per replication is ~5.4 x 10
-10
 (DRAKE et al. 
1998). This means that per round of replication about one in five million E. coli cells harbours 
a TEM-allele with a point mutation (because TEM-alleles are usually plasmidic, the mutation 
rate is increased by a factor 10 assuming an average copy number of 10), which is increased 
to one in five hundred thousand if we assume the alleles reside in weak mutator strains 
(Baquero et al. 2005; Baquero et al. 2004). The exact population size of TEM-carrying 
bacteria in humans is hard to assess. TEM-alleles are most commonly found in bacteria 
isolated from urinary tract infections. Such infections are diagnosed when more than 100,000 
bacterial cells are present per millilitre of urine (WRIGHT et al. 1986). This indicates that 
population sizes in such infections are at least in the order of 10
7
 cells and probably much 
higher.  
For recombination to have any effect at all there needs to be genetic polymorphism in a 
population. The ‘natural’ environment of TEM-alleles seems to promote this; within the 
highly compartmentalized human body, a high diversity of antibiotic concentration gradients 
exists (BAQUERO and NEGRI 1997), which have been shown to promote genetic 
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polymorphism among TEM-alleles (BAQUERO et al. 1997). In agreement with this, multiple 
TEM-alleles are sometimes identified in a single patient (BRADFORD et al. 1994; ESSACK et 
al. 2001; KIM et al. 2004; LAVIGNE et al. 2004). Inter- or intraplasmidic recombination can 
act upon such genetic polymorphism and increase the genetic variation upon which natural 
selection can act.  
An interesting experimental approach to address the importance of recombination would 
be to study the adaptive evolution of TEM-1 mediated resistance to a novel antibiotic in 
normal E. coli cells and in E. coli suppressed in their recombination machinery (rec
-
 mutants). 
Alternatively, in vivo evolution of normal E. coli cells carrying a TEM-allele with a single 
beneficial mutation like G238S could be studied. Cells carrying another single mutant with a 
silent marker and with a positive effect on resistance in the background of G238S (e.g. 
M182T, created by the introduction of a double point mutation) can be continuously added to 
the G238S culture that is evolving in vivo. Whether the G238S culture evolves by point 
mutation or by recombination can now be distinguished (note that transferable plasmids are 
required). 
 
Evidence for selectable yet silent mutations  
In Chapter 5, evidence is presented indicating that a silent mutation can confer an adaptive 
benefit for cefotaxime resistance. Putative mechanisms behind this are discussed and silent 
mutations present in clinical isolates are also analyzed, suggesting that not all of these 
mutations need to be selectively neutral (as is often assumed).  
Under strong antibiotic pressure, the functioning of antibiotic resistance enzymes is 
directly correlated to the fitness of the bacteria they reside in. Thus, the in vitro evolution of 
antibiotic resistance genes may provide a valuable tool for identifying and analyzing silent 
mutations with adaptive effects. It has been noted that compared to the codon usage of E. coli, 
TEM-1 contains a lot of rare codons. It would be interesting to see whether prolonged in vitro 
evolution and selection for improvement of ampicillin resistance would result in any 
translational selection. Frequent lateral transfer between different bacterial species might 
prevent such selection in nature.   
 
 
 
General discussion 
117 
Some other directions for future research 
 
Selection in vivo 
One of the problems of using in vitro evolution protocols is the difficulty of simulating a more 
or less natural mutational process where mutations appear and go to fixation one at a time. 
Although the mutation rate in an error-prone PCR can be accurately controlled, it is 
impossible to achieve a mutation rate that is so low that double mutants are excluded. An 
alternative is to keep the mutational process completely natural, by evolution of the bacteria 
carrying a plasmid with the antibiotic resistance gene to be studied in vivo. Such studies have 
been undertaken and they show that simple daily transfers of bacteria growing in increasing 
amounts of antibiotic yields mutant ß-lactamases within weeks (BLAZQUEZ et al. 2000; 
HOLLOWAY et al. 2007). The evolutionary trajectories described in Chapter 2, as well as 
those described by others (WEINREICH et al. 2006) await testing in such a semi-natural in vivo 
system.   
Another advantage of in vivo evolution is the possibility to follow the evolution of 
antibiotic resistance not only at the level of the plasmidic antibiotic resistance gene, but also 
at the level of evolution of the bacterial chromosome. When the re-transformation step is left 
out, bacterial genes are allowed to evolve along with the gene on the plasmid. Several other 
bacterial genes are known to evolve in response to antibiotic pressure, e.g. those coding for 
the outer membrane proteins and transpeptidases (FRERE et al. 1991; PERILLI et al. 2007). 
While the simultaneous monitoring of the molecular changes at multiple genes may be 
experimentally challenging, it also offers the opportunity to study the interactions between 
mutations at these different genes. A similar and easier approach can be achieved by omitting 
the replacement of the gene in a naïve vector background, which would allow evolution of the 
plasmid as a whole. Although it may seem intuitive that mutations at the regulatory level (like 
promoter mutations or mutations in genes regulating the promoter) result in additive fitness 
effects, increase in protein production can increase the aggregation propensity and thus the 
fitness effect of such regulatory mutations may rely on other mutations that can suppress this 
propensity (WEINREICH et al. 2006).  
 
Fitness-assays 
Since the fitness of a TEM-variant is directly correlated with the maximum concentration of a 
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specific ß-lactam antibiotic that bacteria carrying this variant can tolerate, MIC-assays have 
traditionally been used for assessing the fitness of TEM-alleles. A disadvantage of this 
method is the so-called ‘inoculum effect’; killing of bacteria by lysis result in the release of 
additional ß-lactamases in the test medium and additional hydrolysis of the drug. This effect 
has typically been found with ß-lactam antibiotics against ß-lactamase producing bacterial 
strains (CRAIG et al. 2004). In practice, even when using exactly the same inoculum, slight 
variations in MIC can be recorded the next day (WEINREICH et al. 2006). This can be a 
problem when TEM-alleles that confer subtle differences in resistance level are compared. An 
alternative solution is the use of bacterial strains with neutral phenotypic markers. The fitness 
of different TEM-alleles can be assessed by direct competition between different strains 
carrying different alleles (NEGRI et al. 2000). Easier and more reliable methods relying on 
fluorescence based marker systems are available and could be of great use for more accurate 
fitness measurements of TEM-alleles. 
 
Inaccessible sequence space 
A better understanding of the molecular basis of adaptation is essential for the development of 
evolutionary biology as a predictive science for the study of protein evolution or emergent 
pathogens (COUNAGO et al. 2006). Using the approach of directed evolution, both areas were 
studied in this thesis. It seems that the adaptive solutions found by clinical TEM-isolates 
derive from similar areas in sequence space as the solutions uncovered by directed evolution 
studies, even though some of these studies have employed extremely high rates of 
recombination (STEMMER 1994) and mutation (ZACCOLO and GHERARDI 1999). Interestingly, 
some mutant TEM-variants partially constructed by computational design and optimized 
using directed evolution seem to derived from different areas of sequence space, probably 
because they contain a number of substitutions caused by double or triple nucleotide changes. 
It would be interesting to analyze the fitness (or its ‘proxy’ MIC) of these mutants mutation 
by mutation to see whether there truly is variation that is ‘out of reach’ for adaptive evolution. 
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Antibiotica en hun ontdekking 
Antibiotica zijn stoffen die gebruikt worden voor de bestrijding van ziekteverwekkende 
micro-organismen. Het eerste wereldwijd gebruikte antibioticum, penicilline, wordt 
geproduceerd door bepaalde schimmels. Penicilline speelt een rol in de strijd om 
voedingsstoffen die er woedt in de microbiële wereld. Een schimmel die penicilline 
produceert zorgt er namelijk voor dat er in zijn directe omgeving geen bacteriën kunnen 
groeien. Op die manier worden concurrerende schimmels en andere micro-organismen op een 
afstand gehouden. 
Penicilline werd in 1928 per toeval ontdekt door de Britse microbioloog Alexander 
Fleming. Na terugkeer van zijn zomervakantie ontdekte hij dat veel van zijn achtergelaten 
bacterieplaten met daarop de bacterie Staphylococcus aureus besmet waren door een 
schimmel. Dit was niet zo verwonderlijk, aangezien Fleming bekend stond als een sloddervos 
en er door de aanwezigheid van een schimmellab een verdieping onder het lab van Fleming 
heel wat schimmelsporen door de lucht gezweefd moeten hebben. In eerste instantie zette 
Fleming zijn platen op een stapel in een bak met een ontsmettingsmiddel om de boel te 
desinfecteren. Toen hij die dag een plaat wilde laten zien aan een voormalig collega, greep hij 
een beschimmelde plaat die bovenop de stapel lag en zodoende ontsnapt was aan het 
ontsmettingsmiddel. Pas toen viel hem op dat er rondom de schimmel een gebied te zien was 
waarin geen bacteriën groeiden. Fleming was gefascineerd door deze waarneming. Met veel 
moeite slaagde hij er uiteindelijk in de stof te isoleren die door deze schimmel, genaamd 
Penicillium notatum, geproduceerd werd. Het zou nog tot aan het begin van de Tweede 
Wereldoorlog duren voordat penicilline efficiënt geproduceerd en gebruikt kon worden.  
 
Antibioticumresistentie 
Nog voordat penicilline haar klinische debuut maakte, werd door enkele Britse 
wetenschappers in een laboratorium ontdekt dat bacteriën al bij kortstondige blootstelling aan 
penicilline tekenen van resistentie vertonen. Helaas bleek deze waarneming ook ‘in het veld’ 
te gelden. Binnen enkele jaren na de introductie van penicilline doken de eerste berichten over 
resistente bacteriestammen op. Tegen het eind van de jaren veertig had penicilline veel van 
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zijn aanvankelijke kracht verloren en was men druk doende met de zoektocht naar betere 
antibiotica. Deze zoektocht duurt tot vandaag de dag voort, aangezien tot op heden steevast 
binnen enkele jaren na de introductie van een nieuw antibioticum bacteriële resistentie wordt 
ontdekt. 
Met het probleem van antibioticumresistentie werd ook langzaamaan duidelijk dat 
bacteriën een ontzagwekkend aanpassingsvermogen hebben. Niet alleen bleken bacteriën in 
staat resistentie te ontwikkelen tegen elk nieuw antibioticum dat op de markt werd gebracht, 
ze bleken dit ook nog eens op verschillende manieren te doen. Zo kunnen bacteriën hun 
membranen minder doorlaatbaar maken voor antibiotica, actief antibioticum uit een cel 
pompen, de doelwitten waar antibiotica op aangrijpen aanpassen en zelfs antibiotica afbreken 
met behulp van enzymen.  
Gelukkig heeft ook wat antibioticumresistentie betreft elk nadeel zijn voordeel. Zo is de 
nauwgezette studie van de interactie tussen antibiotica en enzymen die deze antibiotica 
afbreken bijzonder waardevol gebleken voor het beter begrijpen van de interactie tussen 
enzym en substraat, en voor de ontwikkeling van de enzymtechnologie in het algemeen. Ook 
worden antibioticumresistentie genen in de biotechnologie gebruikt om DNA te merken dat in 
bacteriecellen ingebracht wordt; cellen die erin slagen niet eigen DNA op te nemen, nemen 
ook het antibioticumresistentie gen op en zijn op basis van hun nieuw verworven resistentie 
gemakkelijk te scheiden van onveranderde cellen. 
 
ß-lactam antibiotica en de resistentie hiertegen 
In 1961 werd ampicilline op de markt gebracht. Ampicilline is een semi-synthetisch 
antibioticum dat gebaseerd is op penicilline en dat behoort tot de groep van de β-lactam 
antibiotica. Deze antibiotica verstoren de opbouw van de bacteriële celwand, waardoor de 
bacteriecellen uiteindelijk uit elkaar klappen. Net zoals bij alle voorgaande antibiotica volgde 
de eerste melding van ampicilline resistentie binnen enkele jaren en wel in 1963, toen in een 
Atheens ziekenhuis uit een patiënt ampicilline resistente bacteriën werden geïsoleerd. Later 
bleek dat deze resistentie veroorzaakt werd door de productie van een enzym dat ampicilline 
af kan breken. Dit enzym kennen we nu onder de naam TEM-1 β-lactamase . Het eerste deel 
van deze naam is afgeleid van de achternaam van de eerdergenoemde patiënt, Temoneira, 
terwijl het tweede deel aangeeft dat het hier gaat om een enzym dat ß-lactams kan afbreken.  
Aan het begin van de jaren tachtig werd een serie nieuwe β-lactam antibiotica 
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geïntroduceerd. Ook in dit geval werden er binnen enkele jaren resistente bacteriën gevonden. 
Met behulp van experimenten in laboratoria was rond die tijd ook al vastgesteld dat kleine 
veranderingen in het DNA coderend voor TEM-1 β-lactamase de activiteit van dit enzym 
kunnen beïnvloeden. Zulke veranderingen kunnen spontaan ontstaan doordat het 
kopieermechanisme waarmee DNA vermenigvuldigd wordt niet foutloos is. Wanneer er bij 
het kopiëren van het DNA een mutatie optreedt (d.w.z., een foutje wordt gemaakt), kan dat 
ertoe leiden dat er in de keten aminozuren waaruit een enzym bestaat een bepaald aminozuur 
vervangen wordt door een ander aminozuur. Enzymen zijn chemische fabriekjes die één 
bepaalde stof (het substraat) afbreken of bewerken. Enzym en substraat passen op elkaar 
volgens een soort sleutel-slot principe en een kleine veranderingen in de structuur van een 
enzym kan er al toe leiden dat de substraat-voorkeur van een enzym verandert.  
Al gauw bleek dat de problemen met resistentie tegen de nieuwe β-lactam antibiotica door 
precies zo’n mechanisme veroorzaakt werden. Mutaties in het TEM-1 gen zorgden voor 
structurele veranderingen in het ß-lactmase enzym en in zeldzame gevallen zorgde dit ervoor 
dat het enzym op zo’n manier veranderde dat het de nieuwe antibiotica beter kon binden. 
Ondertussen zijn er meer dan 150 van deze gemuteerde varianten van TEM-1 beschreven. De 
meeste van deze varianten kunnen de antibiotica die van penicilline en ampicilline zijn 
afgeleid veel beter afbreken dan TEM-1. 
 
Proeven en resultaten beschreven in dit proefschrift 
In dit proefschrift is onderzocht hoe TEM-1 zich aanpast aan een nieuw antibioticum. Die 
vraag is niet alleen interessant voor de antibioticumresistentie problematiek, maar ook voor de 
evolutiebiologie. Door stap voor stap, of in dit geval mutatie voor mutatie, te bekijken hoe een 
enzym beter wordt in het afbreken van een antibioticum kan namelijk belangrijke informatie 
vergaard worden over de manier waarop mutaties elkaar beïnvloeden. Het effect van mutaties 
kan simpelweg optelbaar zijn, maar ze kunnen elkaars effect ook versterken of afzwakken. 
Door de dynamiek van mutatie-interactie te onderzoeken kunnen we meer te weten komen 
over het zogenaamde fitnesslandschap van een enzym. Zo’n fitnesslandschap kun je voor je 
zien als een plaatje van een berglandschap, waarbij op het platte vlak (d.w.z., langs de x- en 
de y-as) alle mogelijke genotypen (genetische varianten) van een organisme zijn uitgezet, 
terwijl in de hoogte (langs de z-as) de ‘fitness’ van ieder genotype aangegeven is. Deze 
‘fitness’ is een ingewikkelde term, die uitdrukt hoe goed een organisme, of in dit geval een 
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genotype, in staat is zich te reproduceren ten opzichte van andere organismen van dezelfde 
soort die in dezelfde omgeving leven. In de dalen vind je dus de genotypen die slecht 
aangepast zijn aan hun eigen omgeving terwijl de pieken genotypen voorstellen die juist zeer 
goed aan hun omgeving zijn aangepast. Een genotype dat zich in een dal bevindt kan via 
mutaties (die ieder op zich voordelig moeten zijn) uit dit dal klimmen en zich ‘bergopwaarts’ 
begeven. Telkens wanneer er zich een mutatie voordoet die een positief effect heeft op de 
fitness, krijgt het nieuwe genotype dat ontstaat een reproductief voordeel ten opzichte van het 
onveranderde, oude genotype. Het nieuwe genotype zal in een populatie dus het oude 
verdringen totdat er alleen nog nieuwe genotypen over zijn.  
Één van de grote vragen die er bestaan over fitnesslandschap is of je zo’n landschap moet 
zien als een enkele, eenzame top, zeg de Mont Ventoux, of als een verzameling van pieken en 
dalen, zeg de Alpen. Welke van deze twee scenario’s geldt, heeft directe invloed op een breed 
scala aan evolutionaire problemen als van de evolutie van seks, soortvorming en de vraag in 
welke mate evolutie beperkt wordt en herhaalbaar is. 
 
In Hoofdstuk 2 hebben we zo nauwkeurig mogelijk in kaart gebracht hoe TEM-1 zich stap 
voor stap aanpast aan een nieuw antibioticum (cefotaxime) waar het aanvankelijk nauwelijks 
resistentie tegen verleent. Dit is gedaan door natuurlijke evolutie te vervangen door evolutie 
in het laboratorium. Natuurlijke evolutie is afhankelijk van het ontstaan van toevallige foutjes 
in het DNA. Door het TEM-1 gen te vermenigvuldigen in een kopieermachine voor DNA en 
hierbij als het ware ‘slechte inkt’ te gebruiken, kunnen we het evolutieproces in een 
laboratorium nabootsen. Dit resulteert in miljoenen kopieën van het TEM-1 gen waarin 
allerhande ‘foutjes’ zitten. Door deze mutante kopieën in te bouwen in bacteriën en deze 
bacteriën vervolgens bloot te stellen aan steeds hogere concentraties van het antibioticum 
cefotaxime blijven door natuurlijke selectie juist bacteriën met die zeldzame TEM-1 varianten 
over die toevalligerwijs beter zijn geworden in het afbreken van dit ‘nieuwe’ antibioticum. 
Door deze nieuwe varianten te isoleren en het kopieerproces vervolgens te herhalen, kan de 
efficiëntie waarmee TEM-1 cefotaxime afbreekt door slechts drie of vier mutaties meer dan 
honderdduizend-voudig verhoogd worden. De proeven in hoofdstuk twee tonen aan dat 
toevalligheid in dit proces een grote rol speelt. Sommige mutaties werken elkaar namelijk 
tegen; wanneer ze los van elkaar voorkomen, verhogen ze ieder apart de resistentie tegen 
cefotaxime, maar wanneer ze gecombineerd worden, doen ze elkaars effect plotseling teniet. 
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Zulke effecten kunnen zorgen voor een fitnesslandschap met meerdere pieken, en kunnen 
beperkingen opleggen aan het adaptieve vermogen. 
 
In Hoofdstuk 3 wordt de natuurlijke evolutie van TEM-1 vergeleken met de laboratorium 
evolutie van TEM-1 om te onderzoeken in hoeverre natuurlijke evolutie voorspeld kan 
worden met behulp van laboratorium evolutie. Uit deze vergelijking blijkt dat bijna alle 
natuurlijke variatie die er tot nu toe binnen TEM-genen gevonden en beschreven is ook 
gevonden wordt in laboratorium evolutie. Op basis van de verzamelde gegevens worden 
bovendien enkele voorspellingen gedaan over mutaties die tot op heden niet in natuurlijke 
TEM-isolaten gevonden zijn, maar die in de toekomst op zouden kunnen duiken. 
 
Hoewel bacteriën normaal gesproken hun erfelijk materiaal niet recombineren, tonen we in 
Hoofdstuk 4 aan dat er waar het TEM-genen betreft verschillende bewijzen te vinden zijn die 
aangeven dat deze genen wel degelijk kunnen recombineren. TEM-genen worden met name 
gevonden op plasmides. Dat zijn, korte, cirkelvormige stukken DNA die makkelijk 
uitgewisseld kunnen worden tussen bacteriën. Recombinatie tussen twee TEM-genen binnen 
één plasmide kan ervoor zorgen dat er een enkel nieuw gen ontstaat. Dit proces zou kunnen 
resulteren in nieuwe genen die nieuwe combinaties van mutaties met zich meedragen. Er 
bestaat echter bewijs dat mutante TEM-genen minder goed zijn dan TEM-1 in het afbreken 
van penicilline en ampicilline. Gezien de relatief hoge frequentie van ongemuteerde TEM-1 
genen in bacteriële populaties, lijkt het erop dat recombinatie door de invloed van penicilline 
en ampicilline, die beiden nog steeds relatief veel gebruikt worden, er juist voor zorgt dat 
TEM-1 in bacteriële populaties blijft overheersen. 
 
Niet alle veranderingen in de DNA-code veroorzaken veranderingen in de aminozuren 
waaruit een enzym is opgebouwd. Dit is het gevolg van de dubbelzinnigheid van de 
genetische code. Een aminozuur wordt in het DNA gecodeerd door drie opeenvolgende basen 
(een triplet). Het DNA kent 4 verschillende basen en zo zijn er dus 4x4x4 = 64 combinaties 
van basen mogelijk die een aminozuur coderen. Er zijn echter maar twintig aminozuren. Als 
gevolg hiervan worden de meeste aminozuren door meer dan één triplet van basen gecodeerd. 
Een mutatie (de verandering van één van de drie basen in zo’n triplet) hoeft dus niet 
automatisch een verandering in een aminozuur te betekenen. Mutaties die wel het DNA maar 
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niet het aminozuur veranderen, noemen we synonieme mutaties. Tot een jaar of tien geleden 
werd er algemeen aangenomen dat dergelijke mutaties een enzym niet kunnen veranderen, 
aangezien de mutatie niet leidt tot een verandering in de keten van aminozuren waaruit het 
enzym is opgebouwd. Recentelijk zijn er echter overtuigende bewijzen gevonden dat dit niet 
altijd het geval is. In hoofdstuk 5 vinden we aanwijzingen dat tenminste één synonieme 
mutatie in TEM-1 niet neutraal is. Een analyse van alle synonieme mutaties die er in 
natuurlijke TEM-isolaten gevonden zijn toont aan dat er mogelijk meer van dergelijke niet-
neutrale, synonieme mutaties in TEM-genen te vinden zijn. 
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has complied with the educational requirements set by the C.T. de Wit Graduate 
School for Production Ecology and Resource Conservation (PE&RC) which 
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Appendix I 
 
 
Supplementary table 3.1: Frequency of occurrence of amino acid substitutions in clinical and 
laboratory isolates of TEM-alleles. 
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4 S4N  1                1  
5 I5T  1  1                
6 Q6K 4                   
 Q6R  1      1            
7 H7P  1                1  
 H7Q  1                1  
 H7R  1                1  
 H7Y  1                1  
10 V10I  6       2     4      
13 I13T  1                1  
 I13V  1                1  
15 F15C  1                1  
 F15L  1                1  
 F15V  1                1  
16 F16C  1                1  
 F16L 1                   
18 A18V  2 1           1      
19 F19C  2            1    1  
 F19I  1            1      
 F19L  2            1    1  
 F19V  1                1  
21 L21F 21                   
 L21I 1 1            1      
 L21P  3  2              1  
22 F22S  1           1       
23 V23A  2  2                
24 F24C  1            1      
27 P27L  1            1      
 P27S  1       1           
28 E28D 1                   
 E28K 1                   
31 V31A  3               1 1 1 
32 K32R  1                1  
33 V33I  2            2      
34 K34E 1                   
35 D35A  1                1  
 D35P 1                   
36 A36T  1                1  
37 E37D  1                 1 
38 D38G  1            1      
 D38N 1 1            1      
 D38V  1            1      
 D38Y  1       1           
39 Q39K 32 1            1      
 Q39R  2            1    1  
40 L40W  1         1         
41 G41S  1            1      
42 A42G  6 1     1      1 1 1   1 
 A42V 1                   
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47 I47V  4            1  1 1 1  
48 E48V  1            1      
49 L49M 1 3            3      
 L49V  1            1      
50 D50E  1                1  
 L51F  2            1   1   
 L51P 1                   
52 N52D  3                2 1 
52 N52H  1                1  
 N52S  3                2 1 
 N52T  2                2  
 N52Y  1             1     
55 K55E  1                1  
 K55R  1               1   
56 I56T  1                 1 
 I56V  1                1  
58 E58G  1               1   
 E58K  1            1      
59 S59G  1                 1 
60 F60W  1                1  
62 P62S  1                1  
63 E63A  1                1  
 E63D  1                1  
 E63G  1                1  
 E63K  2                1 1 
64 E64K 1                   
69 M69I  4                   
 M69L 12 1             1     
 M69V 9                   
79 A79V  1               1   
80 V80E 1                   
 V80I  1       1           
82 S82E  1                 1 
 S82F  1                 1 
88 Q88E  1                 1 
 Q88H  1            1      
 Q88L  1            1      
90 G90S  1               1   
92 G92D 2 1            1      
 G92S  1 1                 
96 H96D  1       1           
 H96Y  2                1 1 
97 Y97F  1            1      
98 S98T  1               1   
 S98Y  1            1      
99 Q99R  1                1  
100 N100G  1                1  
 N100K  1            1      
 N100S 2                   
102 L102M  1            1      
 L102V 1                   
104 E104A  2               2   
 E104G  2                1 1 
 E104K 42 36 1 1  2 1 7  2  4 1 16  1    
 E104V  1               1   
108 V108M  1               1   
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111 K111E  1                1  
 K111M  2            2      
 K111Q  2                2  
 K111R  3             1   2  
 K111T  2               1 1  
114 T114A  1                1  
 T114M  1            1      
 T114P 1                   
115 D115G 1                   
120 R120E  1                1  
120 R120G  5            1   1 2 1 
 R120S  2                2  
124 S124G  2            1    1  
 S124N 1 1            1      
 S124R  2            1    1  
127 I127V 2                   
129 M129L  1            1      
130 S130G 3 1             1     
140 T140R  1            1      
145 P145A 1                   
 P145L  1            1      
 P145Q  1            1      
147 E147A  1                1  
 E147G  2                1 1 
 E147K  2       1         1  
149 T149A  1            1      
150 A150T  1                 1 
153 H153D  1             1     
 H153L  1            1      
 H153Q  1            1      
 H153R 3 6           1 1   2 1 1 
 H153Y  1            1      
154 N154D  2               2   
 N154S  1                1  
 N154Y  1               1   
155 M155I  4       1     3      
157 D157E 1                   
158 H158N 1                   
 H158Y  1                1  
159 V159A  1                 1 
 V159T                    
163 D163G 1                   
 D163H 1                   
 D163V  1            1      
164 R164C 4 2         1   1      
 R164G  2       1  1         
 R164H 18 15   5   1 6 1 1   1      
 R164N  1      1            
 R164S 26 21  1 11   2 1 1    5      
 R164Y  1            1      
165 W165C  1                   
 W165G  1            1      
 W165R 3                   
167 P167S  1              1    
 P167T  1            1      
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168 E168A  1                 1 
 E168G  1               1   
 E168K  1      1            
 E168V  1                 1 
169 L169P  2            1  1    
 L169R  2   2               
172 A172V  1            1      
173 I173L  1                1  
 I173R  1               1   
 I173T  2      1      1      
 I173V 1 12      3 6  1   2      
174 P174S  1       1           
175 N175D  5       1     3    1  
175 N175I 1                   
 N175Y  1            1      
177 E177K  1                 1 
178 R178C  1         1         
 R178S  1       1           
179 D179E 1                   
 D179G  4   1      1   2      
 D179Y  1   1               
180 T180S  1            1      
182 M182K  1                1  
 M182L  1                1  
 M182R  1                1  
 M182T 21 26 1 1   1 2 2    1 14   1 2 1 
 M182V  2                2  
184 A184T  1            1      
 A184V (3) 4            3  1    
188 T188I  2            2      
 T188R  1            1      
191 R191H  2            2      
192 K192E  2            1     1 
 K192N  1            1      
 K192R  1             1     
195 T195A  1             1     
 T195F  1                 1 
 T195S  1                 1 
196 G196D 1                   
 G196S 1 1            1      
197 E197K  1            1      
198 L198P  1                 1 
199 L199P  1  1                
200 T200S  1            1      
201 L201I  1            1      
 L201P  4            2 1   1  
 L201Q  1                1  
 L201R  1                1  
202 A202V  1  1                
204 R204Q 1                   
205 Q205R  1            1      
206 Q206H  1                 1 
207 L207S  1  1                
208 I208K  1            1      
 I208L  1                1  
 I208M  5            2   1 1 1 
 I208T  1                1  
 I208V  2  1              1  
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209 D209G  1                1  
212 E212K  1               1   
213 A213P  1            1      
215 K215E  1  1                
 K215R  1                1  
216 V216I  2            2      
217 A217S  1            1      
218 G218E 1                   
219 P219S  1               1   
221 L221M 1                   
224 A224V 1 7       1     4   1  1 
227 A227V  1         1         
235 S235T  2            2      
237 A237G 1                   
 A237S  2      2            
 A237T 8 6            6      
238 G238A  3          3        
 G238D 1                   
 G238N 1                   
 G238S 32 57 1 5  2 1 6    4 1 35 1 1    
240 E240G  4  2            1   1 
 E240K  25 13  1    2      10      
 E240R 1                   
 E240V 1 1            1      
241 R241H  4 1 1          2      
243 S243G  1                1  
244 R244C 4 1             1     
 R244G 1                   
 R244H 3                   
 R244L 1                   
 R244S 7 1             1     
 R244T                    
247 I247V  3            1    1 1 
248 A248T  1            1      
249 A249V  3            3      
254 D254G  3  1    1          1  
 D254H  1      1            
 D254N  2  2                
256 K256N  1            1      
 K256Q  1  1                
 K256R  1                 1 
262 V262I 1                   
265 T265A  2  2                
 T265M 20 12    1  2      7    1 1 
266 T266A  1      1            
267 G267A  1            1      
 G267R  2      1  1          
 G267V  1            1      
268 S268G 2 7          4 1 1  1    
 S268N  1       1           
 S268T  1            1      
271 T271A  1                1  
 T271I  2            2      
272 T272A  1             1     
275 R275A 2                   
 R275L 3 1               1   
 R275Q 4 1               1   
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276 N276D 12 3             1 1 1   
 N276R 1                   
 N276S 1 1               1   
277 R277K  1                 1 
278 Q278E  1            1      
 Q278L  1               1   
 Q278R  2            1    1  
280 A280T  1               1   
 A280V 2                   
281 E281-  1            1      
284 A284G 1                   
285 S285T  1                1  
287 I287V  2       1         1  
288 K288E  2              1  1  
288 K288Q  1                1  
 K288R  2               1 1  
 K288T  1                1  
289 H289L                    
 H289Q  1            1      
 H289Y  1       1           
291 ter291K  1            1      
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Appendix II 
 
Supplement to acknowledgements. List of bird species recorded in and from the ‘Dreijen 
Arboretum’ and Botanical Centre, Wageningen, the Netherlands, in the period 2002-2008 
(observations by L. van der Plas and M. Salverda). Explanation of status; 1 = breeding or strong 
indications of territory, 2 = regular but probably non-breeding visitor, 3 = fly over, 4 = rare visitor, 5 = 
rare fly over, 6 = seen during the bird watching excursions of the Botanical Centre (which include a 
walk to the ‘Nevengeul’). 
. 
Nr. Dutch name Status English name Latin name 
1 Fuut 6 Great crested grebe Podiceps cristatus 
2 Aalscholver 2 Great cormorant Phalacrocorax carbo 
3 Kleine zilverreiger 6 Little egret Egretta garzetta 
4 Grote zilverreiger 5 Great egret Casmerodius albus 
5 Blauwe reiger 2 Grey heron  Ardea cinerea 
6 Ooievaar 3 White stork Ciconia ciconia 
7 Lepelaar 5 Spoonbill Platalea leucorodia 
8 Knobbelzwaan 3 Mute swan  Cygnus olor 
9 Kolgans 3 White-fronted goose Anser albifrons 
10 Grauwe gans 3 Greylag goose Anser anser 
11 Wilde eend 2 Mallard Anas platyrhynchos 
12 Kuifeend 6 Tufted duck Aythya fuligula 
13 Rode wouw 5 Red kite Milvus milvus 
14 Bruine kiekendief 5 Marsh harrier Circus aeruginosus 
15 Blauwe kiekendief  5 Hen harrier Circus cyaneus 
16 Buizerd 3 Buzzard Buteo buteo 
17 Wespendief 5 Honey buzzard Pernis apivorus 
18 Sperwer 2 Sparrowhawk Accipiter nisus 
19 Havik 5 Goshawk Accipiter gentilis 
20 Torenvalk 2 Kestrel Falco tinnunculus 
21 Boomvalk 3 Hobby Falco subbuteo 
22 Waterhoen 1 Moorhen Gallinula chloropus 
23 Meerkoet 6 Eurasian coot Fulica atra 
24 Scholekster 3 Oystercatcher Haematopus ostralegus 
25 Kievit 3 Lapwing Vanellus vanellus 
26 Tureluur 6 Redshank Tringa totanus 
27 Grutto 6 Black-tailed godwit Limosa limosa 
28 Wulp 6 Curlew Numenius arquata 
29 Houtsnip 4 Eurasian woodcock Scolopax rusticola 
30 Kokmeeuw 3 Black-headed gull Larus ridibundus 
31 Stormmeeuw 3 Mew gull Larus canus 
32 Zwartkopmeeuw 5 Mediterranean gull Larus melanocephalus 
33 Zilvermeeuw 3 Herring gull Larus argentatus 
34 Kleine mantelmeeuw 3 Lesser black-backed gull Larus graellsii 
35 Visdief 4 Common tern Sterna hirundo 
36 Holenduif 1 Stock dove Columba oenas 
37 Houtduif 1 Woodpigeon Columba palumbus 
38 Turkse tortel 2 Collared dove Streptorelia decaocto 
39 Koekoek 2 Cuckoo Cuculus canorus 
40 Velduil 5 Short-eared owl Asio flammeus 
41 Steenuil 4 Little owl Athene noctua 
42 Gierzwaluw 3 Swift Apus apus 
43 Alpengierzwaluw 5 Alpine swift Apus melba 
44 IJsvogel 2 Kingfisher Alcedo atthis 
45 Zwarte specht 5 Black woodpecker Dryocopus martius 
46 Groene specht 2 Green woodpecker Picus viridis 
47 Grote bonte specht 1 Great spotted woodpecker Dendrocopos major 
48 Kleine bonte specht 4 Lesser spotted woodpecker Dendrocopos minor 
49 Veldleeuwerik 3 Skylark Alauda arvensis 
50 Oeverzwaluw 3 Sand martin Riparia riparia 
51 Boerenzwaluw 3 Barn swallow Hirundo rustica 
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52 Huiszwaluw 3 House martin Delichon urbica 
53 Graspieper 3 Meadow pipit Anthus pratensis 
54 Witte kwikstaart 2 White wagtail Motacilla alba 
55 Gele kwikstaart 6 Yellow wagtail Motacilla flava 
56 Grote gele kwikstaart 5 Grey wagtail Motacilla cinerea 
57 Winterkoning 1 Wren Troglodytes troglodytes 
58 Pestvogel 4 Bohemian waxwing Bombycilla garrulus 
59 Heggenmus 1 Dunnock Prunella modularis 
60 Roodborst 1 Robin Erithacus rubecula 
61 Blauwborst 6 Bluethroat Luscinia svecica 
62 Zwarte roodstaart 1 Black redstart Phoenicurus ochruros 
63 Roodborsttapuit 6 Stonechat Saxicola rubicola 
64 Zanglijster 2 Song thrush Turdus philomelos 
65 Koperwiek 2 Redwing Turdus iliacus 
66 Grote lijster 1 Mistle thrush Turdus viscivorus 
67 Kramsvogel 2 Fieldfare Turdus pilaris 
68 Merel 1 Blackbird Turdus merula 
69 Beflijster 4 Ring ouzel Turdus torquatus 
70 Tuinfluiter 6 Garden warbler Sylvia borin 
71 Zwartkop 1 Blackcap Sylvia atricapilla 
72 Braamsluiper 1 Lesser whitethroat Sylvia curruca 
73 Grasmus 6 Whitethroat Sylvia communis 
74 Sprinkhaanzanger 6 Grasshopper warbler Locustella naevia 
75 Fitis 2 Willow warbler Phylloscopus trochilus 
76 Tjiftjaf 1 Chiffchaff Phylloscopus collybita 
77 Goudhaan 1 Goldcrest Regulus regulus 
78 Vuurgoudhaan 2 Firecrest Regulus ignicapillus 
79 Grauwe vliegenvanger 4 Spotted flycatcher Muscicapa striata 
80 Bonte vliegenvanger 4 Pied flycatcher Ficedula hypoleuca 
81 Koolmees 1 Great tit Parus major 
82 Zwarte mees 2 Coal tit Parus ater 
83 Pimpelmees 1 Blue tit Parus caeruleus 
84 Kuifmees 1 Crested tit Parus cristatus 
85 Glanskop 2 Marsh tit Parus palustris 
86 Staartmees 1 Long-tailed tit Aegithalos caudatus 
87 Boomklever 1 Nuthatch Sitta europaea 
88 Boomkruiper 1 Short-toed treecreeper Certhia brachydactyla 
89 Ekster 1 Magpie Pica pica 
90 Gaai 1 Jay Garrulus glandarius 
91 Kauw 3 Jackdaw Corvus monedula 
92 Zwarte kraai 1 Carrion crow Corvus corone 
93 Spreeuw 2 Starling Sturnus vulgaris 
94 Huismus 2 House sparrow Passer domesticus 
95 Ringmus 4 Tree sparrow Passer montanus 
96 Vink 1 Chaffinch Fringilla coelebs 
97 Keep 4 Brambling Fringilla montifringilla 
98 Kleine barmsijs 4 Mealy redpoll Carduelis cabaret 
99 Putter 2 Goldfinch Carduelis carduelis 
100 Groenling 1 Greenfinch Chloris chloris 
101 Sijs 2 Siskin Carduelis spinus 
102 Europese kanarie 4 Serin Serinus serinus 
103 Goudvink 1 Bullfinch Pyrrhula pyrrhula 
104 Appelvink 1 Hawfinch Coccothraustes coccothraustes 
105 Kruisbek 4 Crossbill Loxia curvirostra 
106 Rietgors 4 Common reed bunting Emberiza schoeniclus 
     
Exotic species and escapes 
107 Nijlgans 3 Egyptian goose Alopochen aegyptiacus 
108 Fazant 6 Ring-necked pheasant Phasianus colchicus 
109 Japanse pestvogel 4 Japanese waxwing Bombycilla japonica 
110 Kanarie 4 Canary Serinus canaria 
 
 
 
143 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
144 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Funding 
The work presented in this thesis was carried out at the Laboratory of Genetics, Wageningen 
University, the Netherlands, with financial support from the Netherlands Organization for 
Scientific Research (NWO), grant number 813.04.003. 
 
 
 
 
 
 
 
Publisher 
Ponsen & Looijen bv, Wageningen, the Netherlands 
